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ABSTRACT
MASS SPECTROMETRY-BASED QUANTITATIVE PROTEOMIC
ANALYSIS OF BIOLOGICAL FLUIDS

PATIENCE AKOSUA AFEDI
2019
Proteomics is a high-throughput approach to study protein expression, structure, function,
interaction, post-translational modifications, and localization in a cell or tissue. Proteomic
shotgun approach was used to analyze changes in proteins in bovine follicular fluid (FF)
and plasma (PL) from cows with high estradiol (HE2) or low E2 (LE2) during the preovulatory period. FF creates a unique microenvironment in follicles necessary for follicle
growth and oocyte maturation, and pre-ovulatory concentrations of E2 have been
reported to impact several processes involved with fertility. Initial steps in the analysis
involved development of an immunodepletion protocol for high abundant proteins
(HAPs) in bovine PL, FF, epididymis sperm and ejaculated sperm. The determined
depletion rates for the HAPs albumin, IgG, and IgA ranged from 98.7 to 99.9%. Similar
depletion rate was observed for alpha-1-antitrypsin based on its gel band. Peptides were
labeled with iTRAQ reagents and quantified using 2-dimentional liquid chromatography
(LC) electrospray (ES)-based mass spectrometry. E2 was associated with protein changes
in PL and FF. Protein expression changes between FF HE2 and FF LE2 were higher than
PL HE2 and PL LE2. There were 15 up-regulated proteins and ten down-regulated
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proteins in FF HE2 compared to FF LE2. Seven proteins were up-regulated and nine
proteins down-regulated in PL HE2 compared to PL LE2. Proteins were more
predominant in PL than in FF but the extent of protein changes with HE2 was greater in
FF than in PL. Several of the differentially expressed proteins function in follicle
development and were mainly categorized under cellular process and metabolic process.
Pathway analysis identified the up and down-regulated proteins were predominantly
associated with the complement and coagulation cascades which support the view that
folliculogenesis and ovulation are hemorrhagic events. The data demonstrates E2
regulates a wide range of reproductive associated proteins in bovine PL and FF and forms
the basis for further investigation of specific processes involved in such regulation. This
work was also interested in characterization and quantification of atherosclerotic lesions
in three regions of aortic root of ApoE-/- mice.
Atherosclerosis is the underlining cause of heart attack and stroke, the two leading cause
of cardiovascular death worldwide. The three regions of the aortic root examined were
the ascending aorta region (AAR), region showing the orifices of the coronary arteries
marking the start of the ascending arch (OCAR) and aortic sinus region (ASR) in ApoE-/male and female mice at different ages. 67 ApoE-/- and 27 wild type C57BL/6J mice
(controls) were fed with a high fat diet (HFD) until age 8, 12, 18, or 24 weeks. Through
systematic classification and quantification of lesions in each region and statistically data
analysis, we found that the complexity and total atherosclerotic lesion areas in ApoE-/mice was location and age dependent. It was slowest in the AAR with lesions progressing
from dominant type I at 8 weeks, type II at 12 weeks, types III at 18 and types III and IV
at 24 weeks of age. Lesion development was comparable in the OCAR and ASR regions;
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types II and III lesions dominated in mice at 8 and 12 weeks of age respectively while
types IV and types IV and V dominated at 18 and 24 weeks of age, respectively. Average
percentage of atherosclerotic lesions typically increased from the AAR to the OCAR to
the ASR at a specific age, and from 8 to 24 weeks of ApoE-/- mice at each region,
correlating with the histological data. These findings would be beneficial in experimental
design and targeting of lesion types in aortic roots of the popular ApoE-/- murine
atherosclerosis model.
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CHAPTER 1
1 LITERATURE REVIEW
1.1 Mass-spectrometry Based Proteomics
Proteomics is a high-throughput approach to study protein expression, structure,
function, interaction, post-translational modifications, and localization in a cell or tissue1.
Proteomic field involves collection of varied disciplines including molecular biology,
biochemistry, bioinformatics, cell imaging by light and electron microscopy, array and
chip experiments, and genetic readout experiments1, 2. This makes proteomics a versatile
tool for studying numerous biological systems. The ability of proteomic to analyze
thousands of proteins and post-translational modifications (PTMs) in a single experiment
with good quality makes it advantageous over traditional methods such as western blots
which often analyze one protein at a time3.
Mass spectrometry is now the de facto method for analyzing proteomic samples,
contributed greatly by advancement in mass spectrometry instrumentation including
advancement in LC systems (e.g. ultra-high-pressure reversed-phase systems) and
development of commercial and public software tools able to identify and quantify
proteins from the numerous data generated from the MS and MS/MS analysis.
Advancement in current mass spectrometry for proteomics [(e.g. quadrupole time-offlight (QTOF), linear trap quadroupole (LTQ) and Orbitrap technology)] include
improved sensitivity (ten to 50 times), data acquisition and speed (five to ten times), and
number of proteins identified and quantified from a proteome (5,000–10,000 proteins)4.
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Because mass spectrometry is central to proteomics and is used in this dissertation, a
theoretical background to the technology and principles is discussed below.
1.2 Mass Spectrometer
Mass spectrometric measurements are carried out in the gas phase on ionized
analytes. The basic components of a mass spectrometer (Figure 1.1) are an ion source, a
mass analyzer that measures the mass-to-charge ratio (m/z) of the ionized analytes, and a
detector that registers the number of ions at each m/z value and displays the results in a
chart form called the mass spectrum.

Figure 1.1. The basic components of a mass spectrometer. Shown in Banerjee and
Mazumdar3. The ion source ionizes the analytes, the mass analyzer measures the mass-tocharge ratio (m/z) of the ionized analytes, and a detector registers the number of ions at
each m/z value, displayed in the mass spectrum.

1.2.1 Ionization Techniques
Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization
(MALDI) are the two techniques most commonly used to volatize and ionize the proteins
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or peptides for mass spectrometric analysis. MALDI method involves subliming and
ionizing the analyte out of a dry crystalline matrix via laser pulses. ESI ionizes analytes
out of a solution. MALDI is relatively used to analyze simple peptide mixtures compared
to ESI method which is preferred for complex matrices2. ESI technique is used in this
dissertation and is thus further discussed.
ESI is a soft ionization process, i.e. very little residual energy is retained by the
analyte which generally results in no fragmentation of the analyte or breakage of very
weak interactions like electrostatic interactions, van der Waals interactions, and
hydrophobic interactions upon the ionization process. ESI also produces multiple charged
ions thereby giving ions with m/z values within the mass range of all common mass
analyzers. These factors make ESI a powerful and reliable tool for ionizing non-volatile
thermally labile large-molecular weight biomolecules (105 Da), such as proteins in the
gaseous states and their subsequent mass spectrometric analysis for rapid identification
and structural characterization on the basis of molecular mass of the analyte. Although
ESI is primarily used for biomolecules, its application has been extended to a broad range
of analytes including polar organic, inorganic, and metal-organic complexes3. The ESI
method is robust and sensitive and can detect peptides at femto levels in microliters
volumes. Because ESI ionizes analytes out of a solution, it is readily coupled to liquidbased separation tools such as chromatography techniques, which allows for
prefractionation of the peptides in complex mixtures thereby reducing the number of
different precursors that enter the mass spectrometer at a time.
Under ESI operation, a dilute solution of the analyte is drawn to the tip of a
capillary tube where a high voltage (2-6 kV) is applied. The applied voltage creates a
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strong electric field which causes the dispersion of the sample solution into an aerosol of
highly charged electrospray (ES) droplets with the same polarity as the applied voltage. A
coaxial nebulizer gas (dry N2) flows around the capillary and enhances the nebulization,
directs the emerging charged droplets towards the mass spectrometer and helps in the
solvent evaporation of the charge droplets. The charged droplets diminishes in size by
solvent evaporation as it moves towards the mass spectrometer until it reaches the point
(Rayleigh limit) where the surface tension can no longer sustain the Coulomb force of
repulsion and results in disintegration into much smaller offspring droplets (Coulomb
fission). Solvent evaporation and Coulomb fission repeats until nanodroplets are obtained
from which gas-phased charge analyte molecules is formed3.
Different models have been proposed for the mechanism for forming the gasphase ions of the analyte from the highly charge droplets. According to the Charge
Residue Model (CRM), this is proposed for large macromolecules like proteins, series of
solvent evaporation and Coulomb fission result in extremely small charged droplet that
contains only one analyte molecule. Desolvation of this droplet causes its charges (on the
surface) to land on the analyte. Based on the Ion Evaporation Model (IEM), series of
solvent evaporation and Coulomb fission decrease the radii of the charged droplets to a
size when the electric field due to the charges at the surface of the droplet is strong
enough to cause direct emission of the solvated ion. Thus formation of extremely small
droplets is not required. Applied positive potential or positive-ion mode results in
positively charged ions and applied negative potential or negative-ion mode results in
negatively charge ions3.
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Figure 1.2. Schematic representation of the electrospray ionization (ESI) process. Shown
in Banerjee and Mazumdar3. ESI is a soft ionization process often used to ionize proteins
for mass spectrometry analysis.

To reduce flow rate which subsequently reduce space charge effect and increases
ionization efficiency, small capillary electrospray emitter tips are employed (nanoelectrospray). Nano-electrospray is able to achieve a constant signal for 10-30 minutes
for a 1 μl sample. The nano-electrospray is more tolerable to high aqueous solvents and
salt contamination compared to conventional electrospray. Because less sample volume is
used in nano-electrospray, sample lasts longer enabling multiple experiments to be
performed3.
1.2.2 Mass Analyzers
The mass analyzer is central to the mass spectrometer. There are four basic types
of mass analyzers currently used in proteomics research. These are the ion trap, time-offlight (TOF), quadrupole, and fourier transform ion cyclotron (FT-MS) which is currently
being replaced by the orbitrap analyzer. These vary in design and in key parameters that
characterize a mass analyzer, namely sensitivity, resolution, mass accuracy, and the
ability to generate information-rich ion mass spectra from peptide fragments. Mass
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analyzers can be stand alone or, in some cases, put together in tandem to take advantage
of the strengths of each. This dissertation used the Finnigan Linear Trap Quadropole
(LTQ) (Thermo Fisher Scientific). It consists of a 2-dimentional (2-D) quadrupole ion
trap analyzer.
Ion trap analyzers are typically composed of four rod-shaped electrodes, to which
DC and AC are applied to produce electric fields that confine ions of interest in space
prior to subsequent MS or MS/MS analysis. AC of same amplitude but opposite sign (i.e.
positive and negative polarity) within the radio frequency (RF) range is applied to pairs
of electrodes (This is referred to as the ‘main RF’) helps to confine ions radially and
induce ion motion. The applied DC helps to confine ions axially. Ions of interest are
isolated (i.e. trapped) and unwanted ions are simultaneously ejected via resonance
ejection. Simultaneous resonance ejection is achieved by applying a superimposed AC
wave containing secular frequency values (q) matching each of the unwanted ion’s
secular motion to the exit rod5. In two dimensional (2-D) trap, also called linear ion tap
(LIT) (Figure 1.3), the forces act on the ions only in the x and y dimensions. This allows
them to spread out axially and increases the ion capacity compared to conventional three
dimensional (3-D) traps. Therefore LIT has increased resolution, sensitivity, and mass
accuracy than the 3-D trap and is more commonly used2, 6. Accordingly, the Finnigan
LTQ mass spectrometer is robust, has high sensitivity, and provides rapid and
reproducible mass spectrometric analysis of complex samples.
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Figure 1.3. Basic design of the two-dimensional quadrupole ion trap. Shown in
Schwartzet et al.6 The Finnigan LTQ mass spectrometer used in this dissertation consists
of this type of analyzer.

1.2.3 Fragmentation Techniques for Proteomics
There are a number of techniques used to generate the fragment ions of precursor
ions. These include collision-induced dissociation (CID), electron-capture dissociation
(ECD), electron-transfer dissociation (ETD), surface-induced dissociation (SID), and
infrared multiphoton dissociation (IRMPD). CID is the most widely used method to
generate fragment ion. In CID, the gaseous precursor ion is allowed to collide with an
inert and neutral target gas (e.g. N2, He, Ar) in the collision cell. Upon the collision, the
precursor ion gains some of the kinetic energy which is converted into internal energy.
Thus, an unstable excited state precursor ion is produced which then decompose into the
product ions. CID mainly forms N-terminal a- and b-fragments, and C-terminal yfragment. Among the ion types, b and y are the most common, formed from the breakage
of the amide bonds of the peptide backbone3. Figure 1.4 shows formation of b- and y-
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ions. a-ion can be formed from neutral loss of carbon monoxide from b-ion. CID was
used in the identification of proteins in high abundant proteins (HAPs) and low abundant
proteins (LAPs)/depleted fractions in plasma and FF in this dissertation.

Figure 1.4. Formation of fragment ions from a peptide backbone. b- and y-ions are
commonly formed with CID and are formed via breakage of the peptide bond. a-ion can
be formed from neutral loss of carbon monoxide from b-ion.
(http://www.alchemistmatt.com/mwthelp/peptidefragmodelling.htm).

1.2.3.1 Pulsed Q Collision-Induced Dissociation (PQD)
Pulsed Q Collision-Induced Dissociation (PQD) was developed by Thermo Fisher
Scientific and implemented exclusively for their LIT mass spectrometers. PQD involves
activating the precursor ion at a high activation (Q) value (0.6-0.8 eV) and using a short
(~100 μs), high amplitude resonance excitation pulse. In this step, the ions with m/z
resonant to this excitation pulse absorb energy and become kinetically excited. Next, ions
are held at the high Q value for a short period (delay time ~ 100 μs), which is long
enough for the kinetic energy of the ions to be converted into internal energy through
collisions, but not long enough for significant dissociation to occur. Subsequently, the
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precursor ions’ Q value is pulsed to a low value by rapidly dropping the RF amplitude
and then allowing the precursor ions to undergo fragmentation at this low Q value7.
PQD generates spectra qualitatively similar to CID but additionally allows the
observation of low m/z fragments that are usually excluded from CID spectra due to the
“1/3 rule”. PQD therefore eliminates the need for MS3 which is often required with CID
in ion trap instruments in order to detect low m/z fragments7, 8. Because of its ability to
detect product ions of low m/z, it has been applied successfully to detect the signature
low-mass reporter ions (ranges from 114.1 to 121.1) of Isobaric Tag for Relative and
Absolute Quantification (iTRAQ) labels for the quantification of peptides9. PQD was also
successfully employed with iTRAQ labeling in this dissertation.
1.2.4 Tandem Mass Spectrometry
Tandem mass spectrometry (MS/MS) is a method where the gaseous ions are
subjected to two or more sequential stages of mass analysis (which may be separated
spatially or temporally) according to quotient mass/charge3. In MS/MS analysis, a
precursor ion (parent ion) is selected by a mass analyser (Q1) and then focused into a
collision cell (q2) where it undergoes gas-phased reactions to generate different fragment
ions (daughter/product ions) of different masses. Another analyser (Q3) scans the masses
of the product ions and generates the product ion spectrum. The MS/MS technique is
selective, accurate, reproducible, and enhances the lower limit of detection for peptides
by up to 100-fold compared to unbiased MS analysis. It also has multiplex capability in
that it can analyze and quantitate hundreds of proteins per run, thereby increasing the
throughput.
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1.2.5 Data Dependent Acquisition and Data Independent Acquisition
LC-MS/MS experiments in Data Dependent Acquisition (DDA) mode10, 11 is the
standard method for proteomic profiling, biomarker discovery, and relative quantification
of proteins through the use of stable-isotope labels. DDA is a method of choice due to its
flexibility, breadth of detection, and the simplicity of its setup and analysis. In DDA, the
instrument cycles through first a short MS1 survey scan of currently eluting peptides
which serves to monitor peptides intensities and identifies the most intense ions and
potential sites to fragment. In the sequential MS2 scans, the most abundant precursor ions
are individually isolated and fragmented in order of decreasing precursor ion intensity.
The number of MS2 scans (or number of the top precursors) can be predefined by the
user up to ten MS2 scans. Both MS scan and MS2 scans can occur in a duty cycle of
approximately 1s up to 2 s with 10 MS2 scans. DDA can be limited in reproducibility and
precision if too many peptides co-elute and appear in a single MS scan and only the most
abundant peptides are selected thereby missing the rest. Also, it can prevent the
measurements of low abundant proteins. Therefore, prior protein and peptide
fractionations can be critical to successful application of DDA. Data generated in this
dissertation used DDA and the optimized DDA parameters12 used are stated at the
relevant sections.
Data Independent Acquisition (DIA) involves repeatedly selecting all peptides
within a large predefined mass ranges for MS2 scans. This generates highly complex
MS2 spectra which can be analyzed aided by spectral libraries derived from prior DIA
experiments or auxiliary DDA data. The complexity of the DIA MS2 data makes it
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difficult to analyze and this is currently the main disadvantage of using this method.
Recently however, DIA is gaining more attention with the development of bioinformatics
softwares such as DIA-Umpire, OpenSWATH, and SWATHProphet, able to analyze
DIA data10. DIA is also limited in reproducibility and measurement of low abundant
proteins as their signals can be dwarfed by more abundant proteins.
1.3 Shotgun/Bottom-up Proteomic Workflow
Advances in all areas of LCMS analysis including LC instrumentation and
bioinformatics for handling MS/MS generated data, generation of complete gene
sequences for a wide variety of organisms, and robust sample preparation and
quantification techniques are increasingly making proteomics a reliable tool for
investigating the proteome13. Proteomic workflows typically follow either the ‘bottom-up
approach’ or top-down approach14. In bottom-up, the analysis is performed on proteolytic
peptides of the protein while in top-down, the intact protein is analyzed. When bottomup analysis is performed on a mixture of proteins it is called shotgun proteomics. Shotgun
proteomics is superior for the analysis of complex matrices. In this dissertation, the
shotgun proteomics approach was optimized and the main steps in our in-house workflow
are shown in Figure 1.5.
1.3.1 Protein Prefractionation
Biological samples are complex matrices that contain wide dynamic range in
protein concentrations. The dynamic range in protein concentrations in plasma is said to
span 10 to 12 orders of magnitude15, 16. Albumin and IgG, the top two high-abundant
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proteins (HAPs) in plasma constitute about 60% of the total plasma proteome17, 18 and the
top 12 abundant proteins make-up ~95% of the total protein mass15, 19. Proteomic analysis
of complex biological samples is therefore limited in the limit of detection (LOD), limit
of quantification (LOQ), and the linear range of response. Shotgun workflows can
incorporate prefractionation methods for separation of proteins mixture to reduce these
limitations. Available prefractionation methods include 1- and 2-dimensional
polyacrylamide gel-electrophoresis, depletion, and isoelectric focusing (IEF)14.
Depletion is done to separate the HAPs from the low-abundant proteins (LAPs). Removal
of the HAPs enhance the detection of LAPs which otherwise are masked by the HAPs.
Immunodepletion involves the use of antibodies in the separation. Our lab optimized
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
immunodepletion for the separation of protein mixtures in bovine plasma (PL), follicular
fluid (FF), ejaculated sperm, and epididymal sperm samples. Detailed description of the
depletion protocol development and optimization is discussed in chapter 2.
SDS-PAGE is a common, simple, rapid, and sensitive fractionation method to
separate intact proteins20. The sodium dodecyl sulfate (SDS) denatures and disrupts the
structure of proteins and confer uniform negative charge to the proteins such that the
proteins separate primarily based on molecular weight. Separated protein gel bands can
be detected by Coomassie Brilliant Blue or silver staining but the former is preferred for
shotgun proteomics due to better linearity of signal and amenability to LC-MS/MS14. For
LC-MS/MS, gel bands are excised and digested by the in-gel trypsin digestion method21
prior to analysis. In this dissertation, SDS-PAGE was used to separate crude, bound, and
depleted fractions of PL, FF, and epididymal and ejaculated sperm samples.
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Figure 1.5. Shotgun proteomic workflow used in-house.

1.3.2 Proteolytic Digestion
Proteolytic digestion of intact proteins generates peptides with masses able to be
analyzed by mass spectrometry. Trypsin has become the gold standard for protein
digestion to peptides for shotgun proteomics13, 14 and is used in this dissertation. Trypsin
cleaves the carboxyl side of arginine and lysine. This sequence specific information is
utilized in the identification of peptides and proteins during database search on LCMS/MS data. Apart from its high specificity, trypsin is also preferred because it generates
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suitable size peptides (10-15 amino acids residue long) and produces double charged
precursor ions which fragment efficiently in CID12.
1.3.3 Peptide Fractionation
The mixture of peptides from proteolytic digests of protein mixture is often too
complex for current mass spectrometers to deal with all at once despite the recent
progress in mass spectrometry. An optimized peptide fractionation method prior to MS
analysis therefore becomes necessary to increase peak capacity (i.e. the number of peaks
that can be resolved in a unit resolution) and to assure that the number of peptides that
simultaneously enter the mass spectrometer stays within analyzable limits. This will
enable more proteins to be identified and quantified22. Among peptide fractionation
methods, liquid chromatography (LC) is often a method of choice because differences in
charge and hydrophobicity of peptides can be exploited to assure high resolution of
peptides. Adequate resolution of peptides of similar masses is crucial for obtaining
distinct no-mixed fragmentation spectra. LC is also commonly used because of its
amenability to mass spectrometry, high throughput, and sensitivity. Coupling nanoelectrospray to reverse-phase nanoflow liquid chromatography (RPnLC) has been shown
to give the largest gain in sensitivity from peptide separation14, 22. Typically, one or more
chromatographic techniques, such as strong cation exchange (SCX) or hydrophilic
interaction chromatography (HILIC), are coupled to RPnLC to further enhance peptide
separations. Multidimensional liquid chromatography techniques are now routinely being
coupled to tandem mass spectrometry to provide a robust method to identify proteins in
complex mixtures.
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Strong-cation exchange-reversed phase (SCX-RP), HILIC-RP, and RP-RP 2D
systems have been shown to provide suitable orthogonality, i.e. the separation properties
in first dimension do not affect that in the second dimension22. Orthogonality is crucial
for maximizing peak capacity. The SCX-RP has become a popular method in shotgun
proteomics, known as multidimensional protein identification technology (MudPIT)23,
due to high sensitivity resulting from the high capacity of strong cation-exchange (SCX)
resin and the high resolution of SCX and RP24. In SCX, peptides are displaced from the
SCX resin by increasing salt concentration. Each collected fraction is then loaded onto a
RP column where it is separated using an organic gradient. The SCX separation can be
done offline or online in which case the eluted fraction is loaded directly onto the RP
column. SCX-RP was successfully used in this dissertation.
1.3.4 Protein identification
Proteins identification with mass spectroscopy is commonly by database search
via a number of approaches. Peptide mass fingerprint or peptide mass map analysis
approaches25 involve determining the masses of experimental peptides derived from
proteolytic digests of the proteins. Proteins are then identified based on comparison of the
experimental masses with theoretical masses of peptides produced in silico by digestion
of sequences in a target database by the same digestion enzyme as used in the
experiment. Because peptide mass fingerprinting basically requires purified target
protein, prior fractionation of proteins is necessary and often 1D and 2-D gel
electrophoresis is used.
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Protein identification using MS/MS data offer greater degree of specificity than
peptide mass fingerprinting as it combines fragment ion patterns with peptide masses.
This approach is more suitable for analysis of complex mixtures and is steadily replacing
peptide mass fingerprinting. It involves scanning the product ion spectra against
comprehensive protein sequence databases using one of a number of different algorithms.
The ‘peptide sequence tag’ approach extracts a short, unambiguous amino acid sequence
from the peak pattern that, when combined with the mass information, is a specific probe
to determine the origin of the peptide. A common approach is to calculate a score based
on comparison of calculated fragments from peptides sequences in the database with
observed peaks. The calculated score reflects the statistical significance of the match
between the spectrum and the sequences contained in a database. In another approach
called the cross-correlation method, the search algorithm uses peptide sequences in the
database to construct theoretical mass spectra and the overlap or ‘cross-correlation’
(known as xcorr) of these predicted spectra with the measured mass spectra determines
the best match2, 13. The xcorr value is thus a statistical measure of the extent of correlation
between measured and theoretical fragment spectra and shows the peptide sequence with
the best match or score.
The cross-correlation approach is used in one of the most popular peak-finding
search engine, SEQUESTTM (Thermo-Fisher Scientific). This work utilized SEQUEST
embedded in Proteome Discoverer (Thermo-Fisher Scientific) and searched the bovine
protein FASTA database. The Proteome Discoverer application extracts relevant MS/MS
spectra from the raw file and determines the precursor charge state and the quality of the
fragmentation spectrum. SEQUEST searches the raw data and generates a peak list and
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relative abundances. The peaks represent the fragments of peptides for a given mass and
charge. SEQUEST then used the cross-correlation scoring system and assigns xcorr
values for peptide candidates. To help increase confidence and validate protein
identifications, the Proteome Discoverer application also uses a probability-based scoring
system to independently rate the relevance of the best matches identified by the
SEQUEST algorithm. The output of this is the false discovery rates (FDRs) or false
positive rates values. FDR value estimates the number of false positive identifications
among all identifications found by a peptide identification search. Determination of FDR
involves searching spectra against a database of decoy (fake) peptides, typically derived
from digesting in silico the inverted or scrambled sequences of expected proteins.
As discussed above, the bulk of proteomic data is generated by database search
using search algorithms. All search engines allow for the setting of a number of variables
such as molecular mass range, polarity, precursor mass tolerance, fragment mass
tolerance, scan type, activation type, proteolytic enzyme used and the maximum allowed
missed cleavage sites by the enzyme, number of charges, maximum number of peptides
considered for a peptide match, maximum protein references per peptide, type of
fragment ion (e.g. b- and y- ions), and possible modifications (either static or dynamic) to
certain residues such as alkylation of cysteine, oxidation of methionine or
phosphorylation of residues including serine, threonine and tyrosine. Search parameters
for database search should be chosen carefully and some parameters such as precursor
and fragment mass tolerance may need to be optimized to generate relevant data.
Summary of search parameters used in this dissertation are stated at the relevant sections.
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1.3.5 Quantitative Proteomics
Protein quantitative data is important for modeling the cellular and metabolic
response of an organism and also help in the designing of inhibitors for specific target in
disease conditions26. Methods for protein quantification by mass spectrometry can be
grouped into two: label-free methods and stable isotope labeling methods. In either
quantitation approach, protein quantity can be estimated by measuring of peptide
quantities.
Label-free methods for quantitation are often used when the introduction of stable
isotopes is impractical (e.g., in many animal studies) or the cost is prohibitive. In labelfree quantitation workflows11, 27 usually the peptide ion peaks or peptide fragment ion(s)
are integrated and used as a measure of quantity. The absolute quantity can be calculated
using a standard curve. Quantitation using fragment ions (as in multiple reaction
monitoring; MRM) is more specific as it requires the masses of the precursor ion and the
fragment ions to be close to the predicted masses. Also, because peptides fragment in a
sequence specific manner, it requires that the relative intensities of the fragment ions do
not deviate from the expected intensities which increase specificity.
Other label free quantitation methods not based on peak integration involves
searching the fragment mass spectra against a protein-sequence collection and
quantitation is subsequently attained using a number of approaches. These include i)
Spectra counting where the number of different fragment spectra that identifies peptides
derived from a given protein is used as a measure of protein quantity. This method is
based on the rationale that peptides from more abundant proteins will be more selected
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for fragmentation and will thus produce a higher number of MS/MS spectra. ii) Calculate
exponentially modified protein abundance index (emPAI), a measure based on the
number of identified peptides of a protein. emPAI is based on the fact that generally more
peptides are detected for larger proteins and is directly proportional to the protein content
in the sample. Label-free quantitation not based on peak integration is generally less
accurate when a small fraction of fragment spectra or peptide is observed for a given
protein11, 27.
To compare samples quantitatively in label-free proteomic workflows, LCMS/MS analysis is performed on each sample separately and the calculated peptides and
proteins quantities in the different samples are compared. Label-free methods are
therefore susceptible to variations in time-instrument response due to the lack of
multiplexity. High reproducibility in sample preparation, high reproducibility of
chromatographic separation, the exact alignment of chromatograms from different
samples, the use of high-scanning rate, high resolution power of the MS, and highly
accurate mass measurement are thus prerequisite for statistical significant results11. The
high-reproducibility requirements in label-free quantitation can put restraints on
prefractionation. Also, analysis time can be greatly increased when the number of
samples to be analyzed is large due to the lack of multiplexity.
Labeling methods involving the use of stable isotopes can be classified into two
main groups: chemical labeling and metabolic labeling. Labeling strategies are based on
the fact that both labeled and unlabeled peptides exhibit the same chromatographic and
ionization properties but can be distinguished from each other by a signature mass-shift11.
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Introduction of labels can help optimize reproducibility of the proteomic workflow. In
metabolic labeling, the label is introduced to the whole-cell organism through the growth
medium. Metabolic labeling therefore provides the earliest possible introduction of
stable-isotope labels into the sample but is not always feasible and can be costly and
time-consuming particularly when applied to the study of complex organisms. Available
metabolic labeling approaches include Stable Isotopic Labeling with Amino Acids in Cell
Culture (SILAC) and 14N/15N Labeling22.
In chemical labeling, proteins or peptides are tagged with the label through a
chemical reaction. Available chemical labeling approaches include Isotope-Coded
Affinity Tags (ICAT), Tandem Mass Tag (TMT), Isotope-Coded Protein Labelling
(ICPL), and Isobaric Tags for Relative and Absolute Quantification (iTRAQ). The
different chemical-labeling approaches differ in the site of reaction, the mechanism of
reaction and the method of quantitation under the mass spectrometer platform11, 22. TMT
share similar characteristics with iTRAQ but the number of identified peptides and
proteins are higher with iTRAQ (4-plex or 8-plex) than TMT 6-plex28, 29. The iTRAQ
technology was used in this dissertation and is thus further discussed.
1.3.5.1 iTRAQ Labeling
iTRAQ is a popular chemical-labeling technique that allows four to eight samples
to be multiplexed in a single run. The iTRAQ technique is a form of isotope labeling in
which the tags are isobaric in nature. The tags contain a peptide reactive group Nhydroxysuccinimide (NHS) ester derivative, a balancer group (carbonyl group), and a
reporter group (based on N-methylpiperazine). For 4-plex reagent, the reporter groups of
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masses 114.1, 115.1, 116.1 and117.1 Da are balanced by corresponding 28, 29, 30 and 31
balancer group to give a total constant mass of 145.1 Da (Figure 1.6). 8-plex reagent has
four additional reporter groups of masses 113.1, 118.1, 119.1, and 121.1 and
corresponding balance masses of all eight reporter masses range is 192-184 Da, giving a
total constant mass of 305.1Da26, 30. The different masses of the reporter groups and
balancer group are achieved by using combinations of 13C, 14N and 18O isotopes. The
iTRAQ derivatization is achieved by reaction of the NHS ester derivative with the Nterminus and ɛ-amino group of the lysine side-chains to form an amide bond. This makes
it possible to label all peptides in a sample.
The iTRAQ protocol often involves reducing, alkylating, and digesting proteins in
individual samples prior to iTRAQ labeling. Reduction and alkylation blocks any
possible reaction of the reagent with cysteine residues. Digested peptides of a sample are
then labeled with an iTRAQ reagent at room temperature and the individual-labeled
samples are mixed together in 1:1 ratio. Often iTRAQ-labeled peptides are separated by
performing strong cation exchange (SCX) followed by reverse-phase liquid
chromatography.
Quantitation with iTRAQ has several advantages over other chemical labeling
techniques. Because the tags are isobaric, individual differentially labeled peptides at a
given m/z elute as a single combined peak in MS, which greatly enhance the signal. This
is an important contrast to non-isobaric labeling techniques such as ICAT in which the
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Figure 1.6. Multiplex quantitation using 4-plex iTRAQ reagent. Shown in Ross et al31.
(A) Structure of 4-plex iTRAQ reagent; (B) Combination of isotopic enrichments used to
achieve constant mass (145.1 Da) for each of the four reagents; (C) Illustration of using
4-plex reagents in an LC-MS/MS experiment.

MS (precursor) signal is split due to mass shift and results in decreased signal. Also,
there is less complexity of the MS spectra, a benefit arising from the same mass of
labeled peptides. At the MS/MS stage, balancer group is loss via neutral loss and the
reporter ion which retains a charge is released and observed in the low mass region of the
MS/MS spectrum. All other fragment ions remain isobaric, and their individual signal
intensities are additive which also increases sensitivity at the MS/MS level26, 30. Figure
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1.7 is an example of the reporter region in MS/MS spectrum observed for a peptide from
a protein digest in our lab.
Because of the multiplexing nature of the iTRAQ tags, variation in time
instrument response is eliminated. Additional benefit of iTRAQ technology is that
proteins can be identified by their signature peptides and fragment ions via database
search using appropriate algorithm in a parallel workflow. The quantification and
identification data are emerged using appropriate algorithm e.g. Proteome Discover,
ProteinPilot, and i-Tracker26. Protein-identification search parameters for iTRAQ labeled
peptides include indicating iTRAQ as a fixed modification at the N-terminal and ɛ-amino
group of lysine residues and iTRAQ as a variable modification at tyrosine residues.
The peak intensities or areas of the reporter ions of different masses are used to
calculate the relative quantities of peptides of proteins. More than one spectrum can be
obtained for a single peptide due to the peptide having more charge states and
corresponding different m/z and retention times. Additionally, this could be because the
peptide has better ionization efficiency and is more abundant. Therefore more than one
peptide ratio and error can be calculated for a single peptide. Spectra ratios are calculated
often using the lowest reporter ion as the reference (114.1 in 4plex or 113.1 in 8 plex
experiment). Spectra ratios corresponding to the same peptide are merged by i) taking the
average of all the representing spectra ratios or the median to represent the peptide or ii)
scoring the spectra and the spectrum that most defines a given peptide is chosen to
represent the peptide. The average (or weighted average) or median of the calculated
peptide ratios of an identified protein is taken to represent the relative quantity of that
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protein. Absolute quantification with iTRAQ can be achieved by labeling a reference
peptide belonging to the protein with one of the iTRAQ reagent and upon mixing with
the other iTRAQ labeled samples and subsequent MS analysis, the intensity or area of the
reporter ion of the reference peptide is used to calculate the absolute value.

A

B

Figure 1.7. Exemplary MS/MS spectrum of an electrospray ionized peptide
fragmented by pulsed q collision induced dissociation (PQD) in Finnigan LTQ.
iTRAQ reporter ions (arrows) in low mass region in A is zoomed in and shown in
B. Reporter ions 114, 115, 116 and 117 are observed.
1.4 Applications of Proteomics in Reproduction Research in Bovine
Mass spectrometry-based proteomics is continuing to provide insights into several
biological systems in human and several species. An important area of its application is

25

molecular research in reproduction. The potential benefits from this area of research are
enormous and include uncovering and broadening the understanding of a variety of
molecular events in reproductive important tissues such as testis, ovary, endometrium,
oviduct, and placenta as well as gametes and embryos; improved understanding of the
effects of reproductive toxicants particularly disease states (e.g. polycystic ovary
syndrome (PCOS), infertility, subfertility, endometrial disorders, and miscarriage) or
hormones and cytokines; and identification of potential protein biomarkers and/or
treatment targets for successful reproduction and fertility interventions32, 33. While
significant proteomic research has been dedicated to human reproduction and fertility33,
very few have focused on that of other species including bovine. A significant contributor
to this drawback is the lack of available comprehensive sequence database for protein
identification in these species. Also, in bovine, established traditional methods for
assessing and improving reproduction and fertility remain the standard practices among
farmers.
Cow-reproductive performance (fertility) is very important as it defines the
attained biological and economic benefits. Traditionally, cow productivity, i.e. the
number of calves produced per lifetime or per unit land area is estimated by a number of
factors including age at first calving, calving (fertility rate), calving interval, number of
services per conception (NSC), age at puberty, and nutrition34. First calving marks the
beginning of a cow's productive life and age at first calving is closely related to
generation interval (the average age of parents at birth of their offspring that in turn will
produce the next generation of breeding animals). Late first calving has been associated
with increasing longer calving intervals. Also, NSC has also been reported to increase in
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increasing age at first calving. In general, earlier first calving increases lifetime
productivity of cows. The commonest estimate of fertility rate is the percentage of mated
or inseminated cows that become pregnant (pregnancy rate) or finally calve (calving
rate). Fertility rates can also be estimated prior to calving as the percentage non-return
rate. This is the number of cows bred that do not come back in heat and are thus assumed
to have conceived. Differences in calving rate between years have been associated with
the quality and quantity of available forage. Calving interval is probably the best index of
a cattle herd's reproductive efficiency. Calving interval is the amount of time (days or
months) between the birth of a calf and the birth of a subsequent calf, both from the same
cow. Calving interval is estimated to be affected by factors such as genetics, age, sex of
the calf, suckling duration, and feeding after calving. Calving interval decreases with
shorter suckling duration, high feeding after calving, and having female calves instead of
males at calving. The shorter calving interval with female calves is attributed to shorter
suckling duration with females than males. Shortest calving interval is observed with
cows of intermediate age (6-9 years) compared to young age (3-6 years) and old age (1216 years). Effective recognition, measurements and management of the reproductive
estimates is essential to the productivity of the cow. Artificial insemination (AI) is a
common practice also used to increase pregnancy rate and cow productivity. In this
respect, accurate detection of oestrus is essential for achieving high pregnancy rate.
Although these traditional reproductive estimates are still being practiced, it is
increasing being recognized that the application of proteomics can provide parallel
information that will enhance reproduction in cattle. Proteomic application potential
benefits include identification of biomarkers (i) predictive of early pregnancy detection,

27

fetus, and maternal survival35, 36; (ii) for evaluation and selection of quality sperm,
oocyte, and embryo37, 38; (iii) monitoring of genetic/physiological and environmental
causal diseases affecting reproduction; and (iv) suitable for use as treatment targets for
successful artificial insemination, pregnancy, and offspring. Accordingly, a number of
studies have been conducted39-43.
Folliculogenesis is the process in which recruited primordial follicle grows and
undergoes stages from primary, secondary, tertiary (pre antral follicle and mid-antral
follicle), dominant to ovulatory follicle with the potential to ovulate its oocyte to be
fertilized or die by atresia44. Follicular fluid (FF) accumulates into the follicle antrum
starting with the early stage of follicle development and becomes the natural environment
of the developing oocyte (Figure 1.8). FF consists of a wide variety of dynamically
changing proteins responsible for growth and development that ultimately affect the
quality and fertilization potential of the oocyte. Therefore, FF is a useful substrate for
proteomic reproduction and fertility research. Moreover, FF is an easily accessible
biological fluid as it is aspirated in abundance from follicles33.
Ferrazza et al.40 recently investigated protein expression profile of bovine FF at
key stages of follicular development. The group identified a total of 143 proteins, twentytwo of which were differentially expressed between stages indicating intrafollicular
changes over development. The group also found that the complement and coagulation
systems, acute-phase response signaling, liver/retinoid X receptor activation, and
biosynthesis of nitric oxide and reactive oxygen were the most significant pathways
associated with the proteins. Another group investigated the effect of bovine FF proteins
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and their acidic and basic groups as maturation media supplements for in vitro embryo
development. They found oocyte maturation rate, the development to the blastocyst stage
rate, and blastocyst cell number were not significantly differing in 10% bovine FF
supplemented in vitro maturation (IVM) medium and controls (supplemented with fetal
bovine serum and hormones). However, inteferon tau (INFτ) and insulin-like growth
factor-2-receptor (IGF-2r) expression levels in the 10% bFF were significantly higher
than in the control. Supplementing the IVM medium with basic bovine FF protein
fraction resulted in significantly higher oocyte maturation rate and blastocyst cell number
and greater expression levels for almost all developmentally important genes, especially
INFτ and HSP70 when compared to supplementing with acidic fraction. INFτ is the
primary factor responsible for maternal recognition of bovine pregnancy45. Binding of
IGF-2r to the growth factor enable pathway for the growth factor regulation of fetal
growth46, 47. The upregulation of both proteins shows the importance of FF proteins in
the establishment of pregnancy and fetal growth. Proteomic approach was also used to
identify eight differentially expressed proteins in FF from preovulatory follicles of less
fertile cows that are important to follicular function48.
These studies show the potential of proteomic analysis of FF to provide better
insights into key factors involved in folliculogenesis, establishment of pregnancy, embryo
development, and the identification of therapeutic targets in bovine. The applications of
the outcomes of such research stand to improve the productivity of the cow. In this
dissertation, proteomic analysis of bovine FF and plasma (PL) was performed and the
effect of high and low estradiol (E2) on protein expressions during the preovulatory stage
was investigated. Detail of this work is discussed in Chapter 3.
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Figure 1.8. Schematic picture of an ovarian antral follicle in mono-ovulant species.
Shown in Fahiminiya et al49

1.5 Atherosclerosis
Atherosclerosis is a multifactorial progressive disease characterized by the
narrowing and hardening of arteries caused mainly by build-up of cholesterol, lipids,
cellular debris, and calcium to form plaque in the intima of large- and medium-sized
arteries50. The plaque formation and subsequent narrowing and hardening of the arteries
result in chronic luminal obstruction, abnormalities of blood flow, and diminished oxygen
supply to target organs51. Complications of atherosclerosis lead to coronary artery disease
(CAD; heart attack), cerebrovascular disease (CeVD; stroke), and diseases of the aorta and
arteries, including peripheral vascular diseases (PVD) and hypertension. Globally, CAD
and CeVD are the leading causes of cardiovascular deaths50. Risk factors for
atherosclerosis include diabetes mellitus, obesity, hypertension, tobacco use, harmful use
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of alcohol, high levels of low density lipoprotein (LDL) cholesterol, low level of high
density lipoprotein (HDL) cholesterol, advancing age, male gender, unhealthy diet (rich in
salt, fat and calories), psychological factors, physical inactivity, poverty, low education
status, and family history of premature CAD50, 52.
Atherosclerosis is viewed as an inflammatory disease53,
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with initial events

involving dysfunction of the endothelium (lining of the artery)55, 56. Endothelia injury is
initiated by a variety of events/substances including dyslipidemia (particularly high levels
of LDL cholesterol), hypertension, infection, presence of free radicals, and low shear stress.
The damaged endothelium allows migration of lymphocytes, monocyte, and lipids,
particularly LDL cholesterol, into the arterial intima. Dysfunction of the endothelium also
promotes expression of cellular adhesion molecules ICAMs (e.g. ICAM-1), vascular cell
adhesion molecules (VCAMs) (e.g. VCAM-1), chemokines, and selectins such as P- and
E selectin. These processes are partially mediated by nuclear factor κB (NF-κB), one of the
transcriptional controllers in vascular inflammation and an integrator in atherogenesis55-57.
Leucocytes and monocytes adhere to the endothelium via VCAM-1 binding and enter the
intima by diapedesis between endothelial cells at their junctions. This process is mediated
through chemokines, such as monocyte chemoattractant protein 1 (MCP-1) and IL-8 as
leukocyte chemoattractant. LDL cholesterol, upon migration into the arterial intima
undergoes oxidation to become oxidized LDL (OxLDL) which are subsequently engulfed
by monocyte-derived macrophages via receptors such as scavenger receptor A (SR-A) and
CD36. A lipid laden macrophage is called a foam cell and is the first type of atherosclerotic
lesion55 (Figure 1.9). The monocytes/macrophages promote the local inflammatory
response secreting cytokines, degrading enzymes [(matrix metalloproteinases (MMPs)] as
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well as growth factors that stimulate smooth-muscle cell (SMC) migration from the media
(deeper layer of the artery) into the site of plaque formation and SMC proliferation. As the
atherosclerosis development continues, a fibrous cap consisting of smooth muscle cells and
collagen forms. Also, the necrotic lipid core is formed when macrophages involved in the
initial reaction begin to die and accumulate and a fibrous cap is formed around the lesion
location. The atherosclerotic lesion (atheromatous plaque) enlarges as cells and lipids
accumulate. The enlarging lesion causes the inner surface of the artery to become irregular
and also bulges into the arterial lumen resulting in narrowing of the lumen. These make it
harder for blood to flow through the artery, resulting in the artery becoming less pliable50,
55

.
The continuous influx of cells into the sub-intimal space elicits chronic

inflammatory response by the adaptive immune system. Also, the microenvironment of the
plaque could elicit adaptive immune response which in such case is coordinated by
lymphocytes rather than macrophages. The selective recruitment and activation of Thelper type 1 (Th1) T lymphocytes represents a key point in the transition from stable
plaque to unstable plaque. In particular, selective recruitment of Th1 T lymphocytes
promotes plaque destabilization/disruption

eliciting vascular inflammation and

downregulating extracellular matrix production by SMCs. Other contributors to the
thinning of the fibrous cap resulting in plaque rapture include activated macrophage
secreted procoagulant proteins and MMPs proteases that can degrade collagen, interferon
(IFN)-γ that strongly inhibit the proliferation of SMCs and the production of interstitial
collagens by vascular SMCs, and ligation of CD40 (expressed by macrophages) which
increases the production of matrix-degrading proteases. Thinning of the fibrous cap and
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subsequent rapture of the plaque releases lipid fragments and cellular debris into the vessel
lumen. Of importance is the exposure of procoagulant factors expressed within lesions to
circulating clotting factors initiating the coagulation cascade responsible for thrombosis. If
the thrombus develops in a coronary artery it can cause heart attack and if it develops in
the cerebral (brain) artery, it can cause stroke50, 55.
Six types of atherosclerotic lesions have been identified, and are differentiated by
morphological features and clinical significance58-60. Types I to III lesions (early types) are
usually clinically silent whereas types IV-VI lesions (advanced forms) are often associated
with the symptoms and complications of the disease61. Description of these lesions is
discussed in section 4.4.4 of Chapter 4.

Figure 1.9. Atherosclerotic plaque development. The numbering and arrows indicate
events leading to plaque development.
(http://www.resverlogix.com/product_development/nexvas_platform/nexvas_vascular_inflammation.html)
Shown in Glaudemans et al, 201055
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1.6 The Apolipoprotein E Knock-Out (ApoE-/-) Mouse Model of Atherosclerosis
Mice are the most popular experimental animals because of their small size, wide
availability, easy of genetic manipulation, short generation time allowing less time
duration for research projects and the relatively low cost in feeding and housing
compared to other experimental animals62, 63. Wild-type mice however have a different
serum-lipid profile of elevated levels of HDL in contrast to elevated levels of LDL in
humans which makes it resistant to developing atherosclerosis unless on a high-saturated
fat and cholesterol diet for prolonged periods. The C57BL/6 wild-type mouse strain was
found to be the most susceptible on such diet but only developed early types of lesions
which were not comparable to that found in humans64. This presented a need for a more
efficient mouse model for studying atherosclerosis.
Among the available mice-atherosclerosis models, the apolipoprotien E knock-out
(ApoE-/-) mouse model65, 66 is popular because of its susceptibility to spontaneously
develop atherosclerotic lesions in a progressive manner and with lesion morphological
features observed in humans63, 67. The ApoE-/- mouse model is based on the function of
apolipoprotein E (ApoE) protein. ApoE is a glycoprotein synthesized in the liver, brain,
and by monocytes and macrophages in vessels. It is a constituent of all lipoproteins
except low-density lipoprotein (LDL). It mediates the cellular uptake of several different
lipoproteins, most notably, cholesterol, atherogenic triglycerides, and very low-density
lipoproteins (VLDL). It also functions in biliary excretion of cholesterol63, 68, 69. Deletion
of the apoE gene thus dramatically increases the serum cholesterol levels mostly in the
form of VLDL remnants and chylomicrons and makes it susceptible to developing
atherosclerotic lesions. The atherogenic process is accelerated when on a high saturated
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fat and cholesterol diet65, 66. Because C57BL/6 mouse strain is more susceptible in
developing atherosclerosis64, 70, it is often the background for ApoE-/- mice71.
The ApoE-/- atherosclerotic model allows for studies on lesion size and
composition and the identification of possible therapeutic targets; nutritional
interventions aimed at the effects of changes in micro- and macronutrients on lesion size
and on atherosclerotic cells/molecules (e.g. monocytes, macrophages, oxLDL) or
mechanisms (e.g. LDL oxidation, uptake of oxLDL by macrophages); the effects of
therapeutic agents on atherosclerotic molecules, lesions, and events; and the genes related
to atherosclerosis62, 63, 68.
1.7 Lesion Analysis in Mice
Atherosclerotic studies in mice often involve estimating the extent of lesions by
histological methods. Two methods widely used are the en face method72 and the serial
cross section method73. The en face method involves removing the entire aorta and
opening it longitudinally to expose the intimal surface by dissecting from the heart to the
iliac arteries. The primary incision follows the ventral side of the aorta and the inner
curvature of the aortic arch. A second incision is made along the outer curvature of the
aortic arch to the subclavian branch to obtain a flat tissue for imaging. Minor branches
are cut off and the aorta, from the heart to approximately 3mm distal to the iliac
bifurcation, is pinned out on a black surface using 0.2mm diameter stainless steel pins.
Staining with, e.g., Sudan IV is performed to enable visualization of lipid-laden lesions
and measurement of lesion surface areas. Lesion area is usually represented as a percent
of the total intimal surface that is covered by atherosclerotic lesions. The en face is a
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rapid method that provides a two-dimensional assessment of lesion size on the entire
aorta but is limited in the assessment of lesion thickness71, 72.
The serial cross-sectioning method involves sequential sectioning of the heart and
the aortic root onto histological slides and subsequent histopathological analysis
including staining (e.g. oil red O) and image analysis by appropriate software is used to
examine and quantify lesions. Analysis of the aortic sinus region requires serial
sectioning 400µm total area starting from the appearance of the aortic sinus cusps and
spanning distal towards the ostia of the coronary arteries. Histological analysis of the
aortic root and the ascending aorta requires serial sectioning spanning about 900µm
stretch of the aortic root60, 73, 74. The serial cross-sectioning method, although labor and
time consuming, enables examination of lesion thickness and composition.
Atherosclerosis studies with the ApoE-/- mouse model have enabled the
identification of predilection sites (Figure 1.10) of atherosclerosis development in mice67,
75

which include the aortic root, carotid arteries, lesser curvature of the aortic arch,

pulmonary artery and the principal branches of the thoracic aorta. These predilection sites
have been the focus for probing of the disease. Of these, the quantification of the aortic
root is considered the standard in many laboratories due to the high susceptibility of this
site to atherosclerosis in mice and lesions develop in mice at earlier age than the other
predilection sites. Also, the aortic sinus cups serve as an anatomical landmark to keep the
area under study constant76. This dissertation characterized and quantified lesions in the
aortic root of ApoE-/- mice at different ages using the serial cross sectioning method and
this is discussed in detailed in Chapter 4.
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1.8 Proteomic in Atherosclerosis Biomarker Discovery
Although clinical assessments remain the primary tool for atherosclerosis and
associated cardiovascular disease management, they pose limitations particularly in
predicting individual risk and risk of recurrence77. A biomarker is defined as “a
characteristic that is objectively measured and evaluated as an indicator of normal
biological processes or pharmacologic responses to a therapeutic intervention”78.
Identification and measurements of atherosclerosis biomarkers, which were originally
introduced to improve existing clinical assessments and to enable the identification

Figure 1.10. Predilection sites of atherosclerosis development on the aorta and
pulmonary arteries of ApoE-/- mice. Predilection sites are shaded black. 1. Aortic root; 2.
Lesser curvature of the aortic arch; 3. Principal branches of the thoracic aorta; 4. Carotid
arteries; 5. Principal branches of the abdominal aorta; 6. Aortic bifurcation; 7. Iliac
artery; and 8. Pulmonary arteries (From Nakashima et al.,67)
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of vulnerable patients79 continue to hold great promise. A suitable biomarker would have
the advantage of identifying high risk individuals, accurately and quickly diagnose
disease conditions and effectively predict and treat patients with the disease79.
Mass-spectrometry-based proteomics technologies are powerful tools that can be
employed in the search for novel biomarkers for atherosclerosis and related diseases due
to the ability of such technologies to identify thousands of proteins in a single
experiment. By these methodologies, several biomarker candidates have been identified.
A comprehensive list compiled by de la Cuesta et al, 201580 include fibrinogen fragment
D, annexins (e.g. A4, A5, A10), cathepsin D, alpha 2 macroglobulin, S100 proteins,
myeloperoxidase (MPO), gelatinase, matrix metalloproteinases (e.g. MMP-3, MMP-9),
vinculin, apo B100, thrombospondin-2 (TSP-2), manganese-dependent superoxide
dismutase (MnSOD), and caspase-9 as potential markers of atherosclerosis; death-inducer
obliterator 1 (DIDO 1), fibrinogen, cardiac troponin I and T ( cTnI, cTnT), inosine, alpha
2 macroglobulin, and serine as potential biomarker for myocardial infarction; haptoglobin
(hp) and serum amyloid A (SAA) as candidate markers for ischemic stroke; proline,
arginine, alanine, ornithine, creatinine, and trimethylamine N-oxide (TMAO) as potential
markers for coronary artery diseases (CAD).
Many of the candidate biomarkers have however not been incorporated into
clinical assessments mainly because they fail to meet all the requirements of a true
biomarker. Protein biomarkers that have been incorporated into clinical assessments such
as oxidized low-density lipoprotein (oxLDL), C-reactive protein, fibrinogen, lipoproteinassociated phospholipase A2 (Lp-PLA2), Lp(a), osteopontin (OPN), osteoprotegerin
(OPG), .MMP-3, MMP-9, myeloperoxidase (MPO) , homocysteine, cardiac troponin I
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and T ( cTnI, cTnT), and tissue factor (TF)80, 81 have however not been able to predict
individual risk above that achieved by the traditional risk factors. Therefore, there is still
an urgent need to find true and useful biomarkers that can identify vulnerable patients and
guide treatment development81.
Circulating blood is the most used sample in proteomic atherosclerotic biomarker
discovery studies probably because of the ease and convenience of sampling82. Other
proteomic samples include urine83, circulating cells extracted from plasma/serum such as
monocytes, platelets and leukocytes, plasma extracellular vesicles such as exosomes and
microvesicles and tissues like carotid artery81, 84, 85. In using the ApoE-/- mice in
atherosclerosis studies, blood and urine samples collected can be viable source for
proteomic work86. Proteomics on blood and tissues from these mice has the benefit of
providing insights into the molecular mechanisms associated with the disease. The
availability of tissues from mice for proteomic work is particularly advantageous since
obtaining similar sufficient tissues from humans is difficult, especially in considering
control samples for comparative analyses80.
Although mice can be a good source for proteomic work, their small size can limit
the amount of samples collected and this should be considered in the experimental design
of such studies. Potential atherosclerotic biomarkers can be determined by comparing the
data generated from ApoE-/- samples to that from control group of the study. A correlation
analysis can also be performed between identified proteins from the proteomic analysis
and lesion components, morphology or size.
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The ApoE-/- mouse model is used in this dissertation to study lesion types and
patterns with factors such as age and also make available blood and tissue samples for
proteomic analysis for biomarkers of atherosclerosis.
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CHAPTER 2
IMMUNODEPLETION OF MULTIPLE HIGH-ABUNDANT PROTEINS
FROM BOVINE FLUIDS
2.1 ABSTRACT
Immunodepletion of high-abundant proteins (HAPs) aids in the identification and
analysis of low-abundant proteins (LAPs) in complex samples. Currently,
immunodepletion methods for bovine samples are very limited whereas greater
availability exists for human and murine animals. In this study, we report the
simultaneous depletion of HAPs from bovine samples using an immunoaffinity depletion
cartridge (the multiple affinity removal system; MARS) designed to target six human
HAPs, while such a depletion kit for bovine samples is not available. Sandwich ELISA
analysis showed 98.7 to 99.9% depletion of albumin, IgG and IgA from bovine plasma,
follicular fluid (FF), ejaculated and epididymis sperm types. A similar percentage is
expected of alpha-1-antitrypsin due to the dramatic removal in its SDS PAGE band
compared to the crude samples. The method has high reproducibility and can be
incorporated into proteomic workflows to increase sensitivity of proteomics analysis of
LAPs in bovine biological fluids.
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2.2 BACKGROUND AND MOTIVATION
Proteomics is a high-throughput approach to study protein expression, structure,
function and post-translational modifications in a cell or tissue. Advancement in
proteomic sample preparation technologies, mass spectrometry instrumentation and
bioinformatics87-89 have increased the application of proteomics to understand various
biological systems. Bovine proteomics i.e. the application of proteomic strategies to
bovine biological samples is an area of increasing interest90. Bovine proteomics potential
benefits are extensive and include identification of biomarkers (i) predictive of early
pregnancy detection, fetus and maternal survival35, 36; (ii) for evaluation of quality sperm,
oocyte and embryo37, 38; (iii) for assessing the quality and safety of meat, milk and dairy
products; and (iv) for detection, diagnosis and monitoring of genetic/physiological and
environmental causal diseases90, 91.
As is characteristic of biological samples, the complexity and wide dynamic range
in protein concentrations found in bovine samples present a challenging step in their
preparation for proteomic analysis92. The wide dynamic range in protein concentrations
results in high abundant proteins (HAPs; 1-100 mg/mL) masking the identification and
characterization of low abundant proteins (LAPs, <100 ng/mL). However, biomarkers of
disease and normal states are most probably of the low abundant types, which make the
ability to characterize these LAPs imperative in proteomic analysis.
To bridge the wide concentration range and reduce sample complexity, proteomic
workflows often incorporate fractionation method(s). Immunodepletion is a popular
fractionation method due to its simplicity, specificity and reliability. Immunodepletion
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method involves using antibodies to remove target HAPs with subsequent enhanced
detection of LAPs. Immunodepletion of HAPs allows for loading of LAPs at higher
concentrations for improved visualization by one-dimensional (1-D) or two-dimensional
(2-D) gel electrophoresis and liquid chromatography (LC) and increase the sensitivity of
proteomics analyses19. The reliability of the immunodepletion method has led to
advancement in immunodepletion technologies including commercialized kits for
humans19 and murine biological samples93, 94. However, a method for immunodepletion
of HAPs in samples from other species, including bovine, is very limited.
In the absence of available immunodepletion technology, the majority of
proteomic analysis of bovine biological samples have used gel-based 2-D gel
electrophoresis and modified forms of 2-DE such as 2-D fluorescence differential gel
electrophoresis (2D-DIGE) followed by mass spectrometry analysis36, 43, 95-97. However,
incorporating immunodepletion of HAPs will enhance the gel-based approach and also
decrease the number of fractionation steps often employed in shotgun proteomic analysis.
Faulkner et al18 presented separate depletion methods for albumin and IgG, the two top
abundant proteins in bovine plasma. However, combinations of depletions each targeting
an abundant protein increase analysis time and can result in sample loss and
contamination. Sequential depletions can also result in a decrease in the number of
uniquely identified peptides98.
2.3 OBJECTIVE OF STUDY
The objective of this study was to develop an efficient and reproducible
immunodepletion method for simultaneous removal of HAPs in bovine fluids. We
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employed the high capacity multiple affinity removal system (MARS) originally
designed to target six HAPs- albumin, Ig G, IgA, transferrin, alpha-1-antitrypsin, and
haptoglobin (hp) in human biological fluids while a similar technology for bovine is not
available. The six target HAPs represent 85-90% of the total protein mass in human
serum. The MARS technology has been successfully utilized in many proteomic
applications of human bio-fluids99-102.
2.4 MATERIALS AND METHOD
2.4.1 Chemicals and Reagents
All chemicals and water were of LC/MS grade. Bio-SafeTM G-250 stain,
Tris/glycine/SDS buffer, 2-mercaptoethanol (β-ME), laemmli sample buffer and 4-20%
Criterion™ TGX precast gel were purchased from Bio-Rad Laboratories Inc. (California,
USA). Formic acid, acetonitrile (ACN), triethylammonium bicarbonate (TEAB), and
water were obtained from Fischer Scientific (New Jersey, USA). Ammonium bicarbonate
(ABC) and iodoacetamide were purchased from Acros Organics (New Jersey, USA).
Dithiothreitol (DTT) and TPCK treated trypsin was purchased from Promega (Wisconsin,
USA).
2.4.2 Cows Experimental Design
All procedures were approved by the South Dakota State University Institutional
Animal Care and Use Committee. Samples in the present study were collected from a
previous study to characterize changes in steroidogenic enzymes and FF steroid
concentrations103. Briefly, 32 beef cows were synchronized by injecting with GnRH (100
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mg as 2 mL of Factrel, intramuscularly; Pfizer Animal Health (Madison, NJ, USA) on
day -7 and prostaglandin F2α (PGF2α) (PG; 25 mg as 5 mL of Lutalyse intramuscularly
(Zoetis, Florham Park, NJ, USA) on day 0. Estrus was monitored every 3 h from PG on
day 0 until hour 33 and at slaughter (hour 36 to 42) with the aid of EstroTect (Western
Point, Inc, Apple Valley, MN, USA) estrus detection aids. Ovaries of all cows were
examined on day -7, -4, and 0 by transrectal ultrasonography using an Aloka 500V
ultrasound with a 7.5-MHz linear probe (Aloka,Wallingford, CT, USA) to assess
follicular dynamics and ovulatory response. Ten cows that were determined to initiate a
new follicular wave by day -4 were slaughtered on day 2 (hour 36 to 42) for ovary
collection.
2.4.3 Follicular Fluid (FF) and Blood Samples Collection
Immediately after ovary collection, follicular fluid (FF) was aspirated from
dominant follicles (DF; >10mm diameter) and the GCs were separated from the FF by
centrifugation (1,000 x g for 1 min). The FF was place in RNase Free Tubes (USA
Scientific), snap frozen in liquid nitrogen and stored at -80oC until ready for analysis.
Blood samples were collected at slaughter to provide better comparison to the FF
collected at slaughter. To obtain plasma, blood collected at slaughter was placed in
EDTA vacutainer tubes (Beckman Dickerson) and centrifuged at 1,200 x g for 30 min at
4°C. The plasma supernatant was snap frozen in liquid nitrogen and stored at -80oC until
ready for further analysis.
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2.4.4 Bulls Experimental Design and Sperms Collection
All procedures were approved by the South Dakota State University Institutional
Animal Care and Use Committee. Ejaculated sperm from bulls (n = 9) were collected by
electro-ejaculation weekly for three consecutive weeks. Collected ejaculated sperm on
the second week was centrifuged at 700 x g for 10 minutes to separate the spermatozoa
from the seminal plasma. The seminal plasma fraction was labeled as ‘ejaculated semen
plasma’. The remaining spermatozoa fraction was washed with a high ionic solution104
and vortexed for one minute to remove any proteins attached and then centrifuged at 700
x g for 10 min. The supernatant was labeled as ‘ejaculated sperm proteins’. Following
third sperm collection, bulls were rested for six weeks to allow epididymal reserves to
renormalize. At the end of the resting period, bulls were slaughtered and the testes and
epididymides collected. Collected epididymides were dissected and epididymal fluid and
sperm collected from the cauda section and processed as described for the ejaculated
sperm. The epididymal fluid fraction collected after separation from the epididymal
spermatozoa was labeled as ‘epididymis semen proteins’. The spermatozoa were than
wash as described above and the liquid fraction from washing off proteins on the
epididymal spermatozoa was labeled as ‘epididymis sperm proteins’. All samples were
stored at -80oC.
2.4.5 Depletion of High Abundant Proteins (HAPs)
Depletion of the different bovine fluids (PL, FF, epididymis sperm proteins,
epididymis semen proteins, ejaculated sperm proteins, and ejaculated semen plasma)
were performed using the High Capacity Multiple Affinity Spin Cartridge (MARS Hu-
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6HC) # 5188-5341 (Agilent Technologies, CA, USA). The MARS Hu-6 system contains
polyclonal antibodies designed to remove six HAPs- albumin, IgG, IgA, transferrin, αantitrypsin, and haptoglobin (Hp) in human biological fluids. The depletion was done
with vendor provided buffers. Initial depletions investigated 2, 4, 6, 8, 10, and 12 µL of
bovine plasma and 4, 5, 7, 10, and 12 µL of bovine FF to determine optimal volume for
depletion. Each plasma and FF sample volume was diluted with 1x buffer A, pH 7.4 (#
5185-5987, Agilent Technologies, CA, USA) to achieve a final volume of 200 µL.
Initial quantification of the crude samples showed the sperm samples were
markedly of lower concentration compared to that of plasma or FF and upon depletion
resulted in very low yield. Therefore, to ensure enough proteins is obtained in depleted
samples for downstream analysis depletion volumes were increased to 60 µL for
ejaculated semen plasma and 154 µL each for ejaculated sperm proteins, epididymis
semen proteins and epididymis sperm proteins. For 154 µL depletion volume, 46 µL of
4x buffer A (# 5188-8283, Agilent Technologies, CA, USA) was added to achieve a total
volume of 200 µL. For depletion volume of 60 µL, 94 µL of water was added after
addition of 46 µL of the 4x buffer A to obtain a final volume of 200 µL. The 4x dilution
buffer A was used for the higher depletion volumes of the sperm to ensure similar neutral
pH achieved with the plasma and FF samples using 1x buffer A.
Diluted samples were transferred to 0.22µm spin filters (Corning Incorporated,
NY, USA) and centrifuged at 16 000 x g for one minute. Filtered samples were applied to
the spin cartridge which was previously equilibrated with 4 mL 1x buffer A. Flowthrough (FT) fraction (i.e. depleted fraction) was collected by centrifuging at 100 x g for
1.5 minutes. To ensure optimal recovery of FT, the cartridge was washed twice each with
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400 µL 1x buffer A. Each wash volume was collected by centrifuging for 2.5 minutes at
100 x g. Collected wash volumes were combined with initial collected FT. Bound
fraction were eluted using 2 mL of elution buffer B (#5185-5988, Agilent Technologies,
CA, USA) at a flow rate of about 0.15 mL/min. Non-depleted samples, eluates, FT, and
buffers were stored on ice throughout the experiment period to ensure protein integrity.
Collected FT and eluates were stored at -80oC until ready for analysis.
2.4.6 Coomassie Bradford Assay
Coomassie (Bradford) assay kit, (#23200, Pierce Biotechnology, IL, USA) was
used to determine protein concentrations of bound, depleted and non-depleted samples.
The quantification was done according to manufacturer’s instruction. Bovine serum
albumin, 2 mg/mL (#23209, Thermo Scientific, IL, USA) was used as a standard for
making a calibration curve which covered a concentration range of 0.00-1500 µg/mL.
2.4.7 Sandwich ELISA Analysis
BSA, IgG and IgA concentrations in non-depleted and depleted (FT) samples
were determined using sandwich ELISA assay kits (Bethyl laboratories Inc., TX, USA).
IgG was analyzed with bovine IgG ELISA quantitation set (Cat. No. E10-118), IgA with
bovine IgA ELISA quantitation set (Cat. No. E10-131) and albumin with bovine albumin
ELISA kit (Cat. No. E11-113). Samples were diluted and washed with vendor-provided
buffers. Specific dilution factors used for the different samples are shown in Table 2. All
quantifications were performed according to manufacturer protocols. Briefly, 100 µL of
dilute IgA or IgG Coating Antibody solution was added to each assay well. The wells
were incubated at room temperature for an hour and washed with 1x Wash Buffer. 200
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µL Blocking Solution was added to each well and incubated at room temperature for 30
minutes to block non-specific binding sites. Wells were then washed with 1x Wash
Buffer. Assay wells for determining BSA concentration were obtained pre-coated with
anti-bovine albumin antibody. 100 µL of the diluted FT or non-depleted fractions were
then added to the assay wells with the coated antibodies. After one hour incubation at
room temperature, unbound proteins were washed with 1x Wash Buffer.
In determining IgA or IgG concentrations, 100 µL of horseradish peroxidase
(HRP) conjugated anti-bovine IgA or IgG Detection Antibody solution was added to each
well and incubated at room temperature for an hour to bind to the captured IgA or IgG.
For albumin determination, 100 µL of Albumin Detection Antibody solution and 100 µL
of HRP solution were added stepwise with incubations at room temperature for an hour
after the Detection Antibody addition and for 30 minutes after the HRP solution addition.
Wells were then washed with 1x Wash Buffer. 100 µl of 3,3’,5,5’-Tetramethylbenzidine
(TMB) Substrate Solution was added to each well and incubated in the dark for 15
minutes in IgA or IgG measurements or 30 minutes in albumin measurement to initiate a
calorimetric reaction which was stopped by addition of 100 µL Stop Solution to each
well. Absorbance was measured at 450 nm by Synergy H1 Hybrid Multi-Mode Reader
(BioTek, VT, USA). BSA, IgA and IgG concentrations were derived from calibration
curves of reference standards included in the quantitation kits.
2.4.8 SDS PAGE
Depleted and bound proteins were buffer exchanged into 0.05% TEAB using zeba
spin desalting columns, 7k MWCO (# 89891, Pierce Biotechnology, IL, USA) according
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to manufacturer protocol. Samples were vacuum dried prior to SDS-PAGE analysis.
SDS-PAGE was performed under reducing and non-reducing conditions. Under reducing
conditions, β-ME was diluted 1:20 in laemmli buffer and the resulting solution diluted
twice with water. 15 µL of the prepared sample buffer was added to each vacuum dried
sample. Samples were vortexed, centrifuged and then boiled in a water bath for three
minutes. Boiled samples were quickly loaded onto a pre-cast gel. Non-reducing
conditions excluded the addition of the β-ME and heating step. Equal amounts of 9 or 20
µg of proteins and 5-8 µL of Precision Plus ProteinTM unstained standard, 10-250 kDa
(Bio-Rad Laboratories Inc., CA, USA) was used in the gel runs. Gels were
electrophoresed in Bio-Rad Power PacTM unit using 1x Tris/glycine buffer and at constant
voltage of 150 for 62 minutes. Gel bands were visualized using Coomassie BioSafe G250
stain according to manufacturer instructions. Images were acquired using Proteineer SPII
(Bruker Daltonics) equipped with SP3 Control software.
2.4.9 In-Gel Tryptic Digestion of Coomassie-Stained Gel Bands
Identities of protein-gel bands from bound fractions (HAPs fraction) were
determined using in-gel digestion nano-LC-MS/MS. For in-gel digestion, each gel band
from the bound protein lane was excised with sanitized cutting blade, transferred onto
previously sanitized glass plate and then chopped into pieces. Gel pieces were transferred
to a 0.5mL microcentrifuge tube and washed with 100µL LC/MS-grade water with gentle
vortexing for five minutes. The water was removed and the gel pieces completely
destained by washing with several 100µL portions of 25 mM ammonium bicarbonate
(ABC) in ACN/ water (v/v = 50/50) solution. Destained gel pieces were dehydrated with
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100 µl ACN for 10 minutes and dried in a speed-vac at 4oC for 5 minutes. Reduction was
done with 100 µl of 10 mM DTT at 55oC for 30 minutes.
After removal of reduction solution, alkylation was carried out by addition of 100
µL of freshly prepared 55 mM iodoacetamide and incubating in a dark room for 45
minutes. Gel pieces were washed with 100µL 25 mM ABC solution for 10 minutes,
dehydrated with 100 µL ACN, and dried in speed-vac at 4oC for five minutes. 30 µL of
freshly prepared cold 20 µg/mL TPCK treated trypsin (P/N 4370282; Ab Sciex Pte Ltd,
MA, USA) in 25 mM ABC solution was then added to each sample and incubated on ice
until gel pieces became fully rehydrated and clear. Excess trypsin solution was removed
and the gel pieces were covered with 30 µL 25 mM ABC solution and incubated for 16 h
at 37oC. To extract tryptic peptides, 25 µL of 25 mM ABC solution was added and the
liquid fraction collected. Then 50 µL of ACN was added and incubated for 10 minutes
with slight shaking and the liquid fraction also collected. Finally, 30 µL water and 50 µL
ACN were added stepwise with 10 minutes incubation with shaking in each step and the
liquid fraction also collected. All extracted liquid fractions were combined, frozen for 15
minutes and dried in a speed-vac at 4oC. Dried peptides were stored at -80oC.
2.4.10 Nano-LC-MS/MS
Dried peptides were purified and concentrated with either Pierce® C18 spin
columns (Pierce Biotechnology, IL, USA) or ZipTip C18 tips (Millipore, MA, USA)
based respectively on high intensity or low intensity of coomassie blue stained-gel band
prior to de-staining. Purification was done according to manufacturer protocols. Purified
samples were dried in a speed-vac at 4oC and stored at -80oC until analysis. Protein
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identification was performed with nano-liquid chromatography tandem mass
spectrometry (nanoLC-MS/MS) analysis by using Eksigent nanoLC - Thermo LTQ mass
spectrometer. The dried, purified digest from each interested protein band was brought up
in water/ACN/formic acid (95%5%/0.1%) and then was loaded on IntegraFrit Sample
trap (ProteoPep IITM C18, 300 Å, 5µm , 100 μm × 25 mm New Objective, Inc., Woburn,
MA). The retained peptides were washed isocratically with water premixed with 0.1%
formic acid pumped from channel 1A to remove any excess reagents. The cleaned
peptides were resolved on an analytical column (ProteoPepTM II C18, 300 Å, 5µm, 75 μm
×100 mm, 75 µm tip size, New Objective, Inc., Woburn, MA) with a multistep gradient
of solvent 2A (water premixed with 0.1% formic acid) and solvent 2B (ACN premixed
with 0.1% formic acid) at a flow rate of 200 nL/min. A 90-min or a 240-min gradient was
used for the peptides separation. The 90-min gradient started at 5% solvent B and was
held for 5 minutes, then linearly increased to 40% solvent B at 55 min and to 95% solvent
B at 65 min and finally held at 95% solvent B for 5 min before allowing to return to
initial 5% solvent B at 73 min. Column re-equilibration with initial 5% solvent B was
done for 17 min. The 240-min gradient started at 5% solvent B and was held for 5
minutes, then linearly increased to 40% solvent B at 190 min and to 95% solvent B at 205
min and finally held at 95% solvent B for 15 min before allowing to return to initial 5%
solvent B at 223 min. Column re-equilibration with initial 5% solvent B was done for 17
min.
The LTQ mass spectrometer was operated in the data-dependent mode. The full
MS spectra were acquired in positive mode within a range of 300-1800 m/z. Top three
ions with intensities exceeding a preset threshold in full mass scan were chosen for
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Table 2.1. Concentrations of crude bovine fluids and data on yield (flow-through proteins) obtained after
immunodepletion of abundant proteins
Concentration of
crude (µg/ml)

Load
volume
(µl)

Sample

Load (µg)

Yield (µg)

Yield (%)

Yield concentration
(µg/ml)

Plasma

63960.2 ± 6523.0

4

255.8 ± 26.1

71.2 ± 11.4

27.9 ± 3.8

17798. ± 2839.4

Follicular fluid

56445 ± 4196.8

5

287.9 ± 19.9

47.9 ± 11.1

17.3 ± 4.2

9988.6 ± 2119.4

Epididymis sperm proteins

582.8 ± 64.3

154

89.8 ± 9.9

30.5 ± 4.5

34.1 ± 4.6

200.5 ± 30.8

Epididymis semen proteins

1857.6 ± 236.7

154

286.1 ± 36.5

109.7 ± 7.33

38.7 ± 3.82

712.6 ± 47.6

Ejaculated sperm proteins

1744.6 ± 42.35

154

268.7 ± 6.52

134.6 ± 9.4

50.9 ± 3.4

874.2 ± 61.13

Ejaculated semen plasma

19678.9 ± 2866.7

60

1238.2 ± 156.8

552.2 ± 66.4

44.6 ± 1.5

9202.9 ± 1106.9

Table 2.2. Dilution factors used in sandwich ELISA assay for measuring BSA, IgG and IgA
concentrations in non-depleted and flow-through (FT) fractions
Dilution factors
Sample

Albumin
Non-depleted
FT

IgG
Non-depleted

Plasma
Follicular fluid
Epididymis sperm proteins
Epididymis semen proteins
Ejaculated sperm proteins
Ejaculated semen plasma

2.5E+05
1.5E+05
3.0E+03
1.0E+04
3.0E+03
1.0E+04

1.0E+05
9.0E+04
1.0E+02
3.0E+02
2.0E+02
3.0E+02

4.0E+02
2.0E+01
1.0E+02
3.0E+02
5.0E+02
2.0E+01

FT

IgA
Non-depleted

FT

2.0
2.0
2.0
8.0
2.0
2.0

7.5E+04
1.5E+04
5.0E+01
5.0E+01
1.0E+02
2.0E+02

3.0
2.0
1.0
2.0
5.0
1.5
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collision- induced dissociation (CID) in LTQ. The Q activation and time was set
respectively at 0.25 eV and 30 ms. The maximum ion injection times used were 5.0 x104
ms for the MS scan and 1.2 x105 for the MS/MS scan. The automatic gain control target
settings were 3.0 x104 for the MS scan mode and 1.0 x 104 for the MS/MS scan mode.
The normalized collision energy was 35 eV and the isolation window employed was 2.5
m/z. The dynamic exclusion settings utilized were repeat count 2, exclusion duration 36
s, exclusion list size 500, exclusion mass width low 1.0 and exclusion mass width high
1.5.
2.4.11 Protein Identification
The LC-MS/MS raw data from nanoLC-LTQ were correlated to theoretical
fragmentation patterns of tryptic peptide sequences from the Fasta databases (Bovine and
human) using SEQUESTTM (Thermo Fisher). The search parameters included (i) fixed
cysteine modifications of +57 Da for carbamidomethyl-cysteines, (ii) variable
modifications allowing +16 Da with methionines for methionine sulfoxide; (iii) restricted
to trypsin-digested peptides and allowed for two missed cleavages; (iv) precursor mass
range was 310-5000 Da; (v) precursor mass tolerance of 2.5 Da and fragment mass
tolerance of ±0.8 Da; (vi) target false discovery rate (FDR) strict was 0.01 and FDR
relaxed was 0.05; (vii) peptide were identified based on top hit(s) with individual cross
correlation exceeding a threshold dependent on the precursor charge state. The proteins
matched with at least two peptides at minimum 95% confidence (false discovery rate
(FDR) of ≤5%) were considered as positive identification.
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2.4.12 Reproducibility and Recovery of MARS Hu-6HC on Bovine Fluids
To determine reproducibility of the MARS Hu-6HC cartridge, the bovine fluids
were subjected to 3-5 replicate depletions on same day for 2-5 separate days.
Reproducibility was assessed by coefficient of variations (CVs) of the percent of total
protein depleted (Table 2.3.) and by SDS PAGE separation of crude, bound and depleted
fractions (Figure 2.2. and 2.4.). Recovery was determined as protein content in bound
plus FT fractions expressed as percent of protein content in non-depleted sample (Table
2.4). Recovery ranged from 73-101%. Recovery of plasma (94%) and FF (101%) were
higher than that of the sperm samples (73-82%).

Table 2.3. *Total protein depleted with the MARS Hu-6HC cartridge on bovine fluids
Sample

Volume
Depleted
(µl)

Total protein depleted on
same day (%)

Total protein depleted on
separate days (%)

Mean ± SD

% CV

Mean ± SD

%CV

Plasma

4

71.9 ± 4.9

6.8

72.1 ± 3.8

5.2

Follicular fluid

5

86.0 ± 3.6

4.2

82.6 ± 3.8

4.6

Epididymis sperm proteins

154

66.2 ± 2.1

3.2

66. 1 ± 4.6

6.9

Epididymis semen proteins

154

58.2 ± 2.9

5

61.3 ± 3.8

6.2

Ejaculated sperm proteins

154

49.7 ± 2.9

5.9

49.8 ± 3.3

6.6

Ejaculated semen plasma

60

53.6 ± 2.4

4.5

53.7 ± 1.9

3.5

*Total protein depleted data were obtained from 2-5 separate days of depletions with n= 3-5
replicates on day depletion.

55

2.5 RESULTS
2.5.1 Depletion Efficiency of Target Proteins from the Bovine Fluids
Percent depletion of the bovine samples by using the MARS Hu-6HC cartridge in
removing the target HAPs was determined by comparing the total protein content in the
FT (depleted) fraction to that of the non-depleted samples. Total protein depleted from
each bovine fluid is shown in Table 3. Total protein depleted, expressed as percent
depletion were comparable for different volumes of plasma or FF investigated: 67.9 ± 3.1
(4.1%) for 2, 4, 6, 8, 10, 12, and 14 µL of plasma and 83.4 ± 6.0 (7.2%) for 4, 5, 7, 10,
12, and 14 µL of FF; mean ± SD (%CV) (Figures 1 and 2). Therefore, 4 µL plasma and 5
µL of FF were used in further investigation to conserve samples. Percent of LAPs (yield)
from each bovine fluid is shown in Table 1. From two to five separate days of depletion,
total protein depleted was highest for the FF sample (82.6 ± 3.8%) followed by the
plasma sample (72.1 ± 3.8%) and then the four sperm- sample types- 66.1 ± 4.6 for
epididymis sperm proteins, 61.3 ± 3.8% for epididymis semen proteins, 49.8 ± 3.3% for
ejaculated sperm proteins and 53.7 ± 1.9% for ejaculated semen plasma. Similar values
were obtained for same day depletions (Table 2.3).
The effectiveness of depletion of abundant proteins was also assessed by SDS
PAGE separation of non-depleted, bound and depleted proteins. Figures 2.2, 2.3, and 2.4
reveal the unmasking and highlighting of LAPs after dramatic removal of HAPs from the
different bovine fluids. In-gel digestion nano-LC-MS/MS analysis of gel bands from
bound fractions identified four out of the six target HAPs namely serum bovine albumin
(BSA), IgG, IgA and α-1-antitrypsin. Gel bands containing these proteins are shown in
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Figure. 2.2. Transferrin and Hp were not identified in the bound fractions by the nanoLCMS/MS method.
2.5.2 Specific Depletion Efficiency of BSA, IgG and IgA
Depletion efficiency (i.e. the extent of removal) of BSA, IgG and IgA from the
different bovine fluids was individually assessed using sandwich ELISA. Results showed
depletion of 98.25 to 99.99% BSA, 98.65 to 99.96% IgG and 98.85 to 99.96% IgA from
all the bovine samples studied (Table 2.5). The observed depletion rates are comparable
to manufacturer specification of 98.9-99.9% obtained for human biological fluids.
Depletion efficiency for α-1-antitrypsin was not measured by the ELISA method.
However, the dramatic removal of its protein gel band (Figure. 2.2) indicates similar
depletion rate for this protein can be expected.

Total protein
depleted (%)
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Plasma volume depleted (µL)

Total protien
depleted (%)

100
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14

Volume of FF depleted (µL)

Figure 2.1. Total
proteins depleted from
different volumes of
bovine plasma and
follicular fluid (FF)
with the MARS Hu6HC cartridge. Total
protein depleted is
similar over 2 (n=1), 4
(n=7 ), 6 (n= 7), 8
(n=2), 10 (n=5), 12
(n=2), and 14 (n=8) µL
of plasma and 4 (n=1),
5 (n=1), 7 (n=3), 10
(n=2), 12 (n=2), and 14
(n=2) µL of FF.
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2.5.3 Specificity of the Immunodepletion
To assess the specificity of the depletion method for the target proteins in bovine
fluids, 1-D SDS PAGE nano-LC-MS/MS analysis was performed on bound fractions.
Concomitant removal of non-target proteins were observed from all the bovine samples
depleted. These are summarized in Table 2.6. Non-target proteins from bound fraction of
the ejaculated sperm types included three major binder of sperm (BSP) proteins namely
PDC-109, BSP-A3 and BSP-30kD (Figure 2.3). Among the BSP depleted, the highest
depletion rate was observed for PDC-109 which forms 25-47% of total BSP proteins105.

Figure 2.2. Reproducibility of the MARS Hu-6HC cartridge on different depletion
volumes of bovine plasma. Lanes: 8D, 10D, 12D and 14D- Depleted fractions
respectively from depletion of 8, 10, 12 and 14 µL of bovine plasma; B8, B10, B12
and B14- Bound fractions respectively from depletion of 8, 10, 12 and 14µL of bovine
plasma; C-Crude bovine plasma; M- Molecular weight marker. Reproducibility of the
separation show similar depletion efficiencies were obtained for the different volumes
of plasma depleted. Arrows show gel bands at the respective molecular weights of
depleted BSA, IgA, IgG, and alpha-1- antitrypsin. 9µg of proteins were loaded on each
lane of 4-20% Criterion™ TGX precast gel and run under reducing conditions using βME. Bands were visualized with Coomassie blue staining

58

2.5.4 Reproducibility
The immunodepletion method had good reproducibility for all the bovine samples
studied. The coefficient of variations (%CVs) of depletion efficiencies determined on the
same day or separate days ranged 3.2 to 6.8 and 3.5 to 6.9 %, respectively (Table 2.3).
The good reproducibility is also supported by the consistent protein band pattern on the
SDS PAGE gel as is demonstrated in Figure 2.4.

Table 2.4. Recovery with depletion method
Sample

Volume
Depleted (µL)

Recovery (%)
Mean ± SD

% CV

Plasma

4

93.96 ± 11.57

12.31

Follicular fluid

5

101.35 ± 10.98

10.83

Epididymis sperm proteins

154

73.65 ± 7.51

10.2

Epididymis semen proteins

154

81.77 ± 7.42

9.08

Ejaculated sperm proteins

154

Ejaculated semen plasma

60

79.65 ± 3.82
81.45 ± 3.53

4.33

4.8

Data obtained from 2-5 separate days of depletions with n= 3-5 replicates on day
depletion

Table 2.5. Depletion efficiencies of BSA, IgG and IgA obtained with the MARS

Hu-6HC cartridge on Bovine fluids from Sandwich ELISA Analysis
% Depletion Efficiency (Mean ± SD)
Sample

Albumin

IgG

IgA

Plasma

98.73 ± 0.29

99.45 ± 0.01

98.85 ± 0.21

Follicular fluid

99.97 ± 0.02

99.96 ± 0.00

98.85 ± 0.60

Epididymis sperm proteins

99.92 ± 0.04

99.61 ± 0.24

98.79 ± 0.45

Epididymis semen plasma

99.98 ± 0.00

99.57 ± 0.21

99.40 ± 0.12

Ejaculated sperm proteins

99.52 ± 0.20

99.52 ± 0.03

99.63 ± 0.04

Ejaculated semen plasma

99.45 ± 0.01

98.65 ± 0.06

99.96 ± 0.02

N= 2 replicates on 1-2 separate day
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Figure 2.3. Unmasking and highlighting of LAPs after removal of HAPs from bovine
ejaculated and epididymis sperm types with MARS Hu-6Hc cartridge. M- Molecular
weight marker. C- Crude sperm sample; D- Depleted fraction; B- Bound fraction. 1, 2,
3, and 4 respectively ejaculated sperm proteins, ejaculated semen plasma, epididymis
sperm proteins and epididymis semen proteins. BSA, IgG and IgA were targeted
proteins depleted. Seminal plasma proteins- PDC-109, BSP-A3 and BSAP-30 kDa
were non-specifically depleted from ejaculated sperm sample types. These seminal
plasma proteins are HAPs found in ejaculated sperm. 20 µg of proteins were loaded on
each lane of 4-20% Criterion™ TGX precast gel and run under non-reducing
conditions. Bands were visualized with Coomassie blue staining.

2.6 DISCUSSION
Immunodepletion methods are popular and often the first step fractionation to
narrow the wide concentration range in biological samples and reduce sample
complexity. To date, available immunodepletion methods for bovine samples are very
limited. This study report a method for simultaneous immunodepletion of abundant
proteins BSA, IgG, IgA and alpha-1-antitrypsin from bovine plasma, FF, epididymis and
ejaculated sperm types with high depletion rates. Depletion rates for BSA, IgG and IgA
were confirmed as 98.7 to 99.9% from all the bovine fluids studied using sandwich
ELISA. The observed depletion rates are comparable to that stated by manufacturer for
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Figure 2.4. Reproducibility of the immunodepletion of bovine plasma and follicular
fluid (FF) with the MARS Hu-6HC spin cartridge. Three replicates of plasma and
two replicates of FF depletions were carried out with respectively 4µL and 5µL
depleted volume in each case. Lanes: M-Molecular weight marker; C-Crude sample;
D- Depleted fraction; B-Bound fraction. 6 µg of proteins were loaded on each lane
of 4-20% Criterion™ TGX precast gel and run under non-reducing conditions.
Bands were visualized with Coomassie blue staining.

these proteins from human fluids which is 98.9-99.9%. The similar depletion rates
indicate sample variability did not significantly affect the affinity of the MARS
polyclonal antibodies for the target proteins in the bovine fluids. Greater sequence
similarities between the target proteins in human and bovine explains the effective
application of this immunodepletion technology on bovine fluids. A search in UniprotKB
database (http://www.uniprot.org) showed human serum albumin and alpha-1-antitrypsin
respectively share greater than 75 and 68% sequence identity with their respective
proteins in bovine. Sequence identity between human and bovine immunoglobulins light
chains range is 53-76% whiles the heavy chains range is 33-65%. The high depletion
rates achieved with the presented method makes it a viable alternative for achieving
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immunodepletion of these abundant proteins in bovine biological fluids while similar
technology is currently unavailable

Table 2.6. SEQUEST results showing non-target proteins* in bound fractions of

bovine plasma, follicular fluid (FF), epididymis, and ejaculated sperms after depletion
with MARS Hu-6HC cartridge.
Accession

No of peptides
identified

Score

Description

B8Y9S9

38

528.63

P07589

27

515.40

Embryo-specific fibronectin 1
transcript variant
Fibronectin

33

395.84

Alpha-2-macroglobulin

8

323.32

F1MAV0

19

238.79

Seminal plasma protein PDC109
Fibrinogen beta chain

A5PJE3

16

229.46

Fibrinogen alpha chain

G3X7A5

17

179.49

Complement C3

P12799

8

173.91

Fibrinogen gamma-B chain

P81019a

3

62.58

P01030

2

42.92

Seminal plasma protein BSP-30
kDa
Complement C4

2

34.56

Seminal plasma protein A3

F1MBL6

2

32.17

F1MI18

2

24.05

Uncharacterized protein
(Fragment)
Uncharacterized protein

E1BIF6

2

19.75

Uncharacterized protein

P23805

4

16.95

Conglutinin

Q28085

2

15.71

Complement factor H

G3N0S9

2

11.42

Uncharacterized protein

F1N5M2

2

8.76

Vitamin D-binding protein

Q7SIH1
P02784

P04557

a

a

Protein Familyᵻ

P13/P14 kinase family
Alpha-2 macroglobin
family
Ubiquitin associated
domain

Sushi CCP/SCR
domain family

*List excludes trypsin and keratin related proteins
ᵻ
Identified from UniProt KB search with accession number
a
Only observed in ejaculated sperm types

Contrary to the lack of effect of sample variability on individual target protein
depletion rate, sample variability seems to affect the total proteins depleted in a sample.
Total protein depleted was about 50- 83% for the bovine samples investigated. This range
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was lower than the manufacturer specifications of 85-90% for human serum. But bovine
FF and plasma were closer to the lower end range; respectively 83% and 71%. The total
protein depleted is based on the levels of the target proteins in certain samples. Thus,
differences in the levels of the target proteins in the different bovine fluids and between
human and bovine would affect the total protein depleted. For instance, albumin, the most
abundant protein in plasma represents more than 50% of the total protein in human
plasma15 and about 42% in bovine plasma106. Plasma and FF are closely related in
composition and majority of proteins in FF are viewed to originate from the blood107-109.
But albumin is higher in FF compared to serum110, 111 which might explain the highest
depletion rate attained with the FF. 2-DE analysis of caudal epididymis fluid found
albumin represented ~21% of all proteins spots detected 42. By contrast, albumin
concentration is very minimal in ejaculated sperm112. Accordingly, total proteins depleted
were lower for the sperm sample types compared to the plasma and FF samples.
The lower total proteins depleted from the bovine fluids are also contributed by
the lack of depletion of Hp and transferrin which are both target proteins of the MARS
Hu-6HC cartridge, contributing to the manufacture stated 85-90% . Sequence homology
could not explain the lack of removal of both proteins as they are highly homologous
between human and bovine, respectively 69% and 75% sequence identity. High
specificity of the MARS Hu-6HC cartridge for human transferrin and Hp appears to be
the primary reason for both proteins not depleted from the bovine fluids. Although Hp
and transferrin were not depleted, the simultaneous rapid depletion of albumin, IgG, IgA
and alpha-1-antitrypsin from all the bovine fluids show the effectiveness of application of
the current immunodepletion method to bovine fluids. Albumin and IgG represents about
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60% of the bovine plasma proteome. Depletion of both proteins increased the number of
spots and intensities on a 2-DE map18. The additional depletion of abundant proteins by
this depletion method is expected to provide more desirable probing of low copied
proteins in gel-based and gel-free proteomic workflows for bovine fluids analysis. As
shown in this study, the depletion of the four major proteins unmasked and highlighted
more protein gel bands in SDS PAGE gels presented. Because the HAPs were removed
in a single step, sample loss is expected to be minimized. Also, time is reduced.
To determine reproducibility of the immunodepletion, replicate depletions on
same day and on separate days were analyzed. The results show the method had high
reproducibility on the bovine fluids as revealed by the low % CV values of total proteins
depleted from different and same volumes. Because immunodepletion is often a first step
fractionation option, a good reproducibility for its application is critical to the accuracy
and further reproducibility of downstream protein separation, identification, and
quantification. Low loading volumes of plasma and FF (4 and 5 µL) did not affect the
reproducibility and this can be beneficial if sample is limiting.
Concomitant removal of non-target proteins in immunodepletion methods is often
inevitable99, 100. Non-target proteins removal from the bovine fluids included other HAPs,
e.g. PDC-109, BSP-A3, BSP-30kD, alpha-2-macroglobulin, complement C3,
complement C4, and fibrinogen. Non-target proteins removal could result from nonspecific binding to cartridge resin, accidental/specific cross reaction of the antibodies, or
interactions with the target proteins. The BSP proteins were consistently removed from
the ejaculated sperm samples. Their dramatic removal is considered beneficial since they
are major proteins constituting 40-57% of the total protein in the seminal plasma

64

component of ejaculates. PDC-109 alone forms 25-47% of the BSP proteins mass105.
Thus, depletion of the BSP proteins can additionally enhance the analysis of LAPs in
these ejaculates. However, caution should be taken when applying this depletion method
to target these seminal proteins since their removal is non-specific. In such cases, a better
approach would be to analyze both the bound and unbound fractions to ensure adequate
estimation of their depletions.
2.7 CONCLUSION
Immunodepletion methods for bovine fluids are currently very limited. This study
describes an immunodepletion method for simultaneous removal of minimum of four
HAPs in different bovine fluids. The high depletion efficiencies (98.7-99.9%) and
reproducibility make it practical for its application in bovine proteomic analyses.
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CHAPTER 3
iTRAQ-BASED QUANTITATIVE ANALYSIS OF BOVINE PLASMA AND
FOLLICULAR FLUID
3.1 ABSTRACT
Bovine follicular fluid (FF) creates a unique microenvironment in follicles necessary for
follicle growth and oocyte maturation, and preovulatory concentrations of estradiol (E2)
have been reported to impact several processes involved with fertility. The objective of
this study was to analyze changes in proteins in FF and plasma (PL) from animals with
high E2 (HE2) or low E2 (LE2) during the pre-ovulatory period. Beef cows were
synchronized with an injection of GnRH on day -7 and an injection of prostaglandin F2α
(PGF2α) on day 0. Follicular dynamics and ovulatory response were monitored using
transrectal ultrasonography. Nine cows were selected and slaughtered, blood samples
were collected at slaughter and FF was aspirated from dominant follicles (DF; >10 mm).
Abundant proteins (albumin, IgG, IgA, and alpha-1-antitrypsin) were depleted from both
PL and FF. Peptides were labeled with iTRAQ reagents and quantified using twodimentional liquid chromatography ESI-based mass spectrometry. Estradiol was
associated with increased protein changes in PL and FF. Protein expression changes
between FF HE2 and FF LE2 were higher than PL HE2 and PL LE2. There were 15 upregulated proteins and 10 down-regulated proteins in FF HE2 compared to FF LE2.
Seven proteins were up-regulated and nine proteins down-regulated in PL HE2 compared
to PL LE2. Proteins were more predominant in PL than in FF but the extent of protein
increase with HE2 was greater in FF than in PL. Several of the differentially expressed
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proteins function in follicle development and were mainly categorized under cellular
process and metabolic process. Pathway analysis identified the up- and down-regulated
proteins were predominantly associated with the complement and coagulation cascades.
The data demonstrates E2 regulates a wide range of reproductive associated proteins in
bovine PL and FF, and can provide the basis for further investigation of specific
processes involved in such regulation.
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3.2 BACKGROUND AND MOTIVATION
Follicular fluid (FF) provides a unique microenvironment for developing oocytes.
It contains substances that primarily originate from circulating blood and from secretions
by granulosa cells (GCs), theca cells, and the oocyte108. Proteins are a major proportion
of the FF with total concentrations comparable with that in plasma113; however, the
composition of the proteins in FF changes with follicle development40, 114 which indicates
their involvement in the development of the follicle and competent oocyte. Accordingly,
FF proteins have been implicated in oocyte meiosis, ovulation, formation of the corpus
luteum, and fertilization108. Thus, FF proteins can reflect the physiological condition of
the follicle and may serve as biomarkers for follicle growth and maturation.
Estrogens are an important component of FF. During the steroidogenesis process,
androgens produced in the theca cells traverse the basement membrane of the
neighboring GCs where they are converted by cytochrome P450 aromatase (CYP19A1)
under the influence of follicle stimulating hormone (FSH) to estrogens115, with Estradiol17β (E2) being the principal form of estrogen present115, 116. The pre-ovulatory follicle is
reported to have the highest intra-follicular levels of E2 mainly because of the large
number of GCs and its capacity for androgen aromatization115.
In developing follicles, E2 stimulates proliferation and differentiation of GCs115,
and promotes growth, gap-junction formation, antrum formation, and inhibition of
atresia117. Perry et al118 reported that among cows exhibiting standing estrus peak
concentration of E2 were greater and positively associated with follicle size, but this
association was not found in cows not exhibiting standing estrus. Cows with increased
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concentration of circulating E2 had an up-regulation of the steroidogenic pathway during
the pre-ovulatory period as evidenced by increased concentrations of steroidogenic
associated enzymes 3β-hydroxysteroid dehydrogenase (3β-HSD), CYP19A1, and
cytochrome P450 side-chain cleavage enzyme (CYP11A1) and steroidogenic products
estradiol and androstenedione103.
An important means by which E2 achieves its regulatory reproductive functions is
via regulation of proteins and protein receptors involved in the relevant functions. Such
proteins include insulin-like growth factor 1 (IGF-1) which promotes proliferation of
GCs and endometrial epithelial cells119, follicle stimulating hormone (FSH) receptors in
GCs, and LH/human chorionic gonadotropin (hCG) receptors in GCs and thecal
interstitial tissues when coupled with FSH120. Quantitative shot-gun proteomics,
incorporating isobaric labeling techniques such as isobaric tags for relative and absolute
quantitation (iTRAQ) and tandem mass tags (TMT), allow measuring of protein changes
in time-dependent manner with greater precision and accuracy than label-free methods26.
This can be applied to determine the influence of E2 on the expression of several proteins
in a short period. Its application to FF is also beneficial considering the large number and
diversity of the FF proteome. Ferrazza et al40 recently utilized TMT labels and identified
22 differentially expressed proteins in bovine FF between different stages of follicle
development. The group also demonstrated a correlation between some of the
differentially expressed proteins (includes modified fibrinogen, alpha-2-macroglobulin,
plasminogen, immunoglobulin M heavy chain, and spondin-1) and concentration of E2 or
progesterone.
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3.3 OBJECTIVE OF STUDY
The objective of this study was to use the iTRAQ proteomic approach to
quantitatively measure PL and FF proteomes and identify the influence of high and low
pre-ovulatory circulating concentrations of E2 on PL and FF proteomes.
3.4 MATERIALS AND METHODS
3.4.1 Materials and Reagents
Ammonium bicarbonate (ABC) and iodoacetamide were purchased from Acros
Organics (New Jersey, USA). Formic acid, acetonitrile (ACN), triethylammonium
bicarbonate (TEAB) and water were obtained from Fischer Scientific (New Jersey,
USA). Dithiothreitol (DTT) was purchased from Promega (Wisconsin, USA). ZebaTM
desalting spin columns from Pierce (Rockford, IL,USA). All chemicals and water were of
LC/MS grade.
3.4.2 Estradiol Measurement
Estradiol (E2) concentrations in PL and FF (PL and FF collected as described in
Chapter Two) were measured by radioimmunoassays (RIA) according to procedures as
previously described121 and animals were then classified as either high E2 (peak estradiol
≥ 6.0 pg/mL; PL: n = 4, FF: n = 4) or low E2 (peak estradiol ≤ 4.5 pg/mL; PL: n = 5,
FF: n = 5) according Jinks et al122. Concentrations of E2 and changes in the
steroidogenic pathway have previously been reported by Larimore and coworkers103.
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3.4.3 Coomassie Bradford Assay Quantitation
The protein contents in depleted samples were quantified using Coomassie
(Bradford) assay kit, #23200 (Pierce Biotechnology, IL, USA) according to
manufacturer’s instruction. Bovine serum albumin (#23209, Thermo Scientific, IL, USA)
was used as a standard for making a calibration curve. The standard (2 mg/mL) was
diluted with 50 mM TEAB and the calibration curve covered a concentration range of
0.00-1500 µg/mL.
3.4.4 Reduction, Alkylation, Digestion, and iTRAQ Labeling of Proteins
Fifty µg of each of the four depleted bovine samples (PL and FF) containing high
or low E2 (i.e. PL HE2, PL LE2, FF HE2 and FF LE2) were pooled and vacuum dried
(Labconco, Kansas, MO, USA) at 4 oC. The dried proteins were prepared with 4-plex
iTRAQ reagents according to manufacturer protocol (Applied Biosystems, Foster City,
CA, USA). Briefly, the dried proteins were re-suspended in 25µL 1M TEAB solution.
The proteins were denatured with 1µL 2% SDS solution, reduced with 2µL 50 mM tris(2-carboxy) ethylphosphine hydrochloride (TCEP), and alkylated with 1 µL of freshly
prepared 84 mM iodoacetamide solution and incubated in dark room temperature for 30
minutes. Each sample (50 µg) was digested overnight at 37 oC with 10 µL of freshly
prepared 1µg/µL TPCK treated trypsin solution, P/N 4370282 (Ab Sciex Pte Ltd, MA,
USA). iTRAQ reagents 114, 115, 116 and 117 were each resuspended in 70µL ethanol
and added individually to the four digested PL and FF protein samples. The samples
were incubated at room temperature for 1h and the reaction quenched by adding 100 µL
of HPLC-grade water and incubating at room temperature for 30 minutes. Each labeled
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peptide was vacuum dried at 4oC, cleaned with ZebaTM desalting spin columns according
to vendor instructions (Pierce, Rockford, IL,USA) and then vacuum dried at 4oC.
Samples were stored at -80oC until ready for analysis.
3.4.5 Off-line Strong Cation Exchange (SCX) Separation
The iTRAQ-labeled peptides were separated using ICAT® Cartridge–Cation
Exchange, # 4326752 (POROS® 50 HS, 50-µm, 4.0 mm × 15 mm), Opti-Lynx Quick
Connect Hardware, # 4326688, and ICAT® Cation Exchange Buffer Pack, # 4326747
(Applied Biosystems, Foster City, CA, USA). The iTRAQ-labeled dried peptides were
each diluted 10-fold with Load Buffer (10mM KH2PO4 in 25% ACN; pH 3) and the four
samples combined in one new vial. Equilibration of the SCX cartridge was done with
1mL of Clean Buffer (10 mM KH2PO4 in 25% ACN / 1M KCl; pH 3) followed by 2mL
Load Buffer. The mixed iTRAQ labeled peptides were then loaded onto the SCX
cartridge. Excess iTRAQ reagents and salts in the cartridge were removed by washing the
cartridge with 1mL of Load Buffer. The bound peptides on the cartridge were eluted by
sequential injection of 500 µL of a series of salt solutions: 0, 30, 40, 50, 60, 70, 85, 100,
130, 160, 350, 500, and 1000 mM KCl in Load Buffer. The flow rate of elution was ~1
drop/second. Each eluted fraction and wash solution was cleaned with ZebaTM desalting
spin columns according to vendor instructions (Pierce, Rockford, IL,USA). Purified
peptides were vacuum dried at at 4oC (Labconco, Kansas, MO, USA) and stored at -80oC
until further analysis.
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3.4.6 Nano-LC-MS/MS Analysis
Aliquots of the dried SCX peptide fractions were analyzed using the ThermoFisher FinniganTM LTQTM mass spectrometer equipped with a nano-electrospray source
(New Objective, Woburn, MA, USA) and coupled with a nano-LC separation system
(Eksigent nanoLC 1D-plus). The LC system is equipped with an autosampler (Spark
Holland 920 Endurance Autosampler). Each peptide fraction was re-suspended in 10 µL
of water/ACN/formic acid (95%/5%/0.1%) and then 3 µL loaded onto IntegraFrit Sample
trap (ProteoPep IITM C18, 300 Å, 5µm , 100 μm × 25 mm New Objective, Inc., Woburn,
MA). The retained peptides were washed isocratically with water premixed with 0.1%
formic acid pumped from channel 1A to remove any excess reagents. Peptide separation
was performed on an IntegraFrit Analytical Column (ProteoPepTM II C18, 300 Å, 5µm,
75 μm ×100 mm, 75µm tip, New Objective, Inc., Woburn, MA) with a multistep 4-h
gradient using solvent A (water premixed with 0.1% formic acid) and solvent B
(acetonitrile premixed with 0.1% formic acid) at a flow rate of 200 nL/min. The gradient
started at 5% solvent B and was held for 5 minutes, then linearly increased to 50%
solvent B at 205 min and to 95% solvent B at 213 min and finally held at 95% solvent B
for 5 min before allowing to return to initial 5% solvent B at 223 min. Column reequilibration with initial 5% solvent B was done for 17 min.
The LTQ mass spectrometer was operated in a data-dependent mode. The full MS
spectra were acquired in positive mode within a range of 400-1800 m/z. The top four
most intense ions in the acquired full mass scan were selected for followed pulsed Q
dissociation (PQD) in LTQ. The Q activation and time was set respectively at 0.7 and 0.1
ms. The maximum ion injection times used were 50 ms for the MS scan and 120 ms for
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the MS/MS scans. The automatic gain control target settings were 3.0 x104 for the MS
scan mode and 1.0 x 104 for the MS/MS scan mode. One microscan of full MS was
performed. The normalized collision energy was 29.5% and the isolation window
employed was 2 m/z. The dynamic exclusion settings utilized were repeat count 2,
exclusion duration 25 s, exclusion list size 500, exclusion mass width low 0.5 and
exclusion mass width high 1.5.
3.4.7 Protein Identification and Quantification
The LC-MS/MS raw data from nanoLC-LTQ were correlated to theoretical
fragmentation patterns of tryptic peptide sequences in bovine protein fasta database using
SEQUESTTM search engine embedded in Proteome Discoverer (version 2.1; Thermo
Fisher Scientific). The search parameters included were as follows: fixed cysteine
modifications of +57 Da for carbamidomethyl-cysteines, +144 Da for lysine-iTRAQ
labeling and N-terminal peptides; dynamic modifications allowing +16 with methionines
for methionine sulfoxide and + 144 Da for Y-iTRAQ labeling; restricted to trypsin
digested peptides and allowed for two missed cleavages; precursor mass range was 3505000 Da; peptide mass tolerance of 2.5 Da and fragment mass tolerance of ±0.8 Da;
target FDR strict was 0.01 and FDR relaxed was 0.05; most confident centroid was
selected for peak integration method and a 0.25 Da integration window tolerance was
allowed. The proteins matched with at least one unique peptide at minimum 95%
confidence (FDR < 5%) were considered positive identifications.
The relative quantification of proteins in the samples was performed with the
Proteome Discover (1.2). The quantification utilized the relative peak intensities of the
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iTRAQ reporter ions derived from MS/MS spectra of all unique peptides that represented
each protein. iTRAQ ratios of the reporter ions were calculated using reporter ions
representing any two samples. The final ratios obtained from the relative protein
quantifications were normalized according to the median protein quantification ratio to
reduce experimental bias. The protein ratios were the median ratio of the corresponding
peptide ratios. To determine protein expression levels, a fold change of >2.0 or <0.5
between any two samples were respectively set for up- and down-regulated proteins.
Functional analysis was performed for all identified proteins and for up- and downregulated proteins.
3.4.8 Bioinformatic Analysis of Identified Proteins
The PANTHER (Protein Analysis Through Evolutionary Relationships)
classification system123 was used to categorize the up- and down regulated proteins based
on their molecular function (MF), biological process (BP), and cellular component
(CC)/localization. Similar PANTHER analysis of all identified proteins in PL and FF are
shown in Appendix 3. Pathway analysis was performed using the Database
for Annotation, Visualization, and Integrated Discovery (DAVID)124. Pathway plot was
derived using Kyoto Encyclopedia of Genes and Genomes (KEGG)125. Protein-protein
intereactiosn were annotated using Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING)126 database.
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Plasma LE2 (n=5)

Plasma HE2 (n = 4)

FF LE2 (n=5)

FF HE2 (n = 4)
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Depletion of HAPs

Depletion of HAPs

Depletion of HAPs

Quantification and 50
µg protein aliquot

Quantification and 50
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Quantification and 50
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Quantification and 50 µg
protein aliquot

Reduction, alkylation,
digestion

iTRAQ label 114
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iTRAQ label 115
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iTRAQ label 116

Reduction, alkylation,
digestion

iTRAQ label 117

4-plex mixture
SCX and nanoLC-MS/MS

Data analysis (Protein identification and quantification)

Figure 3.1. Overview of workflow for identification and relative quantification of proteins in
bovine plasma and follicular fluid containing high and low pre-ovulatory levels of E2.

3.5 RESULTS
3.5.1 General information on iTRAQ Analysis
The overview of our iTRAQ-based SCX nano-LC/MS/MS ESI PQD method for
analyzing the proteomes in bovine PL and FF is show in Figure 1. A total of 231 proteins
matched to 793 unique peptides were identified with high confidence (FDR of 5% or
less) and were subsequently included in further analysis. Details of all 231 identified
proteins are shown in Appendix Table 1. Approximately 61% (140/231) of proteins were
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identified by one unique peptide and ~39% by at least 2 up to 47 unique peptides (Figure
3.2.A). About a third of proteins identified by one unique peptide were identified at 99%
confidence. Analysis of the distribution of the sequence coverage (Figure 3.2.B) of the
detected peptides of the proteins found ~53% (123/231) of identified proteins had greater
than 5% coverage. Protein pI values ranged from 4.41 to 11.05 (Figure 3.2.C). The
molecular mass of the identified proteins ranged from 10.3 to 3811.5 kDa with majority
of the proteins (~60%) between 20 to 80 kDa (Figure 3.2.D). Several of the proteins
identified herein have been previously reported as components of bovine PL and/or FF40,
127

.

3.5.2 Comparative Analysis of Protein Expression in Plasma and Follicular Fluid
Paired comparisons were made to determine differences in protein expression
between any two samples. Figure 3.3 depicts the different paired comparisons and the
number of up- and down-regulated proteins obtained in each analysis. Up- and downregulated proteins were determined using a ratio fold-change of >2.0 or <0.5 between any
two samples. Comparison between same fluid type (i.e. high and low of PL or FF)
revealed nine down-regulated and seven up-regulated proteins in PL HE2 compared to
PL LE2 and 10 down-regulated and 15 up regulated proteins in FF HE2 compared to FF
LE2. Comparison between PL and FF showed more proteins up-regulated in PL
compared to FF. Each PL and FF pair, (i.e. PL LE2 and FF LE2; PL HE2 and FF HE2)
revealed 51 up-regulated proteins in PL. 21 proteins were down-regulated in PL LE2
compared to FF LE2 whereas 27 proteins were down-regulated in the PL HE2 compared
to the FF HE2. 39 up-regulated proteins and 11 down-regulated proteins were commonly
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identified from both PL and FF paired analyses. Overlaps of numbers of proteins from
the different paired comparisons are depicted in Figure 3.4 and the protein details in each
pair are reported in Table 3.1.
The fold change, i.e. iTRAQ ratio value of a protein, is indicative of the extent of
up- or down-regulation of the protein in a sample. iTRAQ ratios of up- and downregulated proteins in PL compared to FF ranged from 2.017 to 27.247 and 0.036 and
0.499 respectively. NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 11
mitochondrial (NDUFB11), dpy-19 like 4 (DPY19L4), apolipoprotein B (APOB),
cytohesin 1 (CYTH1), delta-like protein (JAG1), and gametocyte-specific factor 1-like
(GTSF1L) were among the top up-regulated proteins whereas versican core protein
(VCAN), inhibin alpha chain (INHA), serglycin (SRGN), protein tyrosine phosphatase
receptor type R protein (PTPRR), and dynein heavy chain domain 1 (DNHD1) were
among the top down-regulated proteins in PL compared to FF.
Protein predominance in the HE2 sample was higher after FF HE2/FF LE2
comparison than the PL HE2/PL LE2 (respectively 2.08-6.21 and 2.00-3.71 fold change).
Comparison of FF HE2 to FF LE2 identified keratin type II cytoskeletal 7 (KRT7), serum
albumin (ALB), and cytokine receptor-like factor 3 (CRLF3) as the top three upregulated proteins and hemoglobin subunit alpha (HBA), hemoglobin subunit beta
(HBB), and ubiquitin protein ligase E3 component n-recognin 4 (UBR4) as the top three
down-regulated proteins in the FF HE2. Suppressor of G2 allele of SKP1
homolog(SUGT1), C8G protein (C8G), and SRGN were the top three up-regulated
proteins and DDB1 and CUL4 associated factor 5 (DCAF5), transmembrane protein 186
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(A) Unique peptide number distribution

(B) Distribution of protein sequence coverage
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Figure 3.2. General information on 231 proteins identified by the itraq-based scx nano-LC-MS/MS
ESI PQD method with high confidence. (A) Number of unique peptides of the identified proteins; (B)
Distribution of protein sequence coverage; (C) Distribution of protein pI values. (D) Distribution of protein
molecular weights.
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Figure 3.3. The number of up- and down regulated proteins (y-axis) after
comparisons between any two samples (x-axis). The number of proteins in each
category is shown on the bar. PL HE2: Plasma high E2; PL LE2: Plasma low E2; FF
HE2: Follicular fluid high E2; FF LE2: Follicular fluid low E2.

(TMEM186), and HP the top three down-regulated proteins in PL HE2 compared to PL
LE2. Seven proteins were commonly found from PL HE2/ PL LE2 and FF HE2/FF LE2
analyses: SUGT1, engulfment and cell motility 1 (ELMO1) and family with sequence
similarity 81 member A (FAM81A) had opposite expressions in either fluid; KRT7 was
up-regulated and immunoglobulin lambda-like polypeptide 1 (LOC100297192), HP and
TMEM186 were down-regulated in the HE2 samples compared to the respective LE2
samples of either fluid type.
3.5.3 Functions of Identified Proteins
To determine the functions of all proteins showing expression changes, the upand down-regulated proteins derived from all paired analyses were compiled (103 in
total) and functional analysis performed using PANTHER classification system. The up-
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and down-regulated proteins were categorized into 4 MF, 11 BP, and 7 CC (Figure 3.5).
The major MF were binding (52%) and catalytic activity (40.0%). The BP categorized
were cellular component organization or biogenesis (6.8%), cellular process (33.3%),
localization (6.8%), biological regulation (6.8%), response to stimulus (5.1%),
developmental process (6.8%), multicellular organismal process (6.0%), biological
adhesion (4.3%), locomotion (0.9%), metabolic process (20.5%), and immune system
process (2.6%). The CC analysis revealed majority of the up- and down-regulated
proteins were localized in the cell (31.8%), the extracellular region (22.7%), and
organelle (21.2%). Panther classification for all identified proteins is shown in Appendix
3.

A

B

Figure 3.4. Overlap of number of up-regulated (a) and down- regulated (b) proteins in
Pl and FF after paired analyses. PL HE2: Plasma high E2; PL LE2: Plasma low E2; FF
HE2: Follicular fluid high E2; FF LE2: Follicular fluid low E2. Details of proteins
from each paired analysis are shown in Table 3.1.
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3.5.4 Enriched Pathways
DAVID was used to determine the pathways associated with the up- and downregulated proteins in PL and FF. The databases within the DAVID platform searched
were KEGG and Reactome 128 databases. Results from KEGG showed the complement
and coagulation cascades were enriched (p = 3.5 x 10-14); Figure 3.6. The search in
Reactome supported these enriched pathways by identifying platelet degranulation (p
=8.2 x 10-9), intrinsic pathway of fibrin clot formation (p = 1.4 x 10-5), common pathway
of fibrin clot formation (p = 2.4 x 10-4), scavenging of heme from plasma (p = 6.0 x 10-3),
and terminal pathway of complement (p = 5.7 x 10-2) as the main pathways.
3.6 DISCUSSION
Proteomic workflows utilizing iTRAQ labeling allows for the simultaneous highthroughput identification and quantification of proteins. In this study, 4plex iTRAQ
reagents were used to label PL and FF samples containing high or low concentrations of
E2 (HE2 or LE2). Ovaries of all cows were examined by transrectal ultrasonography and
FF was subsequently aspirated from the DF. Blood was collected at slaughter. To reduce
the masking effect of HAPs and matrix effect due to sample complexity, the samples
were first subjected to an immunodepletion method which dramatically depleted targeted
HAPs ALB, IgG, IgA, and alpha-1-antitrypsin. Subsequent steps in the workflow for the
analysis included reduction, alkylation, and digestion of the plasma and FF proteins prior
to labelling with the iTRAQ reagents. The iTRAQ-labeled peptides from each of the four
samples were mixed at an equal mass ratio. The samples were then analyzed with off-line
SCX and nanoLC-ESI-LTQ (PQD) method. Our approach enabled us to quantitatively
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Table 3.1 Identified Up- and Down- regulated proteins in plasma and follicular fluid containing high or low pre-ovulatory E2
Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
(A) Up-regulated proteins
2-acylglycerol O-acyltransferase 3 (Fragment)

E1BN30

LOC618076

5.370

3.971

Alpha-2-macroglobulin

Q7SIH1

A2M

6.965

7.617

Ankyrin repeat and KH domain containing 1

G3MZJ0

ANKHD1

5.482

7.516

AP complex subunit beta

F6PZ41

AP4B1

Apolipoprotein B

E1BNR0

APOB

Apolipoprotein R

G3N0S9

LOC515150

ApoN protein

Q2KIH2

ApoN

Asparagine-linked glycosylation 5, dolichylphosphate beta-glucosyltransferase homolog (S.
cerevisiae)

Q2KIM7

ALG5

ATP binding cassette subfamily B member 9

E1BKR0

ABCB9

B double prime 1, subunit of RNA polymerase III
transcription initiation factor IIIB

F1MEB1

BDP1

2.144
2.340

2.075

A8YXZ2

C8G

3.000

CAD protein

F1MVC0

CAD

2.359

CCDC80 protein

A5PKA3

CCDC80

2.007

Cell adhesion molecule 1

Q2TBL2

CADM1

F1N0I3

F5

Coagulation factor XII

F1MTT3

F12

Coagulation factor XIII A chain

F1MW44

F13A1

7.312

5.234

4.912
2.809

C8G protein

Coagulation factor V

11.669

2.103

3.265

7.448

3.384

5.131

2.928

6.742
2.680

2.187

2.323
2.418
3.170

2.328
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Table 1. Continued
Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
Cohesin subunit SA-3

E1B9B0

STAG3

3.175

5.194

Complement C1s subcomponent

Q0VCX1

C1S

3.884

6.060

Conglutinin

P23805

CGN1

3.279

3.521

Cumulus cell-specific fibronectin 1 transcript variant

B8Y9T0

FN1

2.620

2.334

Cytochrome P450 20A1

Q5E980

CYP20A1

8.593

4.068

Cytohesin 1 (Fragment)

F1MCV3

CYTH1

5.453

15.900

Cytokine receptor like factor 3

E1BCF2

CRLF3

Delta-like protein

E1BDN7

JAG1

13.738

Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit 1

F1MJ36

LOC539818

2.280

Dpy-19 like 4 (Fragment)

F1MJJ1

DPY19L4

DUOXA1 protein

A6H723

DUOXA1

2.751

Dynein heavy chain domain 1

F1MEF7

DNHD1

2.972

E3 ubiquitin-protein ligase CHIP

F1MUH4

STUB1

Engulfment and cell motility 1

F1MQH0

ELMO1

EPS8 like 1

E1BKS0

EPS8L1

Family with sequence similarity 81 member A

F1N4N5

FAM81A

Fas activated serine/threonine kinase

F1N4L0

FASTK

2.724

FGG protein

Q3SZZ9

FGG

6.258

4.117

Fibrinogen alpha chain

A5PJE3

FGA

9.225

5.720

Fibrinogen beta chain

F1MAV0

FGB

7.909

4.895

2.484
3.048

16.517

12.811

5.914
2.322

2.133

2.360
2.514

2.727
2.279

2.352

2.035
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Table 1. Continued
Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
Fibulin-1

F1MYN5

FBLN1

2.488

2.276

Gametocyte-specific factor 1-like

Q3T026

GTSF1L

8.291

10.840

HEAT repeat containing 5B

E1BB26

HEATR5B

HECT domain E3 ubiquitin protein ligase 2

F1N7A0

HECTD2

2.196

Homeobox D3

E1B856

HOXD3

2.453

Keratin, type II cytoskeletal 7

Q29S21

KRT7

3.123

2.271

2.908

6.209

KRAS proto-oncogene, GTPase

E1BMX0

KRAS

2.192

Kruppel like factor 17 (Fragment)

G3N1K6

KLF17

2.915

Lumican

Q05443

LUM

Lysine methyltransferase 2C (Fragment)

F1MYZ3

KMT2C

3.774

3.229

NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex assembly factor 4

A4FUH5

NDUFAF4

5.033

4.573

NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 11, mitochondrial

Q8HXG5

NDUFB11

27.247

23.059

NIMA (Never in mitosis gene a)-related kinase 2

Q2KIQ0

NEK2

Ornithine decarboxylase 1

E1BG69

ODC1

4.726

4.681

Pantothenate kinase 3

Q08DA5

PANK3

5.058

4.976

Phosphoglycolate phosphatase

Q2T9S4

PGP

Protocadherin Fat 2 precursor (Fragment)

F1MPF3

-

2.807

Regulating synaptic membrane exocytosis 2
(Fragment)

E1B7V2

RIMS2

2.480

2.904

2.215

2.091
2.125
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Table 1. Continued

Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
Serglycin (Fragment)

G5E5K5

SRGN

Serum albumin

P02769

ALB

2.929

SH3 domain and tetratricopeptide repeats 1

G3MZW4

SH3TC1

Sodium/glucose cotransporter 1-like (Fragment)

G3MXJ0

LOC531152

Sphingomyelin phosphodiesterase 5 (Fragment)

F1N6X9

SMPD5

Suppressor of G2 allele of SKP1 homolog

Q2KIK0

SUGT1

Synaptonemal complex protein 1

E1BLN1

SYCP1

5.469

Synaptotagmin 12

E1BEH9

SYT12

4.194

Titin

F1N757

TTN

Trans-2-enoyl-CoA reductase, mitochondrial

Q7YS70

MECR

10.791

Transcription factor 7-like 2

G3N0T7

-

2.519

Transcription initiation factor TFIID subunit
(Fragment)

F1MF62

TAF1

3.579

Transthyretin

O46375

TTR

Uncharacterized protein

E1BPG1

-

Uncharacterized protein

F1MI18

-

2.848

2.311

Uncharacterized protein (Fragment)

G3X6V5

-

5.022

12.917

Vacuolar protein sorting-associated protein 28
homolog

E1BIB3

VPS28

6.898

8.348

Von Willebrand factor A domain containing 5B1

E1BB39

VWA5B1

2.316

2.377

Zinc finger SWIM-type containing 3 (Fragment)

F1MTI1

ZSWIM3

3.527

2.750

5.960
2.137
3.779
2.017
3.741
5.407
2.320

2.403

4.597
2.963

3.208
2.677
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Table 1. Continued
Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
Zona pellucida binding protein 2

Q0VCG8

ZPBP2

5.962

5.099

P34955

SERPINA1

0.392

0.201

C8G protein

A8YXZ2

C8G

0.289

CAD protein

F1MVC0

CAD

0.332

Chromosome 14 open reading frame 166 ortholog

Q3T0S7

RTRAF

0.467

Complement component C6

F1MM86

C6

0.496

Cytohesin 1 (Fragment)

F1MCV3

CYTH1

(B ) Down-regulated proteins
Alpha-1-antiproteinase

0.341

DDB1 and CUL4 associated factor 5

F1N0J7

DCAF5

0.043

Dynein axonemal heavy chain 11

F1N724

DNAH11

0.263

Dynein heavy chain domain 1

F1MEF7

DNHD1

0.493

0.036

Endophilin-A2

Q2KJA1

SH3GL1

0.384

0.478

Engulfment and cell motility 1

F1MQH0

ELMO1

Factor XIIa inhibitor precursor

E1BMJ0

SERPING1

Family with sequence similarity 81 member A

F1N4N5

FAM81A

0.283

Fas activated serine/threonine kinase

F1N4L0

FASTK

0.396

Filamin B

E1BKX7

FLNB

Gasdermin B

F1MCQ4

GSDMB

Haptoglobin

G3X6K8

HP

0.492

0.372

0.453
0.434

0.472
0.245

0.471
0.479
0.211

0.351

0.439
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Table 1. Continued
Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
HECT, UBA and WWE domain containing 1, E3
ubiquitin protein ligase
Hemoglobin subunit alpha
Hemoglobin subunit beta

E1BNY9

HUWE1

P01966

HBA

0.305
0.115

0.200

0.177

0.261

P02070

HBB

Immunoglobulin lambda-like polypeptide 1

F1MLW7

LOC100297
192

0.242

Immunoglobulin lambda-like polypeptide 1
(Fragment)

G3N2D7

LOC100297
192

0.401

Inhibin alpha chain

P07994

INHA

Keratin, type II cytoskeletal 7

Q29S21

KRT7

0.491

Leucine rich repeat kinase 2

E1BPU0

LRRK2

0.422

Lumican

Q05443

LUM

0.469

NIMA (Never in mitosis gene a)-related kinase 2

Q2KIQ0

NEK2

0.453

Plasma serine protease inhibitor

Q9N2I2

SERPINA5

Protocadherin Fat 2 precursor (Fragment)

F1MPF3

-

PTPRR protein

A5PKF8

PTPRR

0.102

Serglycin (Fragment)

G5E5K5

SRGN

0.036

Serpin family E member 2

F1MZX2

SERPINE2

Serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 3

G8JKW7

SERPINA3

P02769

ALB

Serum albumin

0.433

0.499

0.079

0.062

0.353
0.360
0.177
0.140
0.446

0.422
0.302

0.073
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Table 1. Continued
Protein Description

Uniprot
Accession

Gene ID

PL HE2/
PL LE2

FF HE2/
FF LE2

PL LE2/
FF LE2

PL HE2/
FF HE2

iTRAQ Ratio
SPHK1 interactor, AKAP domain containing
(Fragment)

F1MZL5

SPHKAP

Suppressor of G2 allele of SKP1

Q2KIK0

SUGT1

TBC1 domain family member 4

E1BPA1

TBC1D4

Transmembrane protein 186

Q5EA03

TMEM186

Transthyretin

O46375

TTR

Ubiquitin protein ligase E3 component n-recognin 4

G3N0A8

UBR4

Versican core protein

F1N6I7

VCAN

Vitamin D-binding protein

F1N5M2

GC

Zinc finger protein 618

E1BJV7

ZNF618

0.475
0.476

0.200
0.315

0.193

0.435

0.334
0.394
0.257

0.328
0.129
0.393

0.331

0.330
0.309

0.201
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Figure 3.5. Panther analysis of up- and down-regulated proteins identified in bovine
plasma (Pl) and follicular fluid (FF) containing low and high pre-ovulatory E2. The
up- and down- regulated proteins were compiled from PL HE2/PL LE2, FF HE2/FF LE2, PL
LE2/FF LE2 and PL HE2/FF HE2 analyses. Proteins were classified according to (A)
Molecular function (B), Cellular localization, and (C) Biological processes.

measure and compare the proteomes in PL and FF containing high- and low-circulating
levels of E2 during the pre-ovulatory period. Quantitative measurement of protein
changes can confirm and/or provide better understanding of the protein’s functions.
E2 is critical to the development and maturation of ovarian follicles115, 117.
Concentration of E2 in PL and/or FF has been positively correlated to increased oocyte
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quality, fertilization and subsequent embryo quality129, increased follicle size118, and
improved pregnancy success130. Considering the vital role of proteins in cell function and
regulation, this study thus examined the associations between E2 and protein expressions
in FF and PL, because of the significant similarities between PL and FF proteins which
results from the number of PL proteins capable of crossing the blood-follicular barrier
during folliculogenesis131, 132.
A total of 103 proteins significantly changed expression in the presence of E2 as
defined by fold change. To determine a more direct influence of concentration of E2 on
PL or FF proteome, high and low E2 in PL or FF were compared. The number and degree
of fold change of proteins from the comparison between high and low E2 in FF was
higher than the corresponding PL comparison. This suggests pre-ovulatory circulating
concentration of E2 has a greater impact on FF proteome than on PL proteome. This is
not surprising as E2 is produced by the GCs of ovarian follicles116, 133 and FF is the
immediate environment of the developing follicle and oocyte. The only predominant
protein in PL HE2 which was also predominant in the FF HE2 when compared to the
respective LE2 samples was KRT7 (keratin, type II cytoskeletal 7), a member of the
keratin gene family. E2 seems to have a higher influence on KRT7 expression in FF than
in PL evidenced by the higher fold change in FF (6.21 vs 2.27). The greater effect of E2
on KRT7 in FF is further supported when PL and FF were compared. There was no
observable fold change in KRT7 from PL LE2 and FF LE2 comparison but KRT7 was
down-regulated in PL HE2 compared to FF HE2. The function of KRT7 is reported to be
building structure integrity within complexes. Keratin genes are usually expressed in
pairs consisting of one type I and one type II as both are necessary to for an intermediate
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filament134, 135. The presented data supports KRT7 involvement in developing follicles
and possibly eliciting similar structural functions modulated by E2 in FF.
Successful folliculogenesis requires adequate regulation of cellular apoptosis.
ELMO1 promotes cellular apoptosis136. Specifically, ELMO1 is involved in cytoskeletal
rearrangements required for phagocytosis of apoptotic cells and cell motility137. Very few
apoptotic cells were found in primordial, primary, secondary and vital tertiary follicles. In
contrast, apoptosis in atretic tertiary follicles was much more frequent138. Our observation
of down-regulation of ELMO1 in FF HE2 compared to FF LE2 is therefore in support of
decreased apoptosis in the pre-ovulatory follicle. The suppression of ELMO1 in the
presence of E2 at the pre-ovulatory stage seems more localized in FF since it was more
predominant in PL HE2 when compared to PL LE2.
Proteins were more predominant in PL compared to FF which supports the
hypothesis that several FF proteins originate from PL113. It should be noted that proteins
down-regulated in PL compared to FF indicate their predominance in FF and possibly a
more localized role in FF. A greater number of proteins showed expression change in the
comparisons between PL and FF than between high and low E2 PL or FF comparisons.
This is likely due to the inherent differences between PL and FF. The majority (50 out of
72 or 78) of these proteins was common to the different comparisons between PL and FF
and maintained their expressions (i.e. being up- or down-regulated) regardless of the E2
level. Although the expressions for these common proteins did not change, individual
iTRAQ ratios were generally lower for up-regulated proteins and higher for downregulated proteins after PL HE2 and FF HE2 paired comparison than PL LE2 and FF LE2
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paired comparison. This further suggests a greater stimulating effect of high E2 on FF
proteins such that the concentration difference of these proteins in PL and FF is lower
resulting in lower up-regulated iTRAQ ratios and higher down-regulated iTRAQ ratios
for the HE2 pair. Twenty-six out of 39 up-regulated proteins and 5 out of 11 downregulated proteins which were common to the different PL and FF paired comparisons
showed this trend. Common up-regulated proteins showing this trend included FGA,
FGB, FGG, cumulus cell-specific fibronectin 1 transcript variant (FN1), apolipoprotein B
(APOB), A2M, complement C1s subcomponent (C1S), and fibulin-1 (FBLN1). Common
down-regulated proteins with this trend were F13A1, VCAN, endophilin-A2 (SH3GL1),
SRGN, and TBC1 domain family member 4 (TBC1D4).
PANTHER analysis revealed the up- and down-regulated proteins had
multifunctional roles but cellular process and metabolic process were the major functions.
Developing ovarian follicles undergo a series of coordinated cellular processes that
induce morphological and functional changes within the follicle, leading to cell
differentiation and oocyte development139. Further analysis in PANTHER showed the
proteins under cellular function were involved in cell communication (52.4 %), cellular
component movement (23.8%), cell growth (4.8%), cell cycle (14.3%), and chromosome
segregation (4.8%). Coordinated communications between the granulosa, cumulus and
thecal cells, and as well as the oocytes are critical for successful folliculogenesis and the
development of an oocyte capable for ovulation and fertilization140. Of these
communication between the oocyte and GCs is considered the most significant for
growth regulation and maturation of the oocyte and follicular luteinization. The proteins
linked to cell communication included INHA, FN1, FGG, FGB, lumican (LUM),
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synaptotagmin-12 (SYT12), regulating synaptic membrane exocytosis 2 (RIMS2), and
KRAS proto-oncogene, GTPase (KRAS). These proteins play vital roles in follicle
growth and maturation.
Folliculogenesis is highly regulated by gonadotropins and sex hormones. The
secretions of these hormones are in turn regulated by a number of proteins. INHA is one
such protein involved in the regulation of FSH secretion. Specifically, INHA selectively
inhibits FSH secretion from the pituitary in a negative-feedback mechanism141. The
decline in FSH continues to a level that is only able to be utilized by the largest follicle
thereby enhancing its growth to become the DF. The inability of smaller follicles to
utilize the low levels of FSH results in regression of their growth to become subordinate
follicles142, 143. INHA was found highly down-regulated in PL compared to FF with
lower expression in the high E2 pair (PL HE2/FF HE2; iTRAQ ratio 0.062) than the low
E2 pair (PL LE2/FF LE2; iTRAQ ratio 0.079). The high INHA concentration in FF from
DF and with high E2 is consistent to the vital roles of INHA and E2 in the decline of FSH
observed during follicular deviation142, 143. Apart from its role in regulating FSH
secretion, INHA is also a critical regulator of different cellular processes including
differentiation, cell migration, proliferation, and apoptosis144.
SYT12 is another protein involved in regulation of hormonal secretion during
follicular growth. It belongs to synaptotagmin family that serve as Ca2+ sensors for Ca2+
triggered release of hormones, including FSH from the pituitary gland145. RIMS2 is also
involved in synaptic membrane exocytosis that results in the release of neurotransmitters.
It functions by binding to pre-synaptic proteins including synaptotagmin 1 (SYT1), an
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isoform of SYT12146, 147. SYT12 and RIMS2 were up-regulated in PL LE2 compared to
FF LE2. RIMS2 was also up-regulated in FF HE2 compared to FF LE2. The expression
changes in both proteins indicate their involvement in follicle development.
The proteins FN1, FGB, FGG, and apolipoprotein R were up-regulated in PL compared
to FF but iTRAQ ratios indicate concentration increases in these proteins in FF with high
E2 compared to low E2, signifying an influence of E2 on these proteins. These proteins
promote cellular processes by binding to a variety of cells and molecules. Indeed all five
proteins were classified under biological adhesion by PANTHER. Cell adhesion leads to
alterations in cell shape and motility that are required for different cellular functions
during folliculogenesis and the development of a competent oocyte148, 149. Cell shape was
reported to regulate cell proliferation in mouse GCs150 and steroidogenesis in rat GCs151.
FN1 and fibrinogen have been reported to increase proliferation in a number of cells.
Specifically, FN1 has been reported to stimulate proliferation of ovarian GCs152. Fibrin
matrix composed of fibrinogen and thrombin has also been reported in the survival and
proliferation of ovarian cells153 and promoted growth in primordial-primary follicles and
secondary follicles. The growth to secondary follicles was greater compared to
primordial-primary follicle growth154. Successful ovulation and capture of the oocyte by
the oviduct and subsequent transport through the oviduct necessitates formation and
expansion of the cumulus cell-oocyte (COC) matrix155. Stabilization and expansion of the
COC matrix involves binding of several proteins including FN1, VCAN, and laminin 156.
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Figure 3.6. Up-regulated (red) and down-regulated (pink) proteins involved in the complement and coagulation
cascades identified in this study. Up- and down-regulated in plasma (PL) compared to follicular fluid (FF): Alpha-2macroglobulin (A2M), coagulation factor V (F5), coagulation factor XIII A chain (F13), complement C1s (C1S),
complement C6 (C6), alpha-1-antiproteinase (A1AT or SERPINA1), plasma serine protease inhibitor (PCI or
SERPINA5), factor XIIa inhibitor precursor (C1INH or SERPING1), complement C8 gamma chain (C8G; this was also
up-regulated in PL HE2 compared to PL LE2), and fibrinogen (fibrinogen alpha chain (FGA), fibrinogen beta chain
(FGB), and fibrinogen gamma chain (FGG)). Fibrinogen is a ligand of complement receptor types 3 and 4 (CR3 and CR4;
orange). Up-regulated in FF HE2 compared to FF LE2: Coagulation factor XII (F12).
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Follicle development involves independent movements of cells and cellular
components to sites of action and to enable interaction with other relevant molecules.
Proteins with this function were categorized under cellular component movement, a subset of cellular process. The proteins were AKAP domain containing SPHKAP
(SPHKAP), dynein axonemal heavy chain 11 (DNAH11), DNHD1, ELMO1, and LUM.
LUM is a widely distributed protein involved in different biological functions.
Accordingly, LUM was categorized in 7 out of the 12 BP hererin: cellular process,
biological regulation, cellular component organization or biogenesis, developmental
process, locomotion, multicellular organismal process, and response to stimulus. LUM
was up-regulated in FF HE2 compared to FF LE2, indicating a positive association with
E2 in FF. This positive association is further supported by the PL and FF comparisons
where LUM was down-regulated in PL HE2 compared to FF HE2 but showed no
significant expression change from the low E2 comparison.
Metabolic process was the second most associated BP. Primary metabolic process
formed 46.7% of the metabolic processes which in turn was comprised of protein
metabolism (48%) and nucleobase-containing compound metabolic process (28%).
Protein metabolism is integral to the growth and maturation of follicles, occurring in cells
including granulosa, cumulus, and thecal cells and the developing oocyte157. Protein
synthesis competence, patterns, and rate in somatic cells and oocytes can be used as a
measure of maturation of the follicles158, 159. Proteins associated with protein metabolism
in the current study were A2M, dpy-19 like 4 (DPY19L4), vacuolar protein sortingassociated protein 28 homolog (VPS28), HP, E3 ubiquitin protein ligase HUWE1
(HUWE1), F13A1, Asparagine-linked glycosylation 5 (ALG5), dolichyl-
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diphosphooligosaccharide-protein glycosyltransferase subunit 1 ( RPN1), INHA,
phosphoglycolate phosphatase (PGP), and transcription initiation factor TFIID subunit
(TAF1).
The protein A2M was predominant in PL compared to FF irrespective of high or
low E2 levels. The lower concentration in FF than in PL is consistent to previous
report160. However, concentration of A2M increases with follicle growth, promoted by its
secretion by GCs and thecal cells160. A2M is involved in metabolic processes as well as
regulating E2 production and follicular development via binding to a wide range of
reproductive related targets including inhibin, activin, transforming growth factor β and
α (TGFβ, TGFα), and insulin-like growth factors to regulate their functions161-163.
Another important metabolic protein is ALG5, which is involved in the formation of the
COC matrix. The predominant component of the COC matrix is glycosaminoglycan
hyaluronan (HA)140. Glycosylation of amino acids is therefore an important metabolic
process in follicle maturation. ALG5 participates in the synthesis of oligosaccharides for
asparagine-linked glycosylation. Concentration of ALG5 increased in FF and decreased
in PL with high E2 than with low E2 but the expression changes were not significant
(iTRAQ ratios 1.519 and 0.836 respectively). However, ALG5 significantly increased in
PL when compared to FF (iTRAQ ratios 2.103-3.265). This observation shows a
modulation of ALG5 by E2 in follicle growth.
The immune system in the reproductive tract plays a critical role in
simultaneously providing a protective microenvironment to support successful
reproduction processes and conferring protection against potential pathogens. In fact,
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folliculogenesis and ovulation are viewed as a hormone-induced inflammatory process164.
Sex hormones, E2 and progesterone, significantly regulate the reproductive immune
system cells, tissues, and molecules165. This is supported by the results of this study by
expression changes of immune-related proteins in the presence of high and low E2.
Proteins relating to the immune system were categorized under response to stimulusA2M, INHA, ankyrin repeat and KH domain containing 1 (ANKHD1), SPHK1
interactor, AKAP domain containing (SPHKAP), LUM, and Gasdermin-B (GSDMB);
and immune system process- ANKHD1, immunoglobulin lambda-like polypeptide 1
(LOC100297192) and apolipoprotein R (LOC515150).
Follicuclogenesis is a developmental process that results in growth of primordial
follicles into primary, secondary, and tertiary follicles. The proteins JAG1, VCAN,
INHA, FBLN1, LUM, GSDMB, protocadherin Fat 2 precursor (FAT2), and titin (TTN)
functions were classified under developmental process by PANTHER. Cell proliferation
is key to the increase in size and transformation of follicles from one stage to the other.
INHA and LUM promote cell proliferation. VCAN is a component of the extracellular
matrix (ECM) of a variety of tissues. It forms large complexes with HA166 and in the
ovary, binding to the HA of the COC matrix results in stabilization and expansion of the
COC matrix156. VCAN also promotes cross-linking of the COC matrix by binding to
several proteins including FBLN1 and FBLN2167. VCAN was up-regulated in FF
compared to PL in the presence of low or high E2.
A number of proteins were categorized under biological regulation. These
proteins were identified mainly predominant in PL compared to FF. An example of such
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proteins is ornithine decarboxylase (ODC1). ODC1 is the initial and rate-limiting step in
the biosynthesis of polyamines required for growth, differentiation, and transformation of
cells168. Inhibition of ODC1 with α-difluoromethylornithine (DFMO) was demonstrated
to inhibit ovarian growth, the formation of graafian follicles, and the secretion of
progesterone and E2 in immature mice. Administering of DFMO to adult cycling females
on evening/night of proestrus markedly decreased plasma progesterone levels at diestrus
which was linked to down-regulation of cytochrome cholesterol side-chain cleavage
enzyme, steroidogenic factor 1, and steroidogenic acute regulatory protein in the ovary
and to a reduced vascularization of the corpora lutea169. Other proteins in the biological
regulation category were SUGT1, SPHKAP, RIMS2, SYT12, LUM, CGN1, and
epidermal growth factor receptor kinase substrate 8-like protein 1 (EPS8L1).
Folliculogenesis involves proteins that transport and/or maintain substances
including cells, cell components, metabolites, and proteins in specific locations of action.
Proteins involved in this process were categorized under localization. Such proteins
included GC and ALB. GC is the main protein involved in the transport of 25hydroxyvitamin D (25(OH)D), the precursor of the active form of vitamin D, and the
recognized optimal indicator of vitamin D status. Vitamin D level is therefore
predominantly contributed by GC level170, 171. Based on the free hormone hypothesis that
protein-bound hormones are not biologically available and that unbound hormones are
biologically active, down-regulation of GC as found in this study can indicate more
bioavailable 25(OH)D170. Apart from its well-known role in bone morphology, vitamin D
is increasing being viewed as vital for regulation of reproduction physiology. It has been
positively associated with pregnancy, embryo implantation rate and IVF outcomes172 and
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to reproductive steroid hormones173, 174. Our data asserts to a regulation of vitamin D by
E2.
ALB is a major component of PL and FF. Due to its abundance it was prior
depleted to enable detection of lower abundant proteins. ALB transports a wide variety of
substances including proteins, steroids, drugs, fatty acids, metabolites, hormones, and
cations, facilitated by its multiple binding sites and longer circulatory half-life. ALB’s
strong attraction to cations, its low molecular weight and its abundance enable it to play a
central role in maintaining colloidal osmotic pressure (COP) that regulates the
distribution of extracellular fluids between the vascular and extravascular
compartments175, 176. STRING analysis of the up- and down-regulated proteins showed
ALB had the highest interactions with other proteins (Figure 3.7) supporting ALB
versatile role. Identified proteins in this study that bind to ALB include GC, F13, HBA,
C1S, apolipoprotein C-III (APOC3), and kininogen-2 (KNG2)177.
Pathway analysis showed the complement and coagulation cascades were the
predominant pathways, consistent with previous studies on FF40, 178. The stage of follicle
development seems to regulate the proteins involved in coagulation pathway. Proteins
involved in coagulation were found down-regulated in the pre-deviation, early deviation
and pre-ovulatory stages and up-regulated in later deviation to post deviation stages40.
Here, the coagulation and complement pathway involved 13 proteins showing different
levels of expression changes, supporting a dependence on individual protein roles in the
pathway. The predominance of the complement and coagulation cascades supports the
view that the follicle development and ovulation are hemorrhagic and inflammatoryinduced events.
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Figure 3.7. Network of identified up- and down-regulated proteins in bovine PL
and FF containing low and high concentration of estradiol during the pre-ovulatory
stage. A total of 89 proteins are connected with 52 paired interactions annotated by
STRING database. The highest number of interaction is seen with ALB, signifying the
versatility of its function. There are no interaction among majority of the proteins which
can suggest the independence and critical role each play in follicle growth and maturation.
The relationships among proteins were derived from evidence from known interactions
(from curated databases and experimentally determined), from predicted interaction (gene
fusions, gene neighborhood and gene co-occurrence) and from other sources (textmining,
co-expression and protein homology). These are shown in the legend with different colors.
Details of the proteins are shown in Table 3.1.
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The complement cascade and coagulation cascade are closely related and each
activates the other in a reciprocal way. For instance, activated platelets can activate the
classical and alternative complement pathways. Thrombin, coagulation factors FIXa,
FXa, FXIa, and plasmin can activate C3 and C5. F12a can activate C1qrs complex to
activate the classical complement pathway. Conversely, mannan-binding lectin
associated serine protease 2 (MASP-2) and the final stage complement complex C5b–9
are able to generate thrombin through direct cleavage of prothrombin. Thrombin is a vital
coagulation component that converts fibrinogen to fibrin. C5a promotes procoagulant
activity by several actions on cells including inducing mast cell and basophil to switch
from profibrinolytic to prothrombotic activities through the upregulation of the
coagulation component plasminogen activator inhibitor-1 (PAI-1)179.
F12 is the first component of the coagulation pathway and its activation triggers
the intrinsic pathway of the coagulation system179. F12 was up-regulated in FF HE2
compared to FF LE2, indicating a greater influence of E2 on F12 in FF. Five other
proteins were down-regulated in PL compared to FF namely A1AT, PCI, C1INH, C6,
and C8G. A1AT expression in FF HE2 was about double that in FF LE2 when compared
to the corresponding PL samples. A1AT, C1INH, and PCI are protease inhibitors
belonging to the SERPIN superfamily. The SERPINs regulate a wide range of proteins
including those involved in the coagulation, fibrinolysis, and complement pathways180,
181

. Proteins in the coagulation and fibrinolytic system inhibited by A1AT include

neutrophil elastase, activated protein C (APC), cathepsin G, thrombin, plasmin,
coagulation factor X (F10), and coagulation factor XI (F11)182-186. PCI inhibits the down-
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regulation of coagulation system by inhibiting the activation of protein C by thrombin in
the presence of thrombomodulin and by inhibiting APC186. APC down-regulates the
coagulation system by degrading the coagulation factors Va and VIIIa by limited
proteolysis and by eliciting anti-inflammatory response and cytoprotective signaling in
endothelial cells by activating protease-activated receptor 1 (PAR-1)186. PCI also downregulates coagulation by inhibiting proteolytic cleavage of fibrinogen by thrombin in the
presence of heparin187.
C1INH is a vital regulator of complement cascade and functions by inactivating
C1r and C1s, components of C1q, and mannan-binding lectin associated serine proteases
MASP-1 and MASP-2188. C1q is the first component in the classical pathway and MASP1 and MASP-2 are first components in the lectin pathway. C1INH is also a major
regulator of the coagulation cascade. It inhibits inflammation by blocking the activities of
activated F12 and plasma kallikrein, two proteins that participate in the production of
bradykinin which promotes inflammation by increasing vascular permeability188, 189. C6
and C8G are part of the later stage of complement activation and function as membrane
attack proteins. They interact to form membrane attack complexes that are able to
associate with the lipid bilayer of target molecules, leading to eventual disruption of the
lipid bilayer188. The up-regulation of the six proteins in FF indicates their vital roles in
regulation of coagulation and complement cascades during bovine follicular
development.
Other identified proteins in the coagulation and complement system were A2M,
F5, F13, C1S, FGA, FGB, and FGG (up-regulated in PL compared to FF) and C8G (up-
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regulated in PL HE2 compared to PL LE2). The functions and associations of these
proteins in the coagulation and complement pathway are shown in Figure 5. The upregulation of C8G in PL containing high E2 than low E2 suggests greater influence of E2
on this protein in PL.
3.7 CONCLUSION
In conclusion, iTRAQ proteomic enabled probing of protein changes in PL and
FF containing high and low concentrations of E2 during the pre-ovulatory period. E2
influence the expression changes of several proteins in PL and FF. Protein expression
changes is greater with high E2 in FF than in PL when compared to their respective low
E2. But protein expression change with high and low E2 is similar when PL and FF are
compared and this is possibly due to the inherent difference in protein concentrations in
PL and FF. The expression changes of several of the proteins are associated to their
function in follicle growth and maturation. The coagulation and complement cascades are
enriched during bovine follicle development and support the view that folliculogenesis
and ovulation are hemorrhagic events.
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CHAPTER 4
ATHEROSCLEROSIS DEVELOPMENT IN THREE REGIONS OF THE
AORTIC ROOTS OF APOLIPOPROTEIN E KNOCKOUT (APOE-/-) MICE
4.1 ABSTRACT
The aortic root is a predilection site for atherosclerosis development in mice. We report a
investigation of atherosclerotic progression in three specific regions of the aortic roots,
namely the ascending aorta region (AAR), region showing the orifices of the coronary
arteries marking the start of the ascending arch (OCAR) and aortic sinus region (ASR) in
a large population of ApoE-/- male and female mice at different ages. In this study, 67
ApoE-/- and 27 wild-type C57BL/6J mice (controls) were fed with a high fat diet (HFD)
until age 8, 12, 18, or 24 weeks. Through systematic classification and quantification of
lesions in each region and statistical data analysis, we found that the complexity and total
atherosclerotic lesion areas in ApoE-/- mice was location and age dependent. It was
slowest in the AAR with lesions progressing from dominant type I at 8 weeks, type II at
12 weeks, types III at 18 and types III and IV at 24 weeks of age. Lesion development
was comparable in the OCAR and ASR regions; types II and III lesions dominated in
mice at 8 and 12 weeks of age, respectively, while types IV and types IV and V
dominated at 18 and 24 weeks of age, respectively. Average percentage of atherosclerotic
lesions typically increased from the AAR to the OCAR to the ASR at a specific age, and
from 8 to 24 weeks of ApoE-/- mice at each region, correlating with the histological data.
Aatherosclerosis development was found to be slightly faster in female than male ApoE-/mice. As expected, no lesions were observed in wild-type mice. These findings would be
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beneficial in experimental design and targeting of lesion types in aortic roots of the
popular ApoE-/- murine atherosclerosis model.
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4.2 BACKGROUND AND MOTIVATION
The aortic root is a predilection site for lesion development67 in mice and is often
investigated to determine the overall extent of atherosclerosis71 in mice. The aortic root
has three identifiable regions: the ascending aorta region (AAR), the region showing the
orifices of the coronary arteries marking the start of the ascending arch (OCAR), and the
aortic sinus region (ASR) characterized by the appearance of the aortic cusps190. The
apolipoprotein E knock-out (ApoE-/-) mouse model65, 66 is efficient for demonstrating the
progressive atherosclerotic events and lesion-morphological features found in humans191.
ApoE-/- mice spontaneously develop atherosclerotic lesions when fed a normal mouse
chow diet. These conditions are accelerated with a high saturated fat and cholesterol
diet65. The C57BL/6 mouse strain is more susceptible in developing atherosclerosis70 and
is therefore often the background for ApoE-/- mice71. In this study, 67 ApoE-/- female and
male mice on C57BL/6 background were fed a HFD for different periods of time
corresponding to four age groups: 8, 12, 18 and 24 weeks. Serial cross-sectioning
method190 with subsequent staining and calculation of lesion areas with image analysis
software were then used to carefully identify, and quantify atherosclerotic lesions.
4.3 OBJECTIVES
Although different atherosclerosis studies have examined the aortic root, none
have characterized and quantified the three regions simultaneously in a large population.
Our primary objective is to meet this limitation. Data from a large population size will be
beneficial in experimental design of atherosclerotic studies with this mouse model. Other
objectives are to identify atherosclerosis progression trends in the regions and to
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investigate gender-specific differences in the disease development. This study provides
photomicrographs of the different types of atherosclerotic lesions which could be
beneficial, when used in conjunction with related images derived from nuclear and nonnuclear imaging techniques55 for disease diagnosis and target interventions. Future work
is to perform proteomic analysis on blood samples from mice in this study to identify
potential phosphoprotein biomarkers of atherosclerosis.
4.4 MATERIALS AND METHODS
4.4.1 Mice Housing
ApoE-/- on C57BL/6 background and wild-type C57BL/6 mice were bought at
three weeks of age from Jackson Laboratory (Maine). Both ApoE-/- and wild-type
C57BL/6 mice were fed standard chow diet (contained 20% protein by weight, 4.5% fat
by weight, 0.02% cholesterol by weight, no sodium cholate and casein) for one week
upon arrival and then transferred onto a high fat diet (HFD) until they reached 8, 12, 18,
or 24 weeks of age. These feeding periods have been shown to induce different degrees
of atherosclerotic lesions in ApoE-/- mice67. The HFD (Harlan Laboratories, Madison,
WI) contained 21% fat by weight, 0.15% cholesterol and 19.5% by weight casein without
sodium cholate. There were 36 male ApoE-/- mice, with nine mice in each of the four
groups. Female ApoE-/- mice totaled 32 with six mice in the 8 week group, eight mice in
the 12 week group, nine mice in the 18 week group and nine mice in the 24 week group.
One mouse from the 24 weeks female group died after the feeding period and was
excluded from further analysis. For wild-type C57BL/6 male mice, there were four in the
8-week group and three in each of the 12, 18 and 24 week groups (13 in total). There
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were 14 female wild-type mice in total with three mice each in the 8- and 12-week groups
and four mice in each of the 18 and 24 week groups. Mice were given diet and tap water
ad libitum. The mice were housed in pathogen free 12 h dark cycles. All research
protocols in this mouse study were approved by Institutional Animal Care and Use
Committee (IACUC) in South Dakota State University.
4.4.2 Histological Analysis of Aortic Roots
All mice were sacrificed at the end of their designed feeding period and then
dissected and sectioned according to the method previously described190. During
dissection, the heart was separated from the aorta and placed in phosphate-buffered saline
solution. At the time of sectioning, the lower ventricular portion of the heart was cut
away such that the remaining upper cardiac portion was about 30% of the total heart
tissue size. The upper cardiac portion was placed in a tissue mold and then completely
covered with optimal cutting temperature (OCT) compound. Each OCT-embedded tissue
was manipulated to ensure that it was placed center and perpendicular to the tissue mold
and free of any bubbles. The mold was then quickly frozen on dry ice and sectioned
immediately or wrapped in parafilm and frozen at -20oC for later sectioning.
Tissues were sectioned with the upper ventricular portion facing outwards in the
tissue mold. During sectioning, the frozen tissue was mounted on a cryostat (Leica
CM3050 S) and cross-sectioned at 8 µm intervals until all three regions of the aortic root
(i.e. AAR, OCAR, AAR, ASR) are collected, identified by the region spanning the
appearance of the aortic cusps to the region of the disappearance of the circular shape of
the ascending aorta. About 140 sections per mouse were collected spanning the three
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regions. Frozen sections were collected in sequence on histological slides (8 to10 tissue
sections per slide) and frozen at -80 °C until ready for staining.
4.4.3 Oil Red Staining and Imaging
Oil red O is commonly used to assist in quantification of atherosclerotic lesions in
mice. Oil red O stains neutral lipids, enabling determination of lesions areas with image
analysis softwares190. Oil red O stock solution was prepared by dissolving 0.5 g Oil red O
(CI 26125; Sigma Aldrich, Saint Louis, MO, USA) in isopropanol (Fisher Scientific,
Hampton, NH, USA) using a gentle heat of a water bath. Oil red O working solution was
prepared by diluting 30 mL of stock solution with 20 mL of distilled water and filtering.
Working solution was prepared fresh for use at each staining time. For Oil red O staining,
frozen sections were first dried under room temperature for about 15 minutes to reduce
tissue loss resulting from a weak bond with the histological slide. Tissue sections were
fixed in formalin (paraformaldehyde in PBS; 4% w/v, pH = 6.9) and then washed under
running tab water for about 10 minutes and rinsed with 60% isopropanol. Tissues were
then stained with freshly prepared Oil red O working solution, rinsed with 60%
isopropanol and then counter stained with Harris hematoxylin solution (Sigma Aldrich,
St. Louis, MO, USA). Stained tissues were cover slipped with glycerin jelly mounting
medium (Electron Microscopy Sciences, Hatfield, PA) and imaged immediately or
refrigerated overnight or stored at -20 oC until ready for imaging. All tissue sections
collected from each ApoE-/- mouse were stained. For C57BL/6 controls, alternating
histological slides from the serial cross-sectioning were selected for staining. Images of
Oil Red O stained aortic root tissues on histological slides were captured at 35
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magnification using a Leica EZ4HD light microscope (0.057 nA ) equipped with Leica
Acquiring Service, V.4.0 software. 200 (0.4 nA) and 600 (oil immersion nA 1.4-0.6)
magnifications were obtained using Leica DM14000B inverted light microscope
connected to a Cool Snap Pro color video camera (Media Cybernetics) equipped with
QCapture-Pro 5.1 software. Other magnifications (50 µm) were obtained with Olympus
AX70 Upright Compound Microscope equipped with Olympus DP70 Digital Camera.
4.4.4 Classification of Lesions
Lesions were classified based on their size and morphology as previously
described58-60 for atherosclerotic lesions. Lesion classification was done by individuals
not involved in mice experimental design and feeding to prevent classification errors and
bias. Lesion types observed in this study are shown in Figures 4.2 to 4.4. Type I lesions
were characterized by the presence of scattered macrophages containing lipid droplets
(foam cells) (Figure 4.2). Multilayer macrophage foam cells and lipid-laden smooth
muscle cells were characterized as type II lesions (fatty streaks) (Figure 4.2, Panel C and
D). Lesions that had pools of extracellular lipids in addition to features of type II lesions
but lack the lipid rich core (necrotic core) were labeled type III (intermediate) lesions
(Figure 4.3). The necrotic core is a key feature of types IV and V lesions. Type V lesion
(Figure 4.4, Panels C and D) was differentiated from type IV (Figure 4.4, Panel A and B)
by the additional presence of a substantial amount of spindle-shaped fibrous tissues
mixed with the necrotic core lipids (sometimes occurred as multilayers of fibrous tissues
in the lipid core) and/or a fibrous cap covering the top of the lipid core.
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Figure 4.1. Workflow of the experimental design for the characterization and
quantification of atherosclerotic lesions from aortic root regions of ApoE-/- mice.

Type VI lesion, the complicated lesion, is characterized by the presence of fissure,
hematoma, and thrombus, sometimes in addition to features of type IV or V. Type VI
lesion was not observed in aortic roots from mice in this study. The overall disease state
in a region was defined by the highest lesion type observed in tissues from that region.
4.4.5 Quantification of Lesions
Lesion areas and aortic luminal boundaries were manually measured using ImageJ
analysis software developed by NIH. Lesion-area calculation with imageJ was achieved
by tracing along a lesion outer boundary. Measurement of lesion areas was carried out on
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alternating tissue sections on all histological slides collected from the serial crosssectioning of an ApoE-/- mouse. About 70 tissue sections per mouse were quantified. A
total of 15 mice, seven male and eight female ApoE-/- mice, were excluded from the
quantification due to tissue loss from at least one of the regions during sectioning and/or
staining. Thus a total of 29 male and 23 female ApoE-/- mice were quantified. To
determine the percent of lesions in each stained tissue, the sum of all lesion areas
(obtained from ImageJ analysis) in the tissue was expressed as the percent of the area
corresponding to aortic luminal boundary. Average percent lesion for an aortic root
region per mouse was calculated by taking the average of all the percent lesions
calculated for tissues from that region. The average percent for a region per mouse was
used to calculate the average percent of a region for a group, standard deviations and
perform one-way analysis of variance (ANOVA).
ANOVA performed included comparisons between the aortic root regions from
mice within a group, the aortic root regions between the different groups and the aortic
root regions between genders. The comparisons were made to determine whether the
differences in lesion development were purely random or significant. Significant
difference was established at p<0.05.
4.5 RESULTS
4.5.1 Atherosclerotic Lesions Progression and Characteristics in ApoE-/- Mice
Atherosclerosis lesions were observed in all three regions of the aortic root of
ApoE-/- mice but as expected, not in C57BL/6 control mice fed with the same HFD for the
same time periods. Lesion size, distribution, and complexity increased from the AAR to
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the OCAR and to the ASR. The size and severity of lesions also increased in all three
regions with increasing age of mice (Figure 4.6). Lesion types I to V were observed and
the progression occurred faster in female than in male mice. Type I lesions were
dominant in the AAR while type II lesions were dominant in the OCAR and the ASR in 8
week ApoE-/- male and female mice. By 12 weeks of age, type II lesions were dominant in
the AAR. The dominant lesion was type III which were in some cases undergoing
progression to type IV in the OCAR and ASR regions for both genders. At 18 weeks,
lesion progression in the AAR was dominantly type III in females and type II in males.
Both genders showed mainly type IV lesions in the other two regions. The 24-week
group developed dominant type IV lesions and type III lesions in AAR of females and
males respectively. Types IV and V lesions were dominant in the other two regions. The
degree of fibrous tissues, identified at 200 and 630 magnification as spindle- shaped
fibrous tissues in lesions were higher in 24 weeks mice than in 18 weeks mice. In both
the 18- and 24-week groups, fibrous tissues were higher in the ASR compared to the
OCAR. However, fibrous tissues were not quantified. Although advanced lesions (types
IV to V) were dominant feature in older mice (18 to 24 weeks), early lesions (types I to
III) were also observed, often at the shoulder regions of advanced lesions.
The overall disease state in a region was defined by the highest lesion type
observed in tissues from that region. The disease state in the AAR was type I at 8 weeks,
types II at 12 weeks, type III at 18 weeks, and type V at 24 weeks. The disease state in
the OCAR and ASR regions were type II at 8 weeks, type III (in some cases undergoing
progression to type IV) at 12 weeks, and type V at 18 and 24 weeks.
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Figure 4.2. Photomicrographs of type I and type II lesions in tissue from the region
showing the orifice of the coronary artery (OCAR) and from the arotic sinus region
(ASR) respectively in 8 weeks female ApoE-/- mice fed a HFD. Insert in panel A and C
(original magnification x35) are areas shown in Panel B and D (original magnification
x630). Type I lesion consists of scattered macrophage foam cells (arrows). Type II
consists of multilayer of foam cells and lipid-laden smooth muscle cells. Type I and II
lesions are clinically benign. Tissues were embedded in formalin and then stained with
oil red O to detect neutral lipids. Hematoxylin was used as the counter-stain.

4.5.2 Magnitude of Atherosclerotic Lesions in ApoE-/- Mice
Average percent lesion values (Table 4.1) for the ApoE-/- mice correlated well with
histological observation of oil red-stained tissue sections from the regions of the different
age groups. Average percent lesion values increased from the AAR to the OCAR to the
ASR. This trend (Table 4.1, Figure 4.7) was observed in all age groups except in 24-
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Figure 4.3. Photomicrograph of type III (intermediate) lesion from the region showing
the orifice of the coronary arteries (OCAR) from 12 week male ApoE-/- mouse. Insert on
panels A (original magnifications, x35) is area shown on panel B (original magnification,
x200). Type III is an intermediate between the advanced types of lesions that can cause
symptoms of atherosclerosis and the clinically benign lesions of type I and II. Type III is
distinguished from the advanced types by the lack of the presence of necrotic lipid cores.
Mouse was fed with high-fat diet. Tissue was stained with oil red O to visualize neutral
lipids and counter-stained with hematoxylin.

week female mice, whose average percent lesion value was slightly higher for the OCAR
(47.96 ± 5.75) than the ASR (44.51 ± 6.07) but not statistically significant based on result
(p = 0.263) from ANOVA analysis. Results from comparison between aortic root regions
from mice within an age group showed that the average percent lesion value increased
significantly (p<0.05; Table 2) from OCAR to ASR in 8 weeks mice. Comparison was
not made between AAR and OCAR or AAR and ASR due to limited data obtained for the
AAR in this age group. In the 12-week group, the percent lesion difference was
significant between any two of the three regions. Among 18- and 24-week mice groups,
lesion percentage differences were significant between any two regions except between
the OCAR and the ASR of the 18/24- week male mice and of the 24-week female mice.
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Average percent lesion values for the three regions also increased in an agedependent manner as showed in Figure 4.6. Average percentage lesions increased faster
in older mice (18-week to 24-weeks) than younger mice (8 to 12 weeks) in the AAR. By
contrast, it increased slower in older mice in the OCAR and the ASR. The similar
changing trend observed in the OCAR and the ASR suggests that atherosclerotic
development became more similar in these two regions as mice grew.
To determine the significant level of lesion increase between the ages for each
region, an ANOVA statistical analysis was performed. P-values obtained after
comparison between the different ages for each region of the aortic root are listed in
Table 4.3. In the AAR, a significant change (p< 0.05) of average percentage of
atherosclerotic lesions was only observed from 18 to 24 weeks. In the OCAR and ASR,
significant changes were observed from 8 to 12 to 18 weeks for both female and male
ApoE-/- mice. Only female mice showed significantly lesion increase in OCAR from
week 18 to 24. No significant changes were observed in the ASR from week 18 to 24 for
both genders.
As observed in the histological data, the percent values were generally higher in
females than in males (Table 4.1). However, ANOVA comparisons between males and
females for the regions and different ages only found significant differences in the OCAR
of 12-week (p = 0.0005) and 24-week (p=0.0049) male and female mice.
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Figure 4.4. Photomicrographs of types IV and V lesions from the aortic sinus region
(ASR) from 18 weeks respectively male and female ApoE-/- mice. Insert on panels A and
C (original magnifications, x35) are areas shown on panel B and D (50 µm). The necrotic
lipid core (LC) is a distinguishable feature of advanced lesions (types IV and V). A
fibrous cap (arrows) covers the LC. A distinguishing feature of type IV form type V is
substantial amount of fibrous tissues in type V. Both types of lesions can cause
complications of atherosclerosis. Mice were fed with a high fat diet. Tissues were stained
with oil red O to visualize neutral lipids and counter-stained with hematoxylin.

4.6 DISCUSSION
4.6.1 Atherosclerosis in Aortic Root Regions of ApoE-/- Mice
The atherogenic process is progressive in nature68. In this study, increases in lesion
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Figure 4.5. Atherosclerosis in three regions of ApoE-/- mice at ages (from left to right) 8,
12, 18 and 24 weeks. A. AAR. B. OCAR. C. ASR. Lesion distribution and complexity
increase from the AAR to the OCAR to the ASR. Lesions also increased with age of
mice. Mice were fed a high fat diet. Tissues were embedded in formalin and stained with
oil red O and hematoxylin. Original magnification, x35.

Table 4.1. Average % lesions in three regions of the aortic root of ApoE−/− mice.
Age of Mice (Weeks)

AAR

OCAR

ASR

Average %Lesion ± SD (*# of mice quantified)
Males
8
12
18
24

0.90 (1)
2.70 ± 1.47 (5)
4.22 ± 2.84 (5)
21.16 ± 7.65 (6)

1.02 ± 0.78 (3)
6.78 ± 2.90 (7)
33.83 ± 9.75 (7)
37.88 ± 6.33 (8)

3.65 ± 0.77 (5)
14.61 ± 6.99 (7)
37.67 ± 7.66 (8)
41.30 ± 7.04 (9)

Females
8
12
18
24

0.45 ± 0.12 (2)
1.80 ± 1.70 (3)
8.97 ± 2.54 (4)
30.20 ± 1.85 (3)

0.78 ± 0.16 (3)
16.14 ± 2.60 (4)
35.20 ± 6.39 (8)
47.96± 5.75 (8)

4.57 ± 0.36 (3)
22.30 ± 2.72 (4)
43.29 ± 7.39 (7)
44.51± 6.07 (8)

* Total number quantified. This is less than the total number of mice in each age category used in
the overall study.
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Table 4.2. p-values obtained from comparison between aortic root regions from mice
within an age group.
Age of Mice (Weeks)

*AAR vs. OCAR

*AAR vs. ASR

OCAR vs. ASR

8

N/A

N/A

3.47E-03

12

1.66E-02

4.10E-03

1.81E-02

18

6.77E-05

1.60E-06

4.08E-01

24

7.50E-04

1.57E-04

3.11E-01

8

N/A

N/A

7.74E-05

12

2.33E-03

6.98E-04

1.70E-02

18

1.54E-05

1.01E-05

4.05E-02

24

6.47E-04

3.63E-03

2.63E-01

Males

Females

*Comparisons was not done between AAR and OCAR and AAR and ASR of 8 weeks ApoE-/mice due to limited quantification data for the AAR.

severity and percentage from 8 weeks to 24 weeks in different ApoE-/- mice demonstrated
this progressiveness. ApoE-/- mice on C57BL/6 background provided an effective model
for studying disease progression in the aortic root. The aortic root is commonly examined
in murine-atherosclerotic studies due to its predisposition to develop atherosclerosis.
Majority of studies in the mouse aortic root have been focused on the ASR68 because
complicated lesions develops in this region72, 192 and the appearance of the aortic cusps of
the ASR allows for easy comparison between different mice. Accordingly, lesion types
and progression in the ASR has been broadly characterized whiles similar descriptions
for the AAR and OCAR are rare. This study presents simultaneous characterization and
quantification of all three regions of the aortic root in a large population of ApoE-/- mice
on C57BL/6 background.
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Table 4.3. p-values obtained after comparison between the different ages for each region
of the aortic root.
Age of Mice (Weeks)

*AAR

OCAR

ASR

8 to 12

N/A

1.11E-02

6.32E-03

12 to 18

3.19E-01

1.36E-05

4.06E-05

18 to 24

1.19E-03

3.51E-01

3.25E-01

8 to 12

N/A

1.73E-04

1.10E-04

12 to 18

2.46E-02

2.19E-04

4.50E-04

18 to 24

6.67E-05

8.94E-04

9.87E-01

Males

Females

*Comparison was not done between 8 and 12 weeks ApoE-/- mice for AAR due to limited
quantification data for the AAR.

Lesion distribution, size, and complexity increased from the AAR to the OCAR to the
ASR. Differences in the extent of atherosclerotic lesions in these three regions of the
aortic root are linked to hemodynamic factors in each region. The AAR is circular and
straight, which enables uniform laminar blood flow and the generation of high shear
stress on the region’s endothelium lining. Straight arterial segments with high shear stress
have been correlated to minimal/no development of atherosclerotic lesions. Conversely,
areas where shear stress is low, such as the inner curve of the aortic arch, or where flow is
oscillatory, such as near bifurcations, have turbulent blood flow and are associated with
increased or extensive development of atherosclerotic lesions193, 194. Low and/or
oscillatory shear stress (OSS) increases atherosclerosis risk by primarily inducing
dysfunction of the local endothelium57, 195. Endothelial dysfunction is an established
condition that triggers initial atherosclerosis events including increasing the expression of
cellular adhesion molecules ICAMs (e.g. ICAM-1), vascular cell adhesion molecules
(VCAMs) (e.g. VCAM-1), chemokines, and platelets55-57. Progression of atherosclerotic
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lesions can then rapidly occur when risk factors such as hyperlipidemia, diabetes, and
hypertension are present195. The high susceptibility of mouse ASR to develop lesions is a
result of OSS196 caused by the aortic cusps. The extent of lesion formation in the OCAR
is also associated with OSS and/or low shear stress in this region, predisposed by the
branching of the coronary arteries. Also, closer proximity to the ASR potentially
encourages easy spreading of the disease to this region. The generally higher lesion
prevalence in the ASR compared to OCAR suggests higher OSS in the ASR.
The morphology of atherosclerotic lesions is an indication of the severity of the
disease. Accordingly, lesion types in a region corresponded to the severity of the disease
in that region. The observation of complex lesions in the ASR in this study supports the
common use of this region for probing advanced types of lesions However, the AAR can
be of use if early forms of lesion are the target of interest, such as in drug intervention
studies aimed at preventing advancement of early atherosclerotic lesions. This would be
particularly useful as the early types of lesion in OCAR and ASR in the ApoE-/- mice fed
HFD rapidly progresses to advanced forms which could make early lesions difficult to
target or enough time for expected effect of a target drug. In using the AAR for
comparative studies, the, circular shape of this region could be a guide for accurate
identification. The statistical differences or similarities in the average percent lesion
values between regions and ages as shown above can provide a guide for designing future
atherosclerotic studies.
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Figure 4.6. Average percent lesions in three regions (i.e., AAR, OCAR and ASR) of the
aortic root of 8- to 24-week male (a) and female (b) ApoE-/- mice.

4.6.2 Lesion Progression with Age of ApoE-/- Mice
The progression of lesion severity in the three aortic root regions from 8 to 24
weeks observed in our study confirms age as a risk factor of atherosclerosis197. The risk
with age is validated by the types of lesions formed at different ages in a specific region.
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8-week ApoE-/- mice developed type I or II lesions (known to be clinically benign). By
contrast, clinical important types IV and V lesions (necrotic core lesions) developed in
older mice.
4.6.3 Influence of Gender on Lesion Formation in Aortic Root Regions
Histological data from this study revealed that lesion development were generally
faster in female than in males ApoE-/- mice. However, statistical significant difference in
average percentage of lesions between genders was only observed in the OCAR of 12and 24-week mice. Higher disease proliferation in female mice is consistent with
previous report198. However, the opposite is observed in humans. Premenopausal women
are viewed to have lower risk of atherosclerosis and related heart diseases than age
matched males, but the risk become similar in postmenopausal women and men of
comparable age199. The decreased risk with younger women has been linked to protective
effects of estrogen which decrease in women with age. The cardioprotective mechanisms
of estrogen include decreased low-density lipoprotein (LDL), increased high-density
lipoprotein (HDL), and release of vasodilators such as nitric oxide (NO) and prostacyclin
(PGI2) from vessel walls, which results in inhibition of vascular constriction and
lowering of blood pressure, as well as decreased platelet aggregation199. Similar disease
proliferation in both genders with increased age was observed in mice from this study
demonstrated by comparable lesions (in size and type) in higher prevalent regions.
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4.7 CONCLUSIONS
This study showed a simultaneous comparison of atherosclerosis progression in
three regions of the aortic root of ApoE-/- mice fed HFD. The ASR is a predilection site
for lesion development in mice. Lesions in this region progress rapidly to advanced types
of lesions by 18 weeks of age, which implies that this region is better suited for the study
of advanced types of atherosclerotic lesions using the ApoE-/- mouse model. By contrast,
the slowest lesion formation is in the AAR, with lesions progressing to the advanced
forms in this region only in the 24-week mice. Therefore, AAR is suitable for the study of
drug targeted at early types of lesions. Lesion types in the OCAR are mainly of types I
and III in younger mice (8 and 12 weeks) and types IV-V in older mice (18 and 24
weeks). This region is thus best suited for investigating all lesion types guided by the
presented age limits for various lesion developments. The progressiveness and age
dependency of the atherogenic process is also confirmed in this study. The data presented
serve well as a guide in designing future murine atherosclerotic studies.
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CHAPTER FIVE
5.0 SUMMARY AND FUTURE WORK
5.1 Summary
The objectives of this work were (i) develop an immunodepletion method for
bovine fluids, (ii) to analyze changes in proteins in FF and plasma (PL) from cattle with
high E2 (HE2) or low E2 (LE2) during the pre-ovulatory period, and (iii) characterize
and quantify atherosclerotic lesion development in three regions of the aortic root of
ApoE-/- mice.
A proteomic-shotgun (bottom down) approach was selected to achieve our second
objective. This approach is suitable for analyzing complex matrices. An important and
often required step in the shotgun approach is to employ a protein fractionation step. The
protein fractionation method of choice was immunodepletion due to the high selectivity,
sensitivity, and reproducibility reported for this method. However, because
immunodepletion methods for bovine fluids are currently very limited, development of an
immunodepletion method became necessary and this formed our first objective.
Therefore an immmunodepletion method utilizing MARS Hu6-HC was developed for
bovine PL, FF, epididymis sperm types, and ejaculated sperm types. High depletion rates
for targeted HAPs albumin, IgG, IgA, and alpha-1-antitrypsin (or alpha-1-antiproteinase)
was achieved. The depletion rates confirmed by sandwich ELISA for albumin, IgG, and
IgA ranged from 98.7 to 99.9% in all the bovine samples investigated. A similar
depletion rate was expected for alpha-1-anti-trypsin based on dramatic depletion of its gel
band. The observed high depletion rates were primarily attributed to the high structural
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similarity of these proteins between human and bovine. There was also dramatic
depletion of binder of sperm proteins (BSP) - PDC-109, BSP-A3, and BSP-30kDa, which
are HAPs in seminal plasma component of ejaculated sperm, forming 40-57% of the total
protein component. The depletion of the BSP proteins was therefore considered
beneficial if both bound and depleted fractions are analyzed.
Protein quantification in proteomics enables detection of expression changes
between treatments. iTRAQ reagents were successfully used for the quantification. 4-plex
iTRAQ reagents were used to individually label PL HE2, PL LE2, FF HE2, and FF LE2
and subsequent nanoLC-ESI-LTQ (PQD) analysis identified a total of 231 proteins with
high confidence (FDR ≤0.05). 103 of the identified proteins showed expression changes
(up-regulated or down-regulated) after comparisons between samples. Important
information was drawn from our proteomic approach: higher number of proteins showed
expression change between different fluid types (i.e. PL and FF) than between HE2 and
LE2 of a fluid; E2 has a greater effect on FF proteins than PL proteins; the up- and downregulated proteins were mainly localized in the cell, the extracellular region and organelle
and were mainly associated to cellular process and metabolic process. Binding and
catalytic activity were the most associated molecular processes; E2 is critical to the
development and maturation of ovarian follicles. Several of the proteins showing
expression changes play important roles in folliculogenesis and are modulated by E2; and
complement and coagulation pathways were the main pathways associated with the
proteins, supporting the view that folliculogenesis and ovulation are hemorrhagic events.
This work therefore demonstrates the ability of proteomic to provide insights into
reproduction in bovine. The presented data specifically provides the basis for further
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investigation of specific processes involved in E2 regulation of reproductive associated
proteins.
Atherosclerosis is the underlining cause for heart attack and stroke, the two
leading cause of cardiovascular death worldwide. The ApoE-/- -mouse model is popular
for atherosclerosis research. This work characterized and quantified atherosclerosis
development in three regions of the aortic root of ApoE-/- mice. The examined three
regions of the aortic root were ascending aorta region (AAR), region showing the orifices
of the coronary arteries marking the start of the ascending arch (OCAR), and aortic sinus
region (ASR). Lesion development in the three regions was location and age dependent.
It was slowest in the AAR and formed types I-III lesions in this region from 8-18 weeks
of age and type IV at 24 weeks of age. Lesion development was faster in OCAR and ASR
and developed to types IV and V by 18 weeks. Average percent lesion values increased
from the AAR to the OCAR to the ASR, correlating to the histological data. These
findings would be beneficial in experimental design and targeting certain lesion types in
aortic roots of the popular ApoE-/- murine atherosclerosis model.
5.2 Future Work
5.2.1 Identification of phosphoproteins biomarker candidates for atherosclerosis
Protein phosphorylation entails the reversible incorporation of phosphate group to
amino acid side chains of proteins and it is the most studied post-translational
modification (PTM). Phosphoproteins are important biomarker targets for atherosclerosis
because of the crucial regulatory role of protein phosphorylation in most cellular
processes. Cellular processes such as metabolism, contraction and relaxation of muscles,

129

transcription and genetic information, hormonal and nerve signaling, proliferation,
apoptosis, differentiation, cell growth, aging, and inflammation are directly or indirectly
regulated by protein phosphorylation200, 201. Because casual factors for atherosclerosis
development are widely recognized to be multiple, it is expected that alteration in
associated phosphorylation/dephosphorylation regulatory processes could create disease
conditions with the associated phosphoproteins being up- or down-regulated. For
example, the most studied potential phosphoprotein biomarker is VSMC heat shock
protein 27 (HSP27)81, 202. HSP27 expression is reported to increase in normal appearing
vessels adjacent to atherosclerotic lesion whereas levels in the atherosclerotic lesion itself
are significantly decreased. Both lesion and adjacent artery show decreased HSP27
phosphorylation compared with reference vessel81, 203.
The future work would be to use proteomic approach to identify and quantify the
expression levels of phosphoproteins in the plasma samples from the ApoE-/- and control
mice of all the ages from this study. Comparison between the plasma proteome of the
ApoE-/- and control mice, and between the different ages groups could provide more
insights into the differentially expressed phosphoproteins in the development of
atherosclerosis. Possible biomarker candidates could then be sought for and further
investigated.
The experimental approach could employ proteomic bottom-up methods which
could include enrichment of phosphoproteins in the plasma sample, trypsin digestion of
proteins into peptides, iTRAQ labeling of peptides, SCX separation of peptides, and
analysis of samples using nanoLC-MS/MS with subsequent protein identification and
quantification with the SEQUEST and Proteome Discoverer softwares. Enrichment of

130

phosphoproteins is particularly important for three main reasons: 1. Phosphoproteins are
PTMs and therefore are low abundance in nature. 2. Phosphorylation is a transient
modification, so the target protein could present in both the native and phosphorylated
form and 3. Phosphopeptides ionize poorly in MS strategies particularly in the presence
of non-phosphorylated molecules resulting in lower signal intensities204. Phosphoproteins
enrichment can be achieved using metal oxide affinity chromatography (MOAC),
immobilized metal affinity chromatography (IMAC), and titanium dioxide (TiO2)204, 205.
Because the ApoE-/- group developed atherosclerosis as shown in this dissertation,
it is expected the phosphoproteome in this group to differ, with phosphoproteins levels
either up- or down-regulated compared to the control group. Our study shows that ApoE-/mice fed with a HFD developed atherosclerosis as early as 8 weeks, with lesions mainly
in the early-staged form. By 24 weeks, the disease had reached its advanced stage as
visualized by the presence of features like the necrotic lipid core (LC) and greater degree
of fibrous tissues. Therefore, identified phosphoprotein candidates showing expression
changes in plasma samples from younger ApoE-/- mice (8 or 12 weeks) would be better
markers for early stages of the disease whereas those from older ApoE-/- mice (18 and 24
weeks) would be better biomarkers for advanced stage of the disease. Accordingly,
special attention would be given to such proteins. Also, protein candidates that would be
consistently present throughout all the stages of the disease would be sought for as these
would be more robust in predicting risk of the disease.
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5.2.2 Profiling and iTRAQ quantification of Epididymis and Ejaculated Sperm
Proteins
A focus of this dissertation was to profile proteins relevant to productivity of the
cow, specifically at the folliculogenesis stage. Future work will be to profile sperm
proteins relevant to bull productivity. During ejaculation, stored sperms from the cauda
epididymis transit through the vas deferens and secretions from the accessory sex glands
(prostate gland, cowper’s gland, and seminal vesicles) called seminal plasma is added and
is released together with sperm as semen. With the contact with the seminal fluid, sperm
undergoes series of biochemical and structural changes associated with sperm
capacitation. Capacitation is required to make sperm competent to fertilize an oocyte206.
Therefore, the protein composition of epididymis and ejaculated sperms are different.
The future work would use proteomic shotgun approach to investigate these differences.
Proteins of the sperm membranes and in the fluids surrounding either sperm type (herein
labeled as ejaculated sperm proteins, ejaculated semen plasma, epididymis sperm
proteins, and epididymis semen proteins) would be quantitatively measured using iTRAQ
reagents. The immunodepletion method discussed in this work showed high depletion
rates for abundant proteins in either sperm type and would be incorporated in the
analysis.
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APPENDICES
Appendix 1. Details on 231 proteins identified in bovine PL and FF with high and low
E2 during the pre-ovulatory stage.
Description (* indicates protein was
up- or down-regulated in at least
one sample)
*2-acylglycerol O-acyltransferase 3
(Fragment)
Acidic mammalian chitinase

Accession

Coverage

# Peptides

# unique
peptides

Score

E1BN30

2.62

1

1

20.86

Q95M17

3.18

1

1

34.89

Actin, cytoplasmic 1

F1MRD0

4.80

1

1

33.01

Afamin

G3MYZ3

3.15

2

2

81.25

A-kinase anchoring protein 9
(Fragment)
Aldehyde oxidase 4

F1MXF5

0.86

2

1

428.46

E1BL62

1.57

1

1

105.29

Alpha-1-acid glycoprotein

Q3SZR3

52.48

12

12

1535.16

*Alpha-1-antiproteinase

P34955

15.14

5

5

529.12

Alpha-1B-glycoprotein

Q2KJF1

38.37

10

9

1035.57

Alpha-2-antiplasmin

P28800

16.06

4

3

259.00

Alpha-2-HS-glycoprotein

P12763

25.35

6

6

1390.94

*Alpha-2-macroglobulin

Q7SIH1

45.43

48

47

7776.09

Alpha-amylase

F1MJQ3

4.50

2

2

15.59

Angiotensinogen

Q3SZH5

11.79

3

2

91.25

*Ankyrin repeat and KH domain
containing 1
Antithrombin-III

G3MZJ0

0.67

1

1

118.87

F1MSZ6

43.44

14

13

1121.12

*AP complex subunit beta

F6PZ41

3.11

1

1

56.29

AP-2 complex subunit beta

G3X7G4

2.84

1

1

779.71

Apolipoprotein A-I

P15497

63.77

26

26

4696.98

Apolipoprotein A-II

P81644

27.00

4

4

339.84

Apolipoprotein A-IV

F1N3Q7

46.58

16

15

655.00

*Apolipoprotein B

E1BNR0

0.68

2

2

140.79

Apolipoprotein C-III

P19035

16.67

1

1

24.41

*Apolipoprotein R

G3N0S9

8.54

1

1

19.91

*ApoN protein

Q2KIH2

16.54

4

4

110.40

*Asparagine-linked glycosylation 5,
dolichyl-phosphate betaglucosyltransferase homolog (S.
cerevisiae)
*ATP binding cassette subfamily B
member 9

Q2KIM7

10.49

2

2

28.98

E1BKR0

0.96

1

1

61.08
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*B double prime 1, subunit of RNA
polymerase III transcription initiation
factor IIIB
BCL2 interacting protein 2

F1MEB1

0.68

1

1

129.29

F1N6R4

4.46

1

1

53.24

Beta-2-glycoprotein 1

P17690

13.91

4

4

205.18

Beta-2-microglobulin

P01888

10.17

1

1

15.16

C3 and PZP like, alpha-2macroglobulin domain containing 8
C4b-binding protein alpha chain

E1BAA2

0.61

1

1

200.14

Q28065

4.59

2

2

50.60

*C8G protein

A8YXZ2

8.86

1

1

10.66

*CAD protein

F1MVC0

0.90

1

1

119.60

Caspase recruitment domain family
member 10
*CCDC80 protein

F1MW90

1.36

1

1

72.61

A5PKA3

2.41

1

1

80.34

*Cell adhesion molecule 1

Q2TBL2

4.56

1

1

599.16

Ceruloplasmin

F1N076

29.40

22

22

1539.90

Chaperone activity of bc1 complexlike, mitochondrial
*Chromosome 14 open reading frame
166 ortholog
Chromosome 20 open reading frame
96 (Fragment)
Clusterin

Q29RI0

2.01

1

1

84.33

Q3T0S7

5.31

1

1

175.46

F1N466

5.59

1

1

276.11

P17697

5.24

2

2

116.19

F1MVI9

2.23

1

1

71.46

F1MBC5

2.78

1

1

36.96

*Coagulation factor V

F1N0I3

1.83

2

2

37.79

*Coagulation factor XII

F1MTT3

2.78

1

1

14.55

*Coagulation factor XIII A chain

F1MW44

3.96

2

1

89.51

*Cohesin subunit SA-3

E1B9B0

3.43

2

1

363.69

*Complement C1s subcomponent

Q0VCX1

6.39

2

1

27.90

Complement C3

Q2UVX4

50.09

65

1

11912.41

Complement C3

G3X7A5

49.91

65

1

11675.41

complement C3 (Fragment)

E1B805

3.82

4

4

165.08

Complement C5a anaphylatoxin

F1MY85

11.87

15

13

633.38

Complement C8 alpha chain

F1MX87

11.04

4

3

92.83

Complement C8 beta chain

F1N102

12.37

4

3

123.27

complement component 4A

E1BH06

26.88

32

16

1940.14

*Complement component C6

F1MM86

12.88

7

7

256.29

Complement component C7

Q29RQ1

4.15

3

3

50.20

Complement component C9

Q3MHN2

25.36

11

9

700.87

Complement factor B

P81187

32.06

17

17

2031.94

Complement factor H

Q28085

11.73

10

9

766.87

CMP-N-acetylneuraminate-polyalpha-2,8-sialyltransferase
Coagulation factor IX
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Complement factor I

F1N4M7

12.30

6

6

300.36

*Conglutinin

P23805

11.59

4

4

99.90

Corticosteroid-binding globulin

E1BF81

13.37

3

2

86.85

C-reactive protein

C4T8B4

4.46

1

1

62.37

C-type lectin domain family 1 member
A
*Cumulus cell-specific fibronectin 1
transcript variant
*Cytochrome P450 20A1

Q0VCS6

3.96

1

1

85.12

B8Y9T0

2.73

4

4

139.98

Q5E980

2.81

1

1

47.83

*Cytohesin 1 (Fragment)

F1MCV3

3.49

1

1

79.67

*Cytokine receptor like factor 3

E1BCF2

3.19

1

1

33.06

*DDB1 and CUL4 associated factor 5

F1N0J7

1.83

1

1

125.40

DEAH-box helicase 16

E1BF68

2.30

1

1

99.02

*Delta-like protein

E1BDN7

1.40

1

1

71.56

*Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1
*Dpy-19 like 4 (Fragment)

F1MJ36

2.80

1

1

380.50

F1MJJ1

2.77

1

1

74.83

*DUOXA1 protein

A6H723

4.45

1

1

81.06

*Dynein axonemal heavy chain 11

F1N724

0.22

1

1

198.47

*Dynein heavy chain domain 1

F1MEF7

0.78

1

1

68.05

Dystonin

F1MPT5

0.15

1

1

569.35

*E3 ubiquitin-protein ligase CHIP

F1MUH4

7.95

1

1

21.38

*Endophilin-A2

Q2KJA1

7.07

1

1

78.25

*Engulfment and cell motility 1

F1MQH0

3.30

1

1

115.02

*Epidermal growth factor receptor
kinase substrate 8-like protein 1
*Factor XIIa inhibitor precursor

E1BKS0

2.00

1

1

31.95

E1BMJ0

18.80

7

6

341.85

*Family with sequence similarity 81
member A
*Fas activated serine/threonine kinase

F1N4N5

4.38

1

1

32.29

F1N4L0

7.14

1

1

45.88

Fetuin-B

Q58D62

6.20

3

3

90.71

*FGG protein

Q3SZZ9

48.05

16

15

2805.06

*Fibrinogen alpha chain

A5PJE3

38.70

22

22

4967.64

*Fibrinogen beta chain

F1MAV0

58.79

31

30

3584.70

*Fibulin-1

F1MYN5

3.26

1

1

100.67

*Filamin B

E1BKX7

0.91

1

1

188.29

Fragile X mental retardation
syndrome-related protein 2
G1/S-specific cyclin-D1

E1B9L5

4.02

1

1

121.87

Q2KI22

5.42

1

1

157.65

*Gametocyte-specific factor 1-like

Q3T026

12.43

1

1

49.67

*Gasdermin B

F1MCQ4

1.99

1

1

9.35

Gelsolin

F1MJH1

12.18

6

5

252.10
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Glutathione peroxidase

G3X8D7

7.59

1

1

13.51

Glutathione S-transferase

E1BKD8

10.00

1

1

25.42

*Haptoglobin

G3X6K8

12.47

4

4

123.61

HAUS augmin like complex subunit 3

F1MNN1

1.16

1

1

34.23

*HEAT repeat containing 5B

E1BB26

1.45

1

1

345.14

*HECT domain E3 ubiquitin protein
ligase 2
*HECT, UBA and WWE domain
containing 1, E3 ubiquitin protein
ligase
*Hemoglobin subunit alpha

F1N7A0

3.48

1

1

47.44

E1BNY9

0.16

1

1

114.05

P01966

50.00

5

5

461.90

*Hemoglobin subunit beta

P02070

70.34

10

10

1298.93

Hemopexin

Q3SZV7

48.15

16

16

2252.77

Hepatocyte growth factor activator
preproprotein (Fragment)
Histidine-rich glycoprotein

E1BCW0

10.77

2

2

46.89

F1MKS5

18.28

9

5

530.26

P33433

14.65

5

1

282.49

E1B856

4.38

1

1

297.84

F1MLW7

22.65

4

2

313.19

G3N2D7

12.93

1

1

28.07

E1B8Q9

0.87

1

1

48.73

*Inhibin alpha chain

P07994

10.28

2

1

44.05

Insulin like growth factor binding
protein acid labile subunit(IGFALS)
(Fragment)
Inter-alpha-trypsin inhibitor heavy
chain H1
Inter-alpha-trypsin inhibitor heavy
chain H2
Inter-alpha-trypsin inhibitor heavy
chain H3
Inter-alpha-trypsin inhibitor heavy
chain H4
*Keratin, type II cytoskeletal 7

F1MJZ4

9.18

3

3

115.59

F1MMP5

22.30

16

15

1046.27

F1MNW4

18.50

11

10

531.07

P56652

1.12

1

1

99.98

F1MMD7

28.28

21

20

1460.66

Q29S21

4.94

2

2

178.36

E1BGB0

0.59

1

1

50.27

Kininogen-1

P01044

13.85

7

4

339.99

Kininogen-2

P01045

9.69

5

2

314.99

*KRAS proto-oncogene, GTPase

E1BMX0

6.38

1

1

115.89

*Kruppel like factor 17 (Fragment)

G3N1K6

5.88

1

1

124.69

Leucine rich repeat containing 4C

F1MXH5

3.44

1

1

111.10

*Leucine rich repeat kinase 2

E1BPU0

0.36

1

1

147.56

Leucine-rich alpha-2-glycoprotein 1

Q2KIF2

23.41

6

5

697.42

Histidine-rich glycoprotein
(Fragments)
*Homeobox D3
*Immunoglobulin lambda-like
polypeptide 1
*Immunoglobulin lambda-like
polypeptide 1 (Fragment)
Importin 8

Kinesin family member 13B

150

Leucine-rich single-pass membrane
protein 1
L-lactate dehydrogenase B chain

A5PK14

9.38

1

1

137.68

Q5E9B1

5.09

1

1

7.76

*Lumican

Q05443

9.36

2

1

104.51

*Lysine methyltransferase 2C
(Fragment)
Maltase-glucoamylase

F1MYZ3

0.19

1

1

57.82

G3MY87

1.31

2

2

46.70

Mitogen-activated protein kinase
kinase kinase 5
*NADH dehydrogenase [ubiquinone]
1 alpha subcomplex assembly factor 4
*NADH dehydrogenase [ubiquinone]
1 beta subcomplex subunit 11,
mitochondrial
NADPH-dependent diflavin
oxidoreductase 1
*NIMA (Never in mitosis gene a)related kinase 2
Nuclear factor interleukin-3-regulated
protein
Olfactory receptor

F1MXH6

0.73

1

1

55.14

A4FUH5

9.71

1

1

61.89

Q8HXG5

14.94

1

1

21.41

Q1JPJ0

3.02

1

1

49.02

Q2KIQ0

5.22

1

1

17.48

Q08D88

2.81

1

1

87.28

E1BDG1

4.13

1

1

2.87

*Ornithine decarboxylase 1

E1BG69

2.49

1

1

68.78

Pantetheinase

Q58CQ9

6.47

2

2

52.55

*Pantothenate kinase 3

Q08DA5

2.43

1

1

71.93

Paraoxonase 1

Q2KIW1

17.18

4

4

109.17

Peptidoglycan recognition protein 2
(Fragment)
Phosphatidylinositol-3,4,5trisphosphate dependent Rac exchange
factor 2
*Phosphoglycolate phosphatase

E1BH94

5.76

3

3

68.02

E1BDL7

1.18

1

1

74.79

Q2T9S4

6.54

1

1

232.07

Pigment epithelium-derived factor

Q95121

31.01

8

7

399.24

*Plasma serine protease inhibitor

Q9N2I2

9.16

2

2

82.95

Plasminogen

P06868

22.29

15

14

1272.51

Primary amine oxidase, liver isozyme

Q29437

25.07

12

11

1069.72

Progesterone immunomodulatory
binding factor 1
Protein AMBP

E1BCF0

0.92

1

1

51.54

F1MMK9

17.05

4

4

255.61

Protein HP-20

Q2KIT0

28.80

3

3

762.34

Protein HP-25 homolog 1

Q2KIX7

22.17

3

3

177.58

Protein HP-25 homolog 2

Q2KIU3

40.00

5

5

1012.44

Protein phosphatase 1 regulatory
subunit 37
Prothrombin

A7Z026

1.72

1

1

38.25

P00735

40.48

18

17

779.65

*Protocadherin Fat 2 precursor
(Fragment)

F1MPF3

0.41

1

1

59.65

151

PSMD1 protein

A7MBA2

1.05

1

1

149.30

*PTPRR protein

A5PKF8

3.36

1

1

21.91

Pyridine nucleotide-disulfide
oxidoreductase domain-containing
protein 1
*Regulating synaptic membrane
exocytosis 2 (Fragment)
Regulating synaptic membrane
exocytosis 3
RELT, TNF receptor

A7YVH9

5.78

1

1

104.19

E1B7V2

1.56

1

1

62.25

E1BAB7

3.90

1

1

63.55

F1N3F7

3.20

1

1

125.55

Retinoic acid induced 1

E1B9X1

1.01

1

1

52.94

Retinol-binding protein 4

P18902

17.49

3

3

158.77

Ribosomal protein S6 kinase C1

E1BB43

1.70

1

1

122.46

*Serglycin (Fragment)

G5E5K5

5.33

1

1

28.09

Serine peptidase inhibitor, Kazal type
5
Serotransferrin

F1MJH0

1.10

1

1

141.20

Q29443

67.90

48

3

10359.71

Serotransferrin

G3X6N3

69.03

49

2

10020.55

Serpin A3-2

A2I7M9

30.66

11

4

2476.77

Serpin A3-4

A2I7N0

27.01

9

2

1486.42

Serpin A3-7

A2I7N3

14.39

9

9

1090.11

Serpin A3-8

A6QPQ2

21.77

8

6

516.68

*Serpin family E member 2

F1MZX2

6.55

2

2

42.36

*Serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin),
member 3
Serpin peptidase inhibitor, clade A
(Alpha-1 antiproteinase, antitrypsin),
member 7
SERPINA10 protein

G8JKW7

25.24

8

2

1430.95

Q3SYR0

13.14

4

4

130.93

A5PJ69

7.96

3

3

81.88

SERPIND1 protein

A6QPP2

19.15

7

6

323.80

*Serum albumin

P02769

35.91

18

18

1669.86

*SH3 domain and tetratricopeptide
repeats 1
SHBG protein

G3MZW4

0.83

1

1

80.24

A5PKC2

8.73

2

1

33.21

*Sodium/glucose cotransporter 1-like
(Fragment)
Solute carrier family 12 member 7
(Fragment)
*Sphingomyelin phosphodiesterase 5
(Fragment)
*SPHK1 interactor, AKAP domain
containing (Fragment)
Superoxide dismutase [Cu-Zn]

G3MXJ0

2.43

1

1

32.29

F1N140

1.65

1

1

25.10

F1N6X9

3.30

1

1

19.12

F1MZL5

0.68

1

1

25.46

A3KLR9

16.60

3

3

25.75

*Suppressor of G2 allele of SKP1

Q2KIK0

5.62

1

1

66.16

*Synaptonemal complex protein 1

E1BLN1

1.90

1

1

41.64
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*Synaptotagmin 12

E1BEH9

2.85

1

1

103.23

*TBC1 domain family member 4

E1BPA1

2.00

1

1

172.77

Tetranectin

Q2KIS7

18.32

3

3

156.53

*Titin

F1N757

0.13

2

2

1674.93

*Trans-2-enoyl-CoA reductase,
mitochondrial
Transcription elongation factor A Nterminal and central domaincontaining protein 2
*Transcription factor 7-like 2

Q7YS70

6.17

1

1

75.63

A5PKE4

3.85

1

1

20.37

G3N0T7

6.53

1

1

116.94

*Transcription initiation factor TFIID
subunit (Fragment)
*Transmembrane protein 186

F1MF62

0.48

1

1

268.01

Q5EA03

7.55

1

1

289.96

*Transthyretin

O46375

41.50

5

4

295.47

Tubulin beta-6 chain (Fragment)

G3X7R8

5.08

1

1

76.34

Tyrosine-protein kinase

F1MCX4

0.93

1

1

45.94

Ubiquitin carboxyl-terminal hydrolase
2
*Ubiquitin protein ligase E3
component n-recognin 4
*Uncharacterized protein

Q2KHV7

2.15

1

1

158.76

G3N0A8

0.40

1

1

118.70

E1BPG1

2.67

1

1

47.01

*Uncharacterized protein

F1MI18

13.33

16

15

404.88

Uncharacterized protein

E1BH27

1.44

1

1

144.13

Uncharacterized protein (Fragment)

F1MVK1

15.95

20

5

1479.93

*Uncharacterized protein (Fragment)

G3X6V5

1.12

1

1

242.91

Uncharacterized protein (Fragment)

G3N2S5

2.56

1

1

112.08

Uncharacterized protein (Fragment)

G3N1I8

13.01

1

1

11.29

Uncharacterized protein (Fragment);
(Ig-like protein)
Uncharacterized protein (Ig-like
protein)
Uncharacterized protein (Ig-like
protein)
Utrophin

G5E513

3.06

1

1

40.37

F1MH40

6.67

1

1

127.21

F1MLW8

14.16

3

1

123.85

F1MRT9

0.29

1

1

192.91

E1BIB3

8.60

1

1

90.26

F1N6I7

5.95

2

2

91.74

*Vitamin D-binding protein

Q3MHN5

30.17

11

1

1602.50

*Vitamin D-binding protein

F1N5M2

32.07

11

1

1628.97

Vitronectin

Q3ZBS7

7.77

3

3

333.47

Von Willebrand factor A domain
containing 3B
*Von Willebrand factor A domain
containing 5B1
Xin actin binding repeat containing 2

E1BB22

0.82

1

1

75.31

E1BB39

2.12

1

1

86.25

E1BL04

0.34

1

1

326.21

*Vacuolar protein sorting-associated
protein 28 homolog
*Versican core protein
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Zinc-alpha-2-glycoprotein

Q3ZCH5

24.41

5

3

109.60

Zinc finger CCHC domain-containing
protein 7
*Zinc finger protein 618

Q2KIN0

1.65

1

1

260.09

E1BJV7

2.71

1

1

73.67

*Zinc finger SWIM-type containing 3
(Fragment)
*Zona pellucida binding protein 2

F1MTI1

2.03

1

1

108.62

Q0VCG8

12.50

1

1

81.07

Appendix 2. Functions and cellular localization of 231 proteins identified in bovine PL
and FF with high and low E2 during the pre-ovulatory stage.
Description (* indicates
protein was up- or
down-regulated in at
least one sample)
*2-acylglycerol Oacyltransferase 3
(Fragment)
Acidic mammalian
chitinase
Actin, cytoplasmic 1

Afamin
A-kinase anchoring
protein 9 (Fragment)
Aldehyde oxidase 4

Biological Process

Molecular
Function

metabolic process

catalytic activity

metabolic process

catalytic activity

cellular component
organization or biogenesis;
cellular process;
localization
localization

structural
molecule activity

cell part;
organelle

cellular process;
metabolic process

binding;
catalytic activity

cell part

Alpha-1-acid
glycoprotein
*Alpha-1-antiproteinase
Alpha-1B-glycoprotein

Cellular Component

extracellular region
cellular process;
response to stimulus

receptor activity

Alpha-2-antiplasmin

extracellular region

Alpha-2-HS-glycoprotein

biological regulation

catalytic activity

*Alpha-2-macroglobulin

cellular process;
metabolic process;
response to stimulus

binding;
catalytic activity

Alpha-amylase
Angiotensinogen

extracellular region

*Ankyrin repeat and KH
domain containing 1
Antithrombin-III

immune system process;
response to stimulus

*AP complex subunit
beta

localization

cell part
extracellular region
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AP-2 complex subunit
beta
Apolipoprotein A-I

Apolipoprotein A-II

Apolipoprotein A-IV

localization
biological regulation;
cellular component
organization or biogenesis;
cellular process;
developmental process;
localization;
metabolic process;
multicellular organismal
process;
response to stimulus
biological regulation;
cellular component
organization or biogenesis;
metabolic process;
multicellular organismal
process
biological regulation;
cellular component
organization or biogenesis;
cellular process;
developmental process;
localization;
metabolic process;
multicellular organismal
process;
response to stimulus

binding;
catalytic activity;
transporter
activity

extracellular region;
macromolecular
complex

binding;
catalytic activity;
transporter
activity

extracellular region;
macromolecular
complex

binding;
catalytic activity;
transporter
activity

extracellular region;
macromolecular
complex

catalytic activity;
transporter
activity
binding

membrane

catalytic activity

cell part

*Apolipoprotein B
Apolipoprotein C-III
*Apolipoprotein R

biological adhesion;
cellular process;
immune system process

*ApoN protein
*Asparagine-linked
glycosylation 5, dolichylphosphate betaglucosyltransferase
homolog (S. cerevisiae)
*ATP binding cassette
subfamily B member 9

cellular process;
metabolic process

*B double prime 1,
subunit of RNA
polymerase III
transcription initiation
factor IIIB
BCL2 interacting protein
2

cellular component
organization or biogenesis;
cellular process;
metabolic process

Beta-2-glycoprotein 1

cellular process;
metabolic process

cellular process;
developmental process;
metabolic process
biological adhesion;
cellular process;
immune system process

cell part;
macromolecular
complex;
organelle

155

Beta-2-microglobulin

response to stimulus

macromolecular
complex

C3 and PZP like, alpha-2macroglobulin domain
containing 8
C4b-binding protein
alpha chain

cellular process;
metabolic process;
response to stimulus
biological adhesion;
cellular process;
immune system process

binding;
catalytic activity

cellular process;
metabolic process
cellular process

catalytic activity

cell part

catalytic activity

macromolecular
complex;
membrane
cell part;
membrane

binding

cell part;
extracellular region;
organelle

*C8G protein
*CAD protein
Caspase recruitment
domain family member
10
*CCDC80 protein
*Cell adhesion molecule
1
Ceruloplasmin

Chaperone activity of bc1
complex-like,
mitochondrial
*Chromosome 14 open
reading frame 166
ortholog
Chromosome 20 open
reading frame 96
(Fragment)
Clusterin

cellular process

CMP-Nacetylneuraminate-polyalpha-2,8sialyltransferase
Coagulation factor IX

extracellular region

*Coagulation factor V
*Coagulation factor XII

metabolic process

catalytic activity

*Coagulation factor XIII
A chain
*Cohesin subunit SA-3

metabolic process

catalytic activity

cellular process

binding

*Complement C1s
subcomponent
Complement C3

Complement C3

complement C3
(Fragment)

catalytic activity
cellular process;
metabolic process;
response to stimulus
cellular process;
metabolic process;
response to stimulus
cellular process;
metabolic process;

binding;
catalytic activity
binding;
catalytic activity
binding;
catalytic activity

extracellular region

extracellular region
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response to stimulus
Complement C5a
anaphylatoxin
Complement C8 alpha
chain
Complement C8 beta
chain
complement component
4A

cellular process;
metabolic process;
response to stimulus

binding;
catalytic activity

cellular process;
metabolic process;
response to stimulus

binding;
catalytic activity

biological regulation;
cellular component
organization or biogenesis;
cellular process;
localization;
multicellular organismal
process

binding

*Complement component
C6
Complement component
C7
Complement component
C9
Complement factor B
Complement factor H
Complement factor I
*Conglutinin

Corticosteroid-binding
globulin
C-reactive protein
C-type lectin domain
family 1 member A
*Cumulus cell-specific
fibronectin 1 transcript
variant
*Cytochrome P450 20A1

cell part;
extracellular region;
organelle

extracellular region

biological adhesion;
cellular process

binding

extracellular region

binding

cell part;
organelle

*Cytohesin 1 (Fragment)
*Cytokine receptor like
factor 3
*DDB1 and CUL4
associated factor 5
DEAH-box helicase 16

cellular process;
metabolic process
cellular process;
metabolic process

*Delta-like protein

developmental process

*Dolichyldiphosphooligosaccharid
e--protein
glycosyltransferase
subunit 1

cellular process;
metabolic process

binding;
catalytic activity
catalytic activity

catalytic activity

cell part;
macromolecular
complex;
organelle
cell part;
macromolecular
complex;
membrane;
organelle
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*Dpy-19 like 4
(Fragment)

cellular process;
metabolic process

catalytic activity

cell part;
membrane;
organelle

*Dynein axonemal heavy
chain 11

cellular process

binding;
catalytic activity

*Dynein heavy chain
domain 1

cellular process

binding;
catalytic activity

Dystonin

cellular process

binding;
structural
molecule activity

cell part;
macromolecular
complex;
organelle
cell part;
macromolecular
complex;
organelle
cell part

cellular process

binding

*DUOXA1 protein

*E3 ubiquitin-protein
ligase CHIP
*Endophilin-A2
*Engulfment and cell
motility 1
*Epidermal growth factor
receptor kinase substrate
8-like protein 1
*Factor XIIa inhibitor
precursor
*Family with sequence
similarity 81 member A
*Fas activated
serine/threonine kinase
Fetuin-B
*FGG protein

biological regulation;
cellular component
organization or biogenesis;
cellular process

Cell part; membrane;
organelle

extracellular region

cellular process
biological regulation

catalytic activity

biological adhesion

binding

extracellular region

biological adhesion;
cellular process
cellular process;
developmental process

binding

extracellular region

binding;
structural
molecule activity

extracellular region;
extracellular matrix

cellular component
organization or biogenesis;
cellular process;
developmental process;
localization;
metabolic process;
multicellular organismal
process
biological regulation;
cellular component
organization or biogenesis;
cellular process;
metabolic process

binding;
translation
regulator activity

cell part;
macromolecular
complex;
organelle;
synapse

binding;
catalytic activity

cell part;
macromolecular
complex;
organelle

*Fibrinogen alpha chain
*Fibrinogen beta chain
*Fibulin-1

*Filamin B
Fragile X mental
retardation syndromerelated protein 2

G1/S-specific cyclin-D1
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*Gametocyte-specific
factor 1-like
*Gasdermin B

cellular process;
developmental process;
response to stimulus
cellular component
organization or biogenesis;
cellular process
immune system process;
metabolic process;
response to stimulus

binding

binding;
structural
molecule activity
antioxidant
activity;
catalytic activity

cell part;
organelle

*Haptoglobin

metabolic process

catalytic activity

extracellular region

HAUS augmin like
complex subunit 3

cellular component
organization or biogenesis;
cellular process

cell part;
organelle

cellular process;
metabolic process

cell part

Gelsolin

Glutathione peroxidase

Glutathione S-transferase

*HEAT repeat containing
5B
*HECT domain E3
ubiquitin protein ligase 2
*HECT, UBA and WWE
domain containing 1, E3
ubiquitin protein ligase
*Hemoglobin subunit
alpha
*Hemoglobin subunit
beta
Hemopexin

extracellular matrix

Hepatocyte growth
factor activator
preproprotein (Fragment)
Histidine-rich
glycoprotein
Histidine-rich
glycoprotein (Fragments)
*Homeobox D3

metabolic process

catalytic activity

biological regulation

catalytic activity

biological regulation

catalytic activity

*Immunoglobulin
lambda-like polypeptide
1
*Immunoglobulin
lambda-like polypeptide
1 (Fragment)
Importin 8

immune system process

*Inhibin alpha chain

Insulin like growth
factor binding protein

extracellular region

immune system process

biological regulation;
cellular process;
localization;
response to stimulus
cellular process;
developmental process;
metabolic process;
response to stimulus
biological regulation;

transporter
activity

cell part;
organelle

binding

extracellular region

binding
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acid labile
subunit(IGFALS)
(Fragment)

Inter-alpha-trypsin
inhibitor heavy chain H1
Inter-alpha-trypsin
inhibitor heavy chain H2
Inter-alpha-trypsin
inhibitor heavy chain H3
Inter-alpha-trypsin
inhibitor heavy chain H4
*Keratin, type II
cytoskeletal 7
Kinesin family member
13B
Kininogen-1

cellular component
organization or biogenesis;
cellular process;
developmental process;
locomotion;
multicellular organismal
process;
response to stimulus
metabolic process
metabolic process
metabolic process
metabolic process

binding;
catalytic activity
binding;
catalytic activity
binding;
catalytic activity
binding;
catalytic activity

cellular process;
metabolic process
biological regulation

binding;
catalytic activity
catalytic activity

Kininogen-2

biological regulation

catalytic activity

*KRAS proto-oncogene,
GTPase

biological adhesion;
cellular process;
localization;
multicellular organismal
process
cellular process;
metabolic process

binding;
catalytic activity

metabolic process

catalytic activity

biological regulation;
cellular component
organization or biogenesis;
cellular process;
developmental process;
locomotion;
multicellular organismal
process;
response to stimulus

binding

metabolic process

catalytic activity

*Kruppel like factor 17
(Fragment)
Leucine rich repeat
containing 4C
*Leucine rich repeat
kinase 2
Leucine-rich alpha-2glycoprotein 1
Leucine-rich single-pass
membrane protein 1
L-lactate dehydrogenase
B chain
*Lumican

*Lysine
methyltransferase 2C
(Fragment)
Maltase-glucoamylase

binding

cell part;
organelle

cell part;
organelle
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Mitogen-activated protein
kinase kinase kinase 5

*NADH dehydrogenase
[ubiquinone] 1 alpha
subcomplex assembly
factor 4
*NADH dehydrogenase
[ubiquinone] 1 beta
subcomplex subunit 11,
mitochondrial
NADPH-dependent
diflavin oxidoreductase 1
*NIMA (Never in mitosis
gene a)-related kinase 2
Nuclear factor
interleukin-3-regulated
protein
Olfactory receptor
*Ornithine decarboxylase
1
Pantetheinase

biological regulation;
cellular process;
metabolic process;
response to stimulus

catalytic activity;
signal transducer
activity

catalytic activity

binding;
catalytic activity

cell part

cellular process;
metabolic process;
rhythmic process

binding

cell part;
organelle

biological regulation;
cellular process;
metabolic process
cellular process;
metabolic process

catalytic activity

cell part

catalytic activity

*Pantothenate kinase 3
Paraoxonase 1
Peptidoglycan
recognition protein 2
(Fragment)
Phosphatidylinositol3,4,5-trisphosphate
dependent Rac exchange
factor 2
*Phosphoglycolate
phosphatase
Pigment epitheliumderived factor
*Plasma serine protease
inhibitor
Plasminogen
Primary amine oxidase,
liver isozyme
Progesterone
immunomodulatory
binding factor 1
Protein AMBP
Protein HP-20
Protein HP-25 homolog 1
Protein HP-25 homolog 2

catalytic activity

cellular process;
metabolic process;
response to stimulus

binding;
catalytic activity

membrane

cellular process;
metabolic process

catalytic activity

cell part
extracellular region
extracellular region

catalytic activity
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Protein phosphatase 1
regulatory subunit 37
Prothrombin
*Protocadherin Fat 2
precursor (Fragment)
PSMD1 protein

immune system process;
metabolic process;
response to stimulus
metabolic process;
response to stimulus
developmental process

binding

cellular process;
metabolic process

catalytic activity

catalytic activity

cell part;
macromolecular
complex;
organelle

*PTPRR protein
Pyridine nucleotidedisulfide oxidoreductase
domain-containing
protein 1
*Regulating synaptic
membrane exocytosis 2
(Fragment)
Regulating synaptic
membrane exocytosis 3

catalytic activity

biological regulation;
cellular process;
multicellular organismal
process
biological regulation;
cellular process;
multicellular organismal
process

binding

cell part;
organelle;
synapse

binding

cell part;
organelle;
synapse

cellular process;
metabolic process
localization

binding

cell part;
organelle

biological regulation;
cellular process;
metabolic process;
response to stimulus

catalytic activity

RELT, TNF receptor
Retinoic acid induced 1
Retinol-binding protein 4
Ribosomal protein S6
kinase C1

*Serglycin (Fragment)
Serine peptidase
inhibitor, Kazal type 5
Serotransferrin

binding

Serotransferrin

binding

binding

Serpin A3-2

cell part;
macromolecular
complex;
membrane;
organelle
cell part;
macromolecular
complex;
membrane;
organelle
extracellular region

Serpin A3-4

extracellular region

Serpin A3-7

extracellular region

Serpin A3-8

extracellular region

*Serpin family E member
2

extracellular region
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*Serpin peptidase
inhibitor, clade A (alpha1 antiproteinase,
antitrypsin), member 3
Serpin peptidase
inhibitor, clade A (Alpha1 antiproteinase,
antitrypsin), member 7
SERPINA10 protein

extracellular region

SERPIND1 protein

extracellular region

*Serum albumin

extracellular region

extracellular region
localization

*SH3 domain and
tetratricopeptide repeats 1
SHBG protein
*Sodium/glucose
cotransporter 1-like
(Fragment)
Solute carrier family 12
member 7 (Fragment)

*Sphingomyelin
phosphodiesterase 5
(Fragment)
*SPHK1 interactor,
AKAP domain
containing (Fragment)
Superoxide dismutase
[Cu-Zn]

*Suppressor of G2 allele
of SKP1
*Synaptonemal complex
protein 1
*Synaptotagmin 12

*TBC1 domain family
member 4

Tetranectin
*Titin

cellular process;
localization

transporter
activity

biological regulation;
cellular process;
localization;
multicellular organismal
process

transporter
activity

biological regulation;
cellular process;
response to stimulus
cellular process;
response to stimulus

binding

cell part

antioxidant
activity;
binding;
catalytic activity

cell part;
extracellular region

binding

membrane

binding;
catalytic activity

cell part

biological regulation;
metabolic process

biological regulation;
cellular component
organization or biogenesis;
cellular process;
multicellular organismal
process
cellular component
organization or biogenesis;
cellular process;
localization;
metabolic process
multicellular organismal
process
cellular component
organization or biogenesis;
cellular process;

extracellular region
binding;
structural
molecule activity

cell part;
macromolecular
complex;
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*Trans-2-enoyl-CoA
reductase, mitochondrial
Transcription elongation
factor A N-terminal and
central domaincontaining protein 2
*Transcription factor 7like 2
*Transcription initiation
factor TFIID subunit
(Fragment)
*Transmembrane protein
186
*Transthyretin
Tubulin beta-6 chain
(Fragment)

developmental process;
multicellular organismal
process
cellular process;
metabolic process
metabolic process

cellular component
organization or biogenesis;
cellular process;
metabolic process

cellular process;
metabolic process
cellular component
organization or biogenesis;
cellular process

organelle

catalytic activity

cell part;
organelle

binding

binding;
catalytic activity

cell part;
macromolecular
complex;
organelle

binding;
structural
molecule activity

cell part;
organelle

Tyrosine-protein kinase
Ubiquitin carboxylterminal hydrolase 2
*Ubiquitin protein ligase
E3 component n-recognin
4
*Uncharacterized protein
*Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
(Fragment)
*Uncharacterized protein
(Fragment)
Uncharacterized protein
(Fragment)
Uncharacterized protein
(Fragment)
Uncharacterized protein
(Fragment); (Ig-like
protein)

Uncharacterized protein
(Ig-like protein)

cellular process;
metabolic process
cellular process;
metabolic process;
response to stimulus

catalytic activity

biological regulation;
cellular component
organization or biogenesis;
cellular process;
immune system process;
localization;
metabolic process;
multicellular organismal
process;
response to stimulus
immune system process

binding

binding;
catalytic activity

extracellular region;
macromolecular
complex;
membrane
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Uncharacterized protein
(Ig-like protein)
Utrophin
*Vacuolar protein
sorting-associated protein
28 homolog

*Versican core protein

*Vitamin D-binding
protein
*Vitamin D-binding
protein
Vitronectin
Von Willebrand factor A
domain containing 3B
*Von Willebrand factor
A domain containing 5B1
Xin actin binding repeat
containing 2
Zinc-alpha-2glycoprotein
Zinc finger CCHC
domain-containing
protein 7
*Zinc finger protein 618
*Zinc finger SWIM-type
containing 3 (Fragment)
*Zona pellucida binding
protein 2

immune system process
cellular component
organization or biogenesis
cellular process;
localization;
metabolic process

binding

cell part;
macromolecular
complex;
membrane;
organelle
extracellular region;
extracellular matrix

structural
molecule activity

cell part

developmental process;
multicellular organismal
process
localization
localization
cellular process

cellular process

extracellular region

metabolic process

binding
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Appendix 3

(A) Molecular Function

translation regulator
activity (0.7%)
binding (42.7%)

(B) Cellular Component

synapse (2.0%)
membrane (8.1%)

receptor activity
0.7%)
structural molecule
activity (4.9%)
signal transducer
activity (0.7%)
catalytic activity
(44.1%)
antioxidant activity
(1.4%)
transporter activity
(4.9%)

macromolecular
complex (12.8%)
extracellular matrix
(2.0%)
cell part (29.7%)
organelle (20.3%)

(C) Biological Process
immune system process

3.6%
21.8%

metabolic process
locomotion
biological adhesion

0.7%
2.5%
5.7%

multicellular organismal process
rhythmic process
developmental process
response to stimulus
biological regulation
localization

0.4%
4.6%
9.6%
8.9%
6.8%
28.2%

cellular process
cellular component organization or biogenesis

7.1%

PANTHER analysis of all identified proteins (231 in total) in bovine plasma (PL) and
follicular fluid (FF) containing low and high pre-ovulatory E2. Proteins were classified
according to (A) Molecular Function (B), Cellular Component, and (C) Biological Processes.
The percentages in the different categories are comparable to that from the analysis of only
proteins showing expression changes.

